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Chapter I 
To perform the complicated tasks associated with normal life our body requires a sufficient 
supply of energy and water, which is mainly provided by the intake of nutrition and fluids. 
Although the human body can be deprived of food for two to eight weeks, survival without 
water is usually limited to three to four days. The story becomes completely different with 
respect to our need of oxygen. Although some people can survive for almost nine minutes 
with one gasp of breath (lying motionless submerged in water) most of us can last for only 
one or two minutes. The reason that we are so heavily dependent on breathing air, engulfing 
a substantial amount of oxygen, lies at the heart of our cells, in organelles called 
mitochondria. 
 
Mitochondria, the basics 
Mitochondria are essential organelles, present in large numbers in virtually every cell. 
Together with the glycolytic pathway in the cytosol, mitochondria are responsible for the 
generation of ATP (adenosine triphosphate), the major form of cellular energy. Mitochondrial 
ATP production is an aerobe process, which consumes ~98% of the oxygen we breathe (68). 
Mitochondria are composed of a double membrane system, which separates two aqueous 
compartments (the mitochondrial matrix and inter membrane space; IMS) from the cellular 
environment (Fig. 1). Whereas the outer mitochondrial membrane (OMM) is almost freely 
permeable to small solutes the inner mitochondrial membrane (IMM) is not.  
 
Figure 1: Overview of mitochondrial structure and mitochondrial reticulum in living cells - A) Schematic 
representation of the mitochondrial structure. B) Confocal image of the mitochondrial reticulum in a single living 
human skin fibroblast visualized with rhodamine 123 (R123). Image was acquired after R123 pulse staining, 
averaged (N=32) and contrast optimized according ref. 136. 
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Chapter I 
Furthermore, the IMM is highly invaginated (cristae) and protrudes into the mitochondrial 
matrix (68). In addition mitochondria contain multiple copies of their own genetic material, 
present as circular double stranded DNA molecules (mtDNA) in the mitochondrial matrix. In 
living cells, mitochondria (Greek: mitos = thread + khondrion = granule) are very dynamic 
structures that are mobile and continuously change shape by fission and fusion. As a result, 
mitochondria occur as individual bean-shaped objects, elongated filaments or as part of an 
interconnected mitochondrial reticulum (Fig. 1, 46).  
 
Mitochondrial and cellular function is tightly integrated 
In addition of being the major generators of cellular ATP, mitochondria are also involved in 
many other biochemical and cellular processes. For example, they harbor essential 
components of biochemical pathways for the biosynthesis of iron-sulfur clusters, heme, 
pyrimidines, amino acids, phospholipids and nucleotides and for the breakdown of fatty acids 
(68,152,161). Furthermore,  mitochondria are central to cellular (patho)physiology given their 
critical roles in heat generation (237), transduction of electrical signals (112), calcium 
homeostasis (25,213,293), generation of reactive oxygen- and nitrogen species (ROS/RNS; 
14,65,209,265) and apoptosis (8,98). 
 
The mitochondrial oxidative phosphorylation system 
Virtually all mitochondrial functions require the presence of a sufficiently negative membrane 
potential (∆Ψ) across the IMM (68). Maintaining a proper ∆Ψ is essential for ATP generation, 
mitochondrial fusion and transport of calcium ions and other solutes across the IMM 
(24,63,115,168,283). During aerobic conditions, generation of ∆Ψ and ATP production are 
coupled via the mitochondrial oxidative phosphorylation (OXPHOS) system (Fig. 2). This 
system is embedded in the IMM and composed of five multi-protein assemblies (62).  
The first four complexes, together with two electron carriers (ubiquinone and cytochrome c), 
constitute the electron transport chain (ETC). Oxidation of reduced nicotinamide adenine 
dinucleotide (NADH) at complex I (CI or NADH:ubiquinone oxidoreductase, EC 1.6.5.3.) and 
succinate at complex II (CII or succinate:ubiquinone oxidoreductase, EC 1.3.5.1.) liberates 
electrons that are subsequently transported to complex III (CIII or ubiquinol:cytochrome c 
oxidoreductase, EC 1.10.2.2) and IV (CIV or cytochrome c oxidase, EC 1.9.3.1). At the latter 
complex the electrons are finally donated to molecular oxygen resulting in the formation of 
water. During electron transport, the energy released is utilized to expel protons (H+) from 
the mitochondrial matrix into the IMS (at CI, CIII and CIV), resulting in an inside-negative 
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membrane potential (∆Ψ) across the IMM. The electrochemical proton gradient is used by 
complex V (CV or F1F0-ATPase, EC 3.6.3.14) to drive the synthesis of ATP from ADP 
(adenosine diphosphate) and Pi (inorganic phosphate) in the mitochondrial matrix. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: The mitochondrial oxidative phosphorylation system - Creative drawing of the oxidative 
phosphorylation system adapted from ref. 301. Top: respiratory chain complexes, representing complex I-V. 
OXPHOS system: nuclear-encoded subunits are shown in light grey. Subunits of mitochondrial origin, embedded 
in the midst of nuclear-encoded subunits, are shown in darker grey. mtDNA: subunit encoded by the mtDNA in 
which disease-causing mutations have been identified (120). nDNA: nuclear-encoded subunit in which disease-
causing mutations have been found (references: see text and ref. 120). Recently disease-causing mutations have 
been identified in the nuclear-encoded proteins COQ2 (206) and PDSS2 (158) involved in the biosynthesis of 
coenzyme Q, not shown. Total: number of structural components of the oxidative phosphorylation system. 
Abbreviations: see text. 
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The OXPHOS system consists of at least 89 different proteins (62). Only a small subset of 
these proteins is derived from the mtDNA (seven for CI, one for CIII, three for CIV and two 
for CV) whereas the remainder is encoded by the nuclear genome (nDNA) (242). Therefore, 
the large majority of the OXPHOS subunits, together with many other nuclear-encoded 
mitochondrial proteins (>1000) need to be imported from the cytosol. This task is carried out 
by a dedicated mitochondrial protein import machinery consisting of a translocase in the 
OMM (TOM complex) and a translocase in the IMM (TIM complex; 295), the latter of which is 
∆Ψ-driven and requires ATP. 
Importantly, given the large number of different OXPHOS proteins and their bi-genomic 
nature, biosynthesis of functional OXPHOS complexes requires coordination between 
nuclear and mitochondrial transcription/translation machineries (225). Within the 
mitochondrion, OXPHOS complexes are assembled and maintained by specific 
proteinaceous factors (53,62,185,284,285,287). Currently, detailed mechanistic insights into 
the regulation of OXPHOS expression and assembly are lacking (192). 
 
Deficiency of the oxidative phosphorylation system 
Mitochondrial dysfunction is associated with a variety of human diseases including cancer, 
diabetes, neurodegenerative disorders such as Parkinson, Alzheimer and Huntington 
disease and inborn errors of metabolism (1,14,88,101,161,230,242,248,291,302) 
Furthermore, functional deterioration of mitochondria has been observed during normal 
aging (96,269). Although the term ‘mitochondrial dysfunction’ is rather broad, it usually refers 
to disturbances of the OXPHOS system. For inborn errors of metabolism, deficiencies of the 
OXPHOS system have an estimated incidence of at least 1 in 5000 live births. OXPHOS 
disorders are genetically and clinically heterogeneous and the biochemical defect is either 
isolated or combined, meaning that one or more OXPHOS complexes are affected (120). 
Furthermore, OXPHOS defects can be systemic or occur in a tissue specific manner. The 
latter is likely caused by different types of cells/tissues being more or less sensitive to 
malfunction of individual OXPHOS complexes (218). 
OXPHOS deficiency predominantly affects tissues with a high energy demand including 
skeletal muscle, heart and brain. Clinically, the deficiency can present itself at any age but is 
often seen as an early-onset, progressive metabolic syndrome associated with a diverse 
array of neurological, neuromuscular, cardiac and endocrine disorders (62,274,302). Most 
patients suffer from Leigh or Leigh-like syndrome (120,148,210) and die within a few years 
after the first clinical manifestations. 
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Due to the bi-genomic origin of complex I, III, IV and V, OXPHOS deficiency can be caused 
by mtDNA mutations, which are maternally inherited, and/or nDNA mutations (Fig 2. 
33,107,264,274,292,30). Therefore, different modes of inheritance (maternal, autosomal 
recessive or dominant and X-linked) can contribute to the genetic heterogeneity of OXPHOS 
disorders (120). In most patients, the decrease in OXPHOS activity is associated with a 
deficiency of CI (OMIM 252010) making it the most frequently encountered enzymatic 
deficiency (157,224,288). 
 
Complex I: composition, biogenesis and disease 
Mammalian complex I (CI) is the largest enzyme of the OXPHOS system. Its structure is L-
shaped and consists of a hydrophobic part, embedded in the IMM and a hydrophilic part, 
perpendicularly protruding into the mitochondrial matrix (Fig. 3, 81,90). CI couples the 
oxidation and reduction of NADH and ubiquinone, respectively, to the translocation of 
protons across the IMM (104). Oxidation of NADH liberates two electrons which are 
transferred to the primary electron acceptor of CI, a non-covalently bound flavin 
mononucleotide (FMN). Subsequently, the electrons are transported via a series of eight 
iron-sulfur clusters to their final electron acceptor ubiquinone (CoQ), resulting in the 
formation of ubiquinol (CoQH2) and the translocation of four protons to the IMS (103). 
Although different mechanistic models have been proposed for the above process 
(103,187,280), its exact molecular mechanism remains to be determined. 
Mammalian CI has a molecular mass of approximately 1 MDa and consists of 45 structural 
subunits (Fig. 3) 14 of which (including all mtDNA-encoded proteins) are evolutionary 
conserved (44,45,83). The latter proteins constitute the catalytic core of CI and carry the 
substrate binding site, all redox centers and, in principle, suffice to perform the bioenergetic 
functions of CI. In addition, mammalian CI has 31 nuclear-encoded ‘accessory’ subunits, 
which functions are largely unknown (104,118). CI assembly involves the coordinated 
combination of individual subunits in evolutionary conserved protein modules (82,272,287). 
Next, these modules are assembled to a fully functional complex. CI assembly requires 
assistance of specific assembly factors including NDUFAF1 (286), B17.2L (185) and Ecsit 
(285). In addition, biochemical, structural and functional approaches suggest that CI 
complexes are organized into higher order supercomplexes that also contain CIII and CIV 
(27,227,228,229). It is hypothesized that these supercomplexes allow efficient substrate 
channeling between complexes, stabilize the structure of the participating complexes and 
prevent leakage of reactive intermediates (229). 
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Figure 3: Structural composition of mammalian complex I - Complex I structure was adapted from ref. 90 
and CI subunit composition and annotation were based on ref. 104. #With the aid of chaotropic agents, bovine CI 
can be divided into an alpha (Iα) and beta (Iβ) subcomplex. Subunits in which a disease-causing mutation is 
identified are shown in bold; mtDNA-encoded subunits are underlined. Asterisks indicate that protein is present in 
substochiometric amounts. %Not assigned: subunits which belong to complex I but could not be assigned to the 
Iα or Iβ subcomplex.  
 
In most pediatric cases, CI deficiency is caused by mutations in nDNA-encoded structural CI 
subunits (246). Thus far, autosomal recessive mutations have been demonstrated in the 
NDUFA1, NDUFS1, NDUFS2, NDUFS3, NDUFS4, NDUFS6, NDUFS7, NDUFS8, NDUFV1 
and NDUFV2 subunits of CI and in the CI assembly factor B17.2L 
(22,40,41,74,120,130,165,205). Regarding the possible consequences of these mutations, 
concentrations of lactic acid and Kreb’s cycle intermediates as well as lactate:pyruvate ratios 
can be increased in body fluids and cells of patients with CI deficiency (71,157,204). The 
latter phenomenon results from a disturbed mitochondrial NADH/NAD+ redox balance in 
which accumulation of NADH as a result of CI deficiency leads to inhibition of the Kreb’s 
cycle and thereby accumulation of Kreb’s cycle intermediates and pyruvate. The latter is 
converted into lactic acid by NADH-dependent lactate dehydrogenases, resulting in an 
elevated lactate:pyruvate ratio (248). 
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Studies on fibroblasts from patients with an isolated CI deficiency revealed aberrations in 
cellular and mitochondrial calcium handling and calcium-stimulated mitochondrial ATP 
production during hormone stimulation (281,282,283). Another cellular study revealed that 
mitochondrial morphology was aberrant in CI deficient patient fibroblasts (ranging from 
fragmented to highly elongated) and positively correlated with residual CI activity (139). This 
suggests that CI deficiency affects mitochondrial structure or vice versa. 
 
Complex I deficiency: Involvement of free radicals 
Over 90% of the cellular reactive oxygen species (ROS) is produced by mitochondria as a 
normal consequence of electron transport (14,68). This ROS results from the fact that a 
small portion of molecular oxygen (~0.2%), consumed by the ETC, is incompletely reduced 
thereby resulting in the formation of reactive intermediates (255). ROS comprise a group of 
chemically diverse molecules like superoxide (O2-), hydrogen peroxide (H2O2) and hydroxyl 
radical (OH.) (117) with different (patho)biological actions (Fig. 4).  
The primary source of cellular ROS is O2-, which is mainly generated at CI in living cells 
(2,144,175,184,255). Superoxide is membrane impermeable and fairly reactive. Under 
normal conditions virtually all O2- is enzymatically converted into H2O2 by the combined 
action of manganese superoxide dismutase (MnSOD) in the mitochondrial matrix and 
copper-zinc superoxide dismutase (CuZnSOD) in the cytosol (117,208). In contrast to O2-, 
H2O2 is not very reactive and can cross membranes readily (6,254). Mitochondria-generated 
H2O2 can be degraded by the enzymatic action of glutathione-dependent peroxidases (113) 
or peroxiredoxins (122), causing thiol oxidation of glutathione and thioredoxin which may be 
used as a regulatory signal (106,117). 
Mitochondrial O2- can also react with nitric oxide (NO) resulting in formation of the reactive 
nitrogen species (RNS) peroxynitrite (ONOO-), (117). NO itself can easily diffuse into 
mitochondria and may also be produced there by the action of nitric oxide synthases (38,86). 
As formation of ONOO- is faster than the decomposition of O2- by MnSOD (207), ONOO- 
generation by this reaction is possibly biologically relevant. When not properly scavenged, 
O2- can damage iron-sulfur proteins thereby liberating ferrous iron (Fe2+) (276). In an 
alternative reaction although not confirmed in vivo, O2- can be protonated to the membrane 
permeable hydroperoxyl radical (HO2.) that, on its turn, can induce lipid peroxidation (7,117). 
The importance of a functional mitochondrial O2- scavenging system is stressed by results 
obtained in mice in which the gene for MnSOD was ablated. These mice die of a 
mitochondrial disorder shortly after birth (110,149). 
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Figure 4: Overview of mitochondrial free radical metabolism - Schematic overview of mitochondrial ROS 
reactions adapted from ref. 117. Superoxide (O2-) produced by CI can be dismutated by superoxide dismutase 
(SOD) to hydrogen peroxide (H2O2) but can also react with iron–sulfur proteins producing ferrous iron (Fe2+) and 
nitric oxide (NO) to form peroxynitrite (ONOO-). H2O2 can be degraded by peroxiredoxin III (PRxIII) or by 
glutathione peroxidases (GPx) which use thioredoxin (Trx) or glutathione (GSH) as electron donors, respectively. 
In the presence of Fe2+, H2O2 breaks down to form the hydroxyl radical (OH.) whereas the breakdown of ONOO- 
results in a species with similar reactivity as OH.. OH. can remove H. from lipids (RH) initiating formation of 
peroxolipids (ROO.) which can start a cycle of lipid peroxidation that includes the formation of peroxides (ROOH) 
and alkoxy radicals (RO.). These can be detoxified to alcohols (ROH) by the action of antioxidants and 
glutathione peroxidase 4. GR: glutathione reductase; GSSG: oxidized GSH; NADPH: nicotinamide adenine 
dinucleotide phosphate reduced form); TR, thioredoxin reductase; TRx, thioredoxin.  
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When H2O2 levels become too high, this molecule can participate in the Fenton reaction 
comprising the Fe2+-catalyzed formation of the extremely reactive hydroxyl radical (OH.). 
Within a lipid environment, hydroxyl radicals initiate lipid peroxidation. In non-lipid 
environments, this radical can induce non-specific damage to all biological molecules at its 
site of production. Currently, no enzymatic scavenging system for hydroxyl radicals has been 
identified. 
Next to enzymatic systems, several non-enzymatic ROS scavenging systems exist that 
protect the cell from the detrimental effects of ROS/RNS during normophysiological 
conditions. These include membrane-bound vitamin E (with α-tocopherol being the most 
effective form), vitamin C (ascorbic acid), and glutathione (GSH; L-γ-glutamyl-L-cysteinyl-
glycine) (56). GSH is the predominant low-molecular-weight thiol in animal cells and is 
important in the protection against oxidative damage, both by direct reaction with ROS and 
as electron donor for peroxidases (111,297) Because of the high intracellular GSH 
concentration (0.5-10 mM) the 2GSH/GSSG couple is believed to be the major determinant 
for cellular redox homeostasis and antioxidative capacity (226,297). 
A small part of the ROS produced is believed to function in cellular signal transduction 
(80,153). However, excessive production of ROS/RNS can overwhelm cellular antioxidant 
mechanisms and inflict damage to all major cellular biomolecules including DNA, lipids and 
proteins (117,208). Changes in ROS/RNS levels as a consequence of CI deficiency may 
alter mitochondrial and/or cellular redox homeostasis leading to activation of redox-sensitive 
signaling pathways (65,265). Evidence has been provided that these pathways modulate 
cellular calcium signaling (28), regulate cellular antioxidant capacity (204,296) and control 
mitochondrial biogenesis (147,171,172). 
 
Aim and outline of this thesis 
At present, our understanding of the consequences of CI mutations at the cellular level is 
very limited. This lack of insight severely hampers the rational design and testing of effective 
therapeutics. Since CI is a major contributor to cellular ROS production, disturbances in the 
function of this complex due to an inherited mutation in one of its subunits could result in 
increased free radical levels. Such an increase might result in cellular damage and/or 
alterations in cellular signaling pathways (80,153,208). Previous studies using isolated 
mitochondrial preparations demonstrated that (I) a decrease in CI activity is associated with 
increased ROS levels and induction of lipid damage (16,160,204) (II) conditions of oxidative 
or nitrosative stress can result in CI protein modifications and a reduced activity 
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(18,26,47,55,196,263). However, given the tight interconnection between mitochondrial and 
cellular function, the use of isolated mitochondria precludes proper evaluation of the cell 
biological consequences of CI deficiency, in relation to human disease. 
Therefore, the aim of the research described in this thesis was to gain more insight into 
the consequences of human CI deficiency with respect to free radical biology in the context 
of the living cell. To investigate this, we used two model systems: one in which CI deficiency 
was induced by rotenone in healthy control cells and another where a cohort of patient-
derived fibroblasts with an inherited CI deficiency was used. With the aid of chemical and 
genetically-encoded fluorescent reporter molecules, life-cell imaging, biochemical, immuno-
histochemical and enzymatic techniques, the quantitative relationship between CI protein 
expression, ROS levels, lipid peroxidation and redox homeostasis in human CI deficiency at 
the (sub)cellular level was investigated. 
In chapter 2 a novel method for simultaneous quantification of oxidative stress and cell 
spreading in CI deficiency is described and validated. Using the method described in the 
previous chapter, chapter 3 and 4 investigate the effect of the vitamin E-derived antioxidant 
Trolox on cellular oxygen radical levels and CI expression and activity. Chapter 3 
demonstrates that increased cellular ROS levels in patient cells are normalized by Trolox-
treatment. In parallel, Trolox increased the expression of fully assembled CI and its activity. 
Comparison of the Trolox-induced change in CI expression and activity revealed a variable 
intrinsic catalytic problem in the patient cell lines. In chapter 4 Trolox was used as a tool to 
investigate the pathological mechanism of CI deficiency in a subset of patient cell lines with 
a mutated NDUFS4 subunit. This revealed that, although these patient cells displayed only a 
catalytically inactive CI subcomplex of reduced size on native gels, substantial biochemical 
CI activity was present within the context of the intact cell. This suggests that the mutations 
in the NDUFS4 subunit lead to CI destabilization. In chapter 5, a cohort of 21 CI deficient 
patient cell lines was studied to determine the relationship between superoxide levels, 
expression of fully assembled CI protein and CI activity. It was demonstrated that human CI 
deficiency results from decreased expression of fully assembled CI, which is paralleled by a 
proportional increase in cellular O2- levels. Chapter 6 investigated whether patient cells 
displayed alterations in mitochondrial/cellular redox state and extent of lipid peroxidation. No 
aberrations in redox status and lipid peroxidation were observed, suggesting that the cells 
successfully adapted to the increased ROS levels described in chapter 3-5. Chapter 7 
describes the findings obtained using the rotenone model and the effect of the mitochondria-
targeted antioxidant Mitoquinone (MitoQ). It is demonstrated that chronic partial CI inhibition 
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induces mitochondrial branching, and increases O2- and lipid peroxidation in control cells. 
The presence of MitoQ effectively blocked the rotenone-induced mitochondrial branching 
and lipid peroxidation without, however, reducing the elevated O2--levels. These findings 
suggest that CI deficiency can alter mitochondrial morphology via O2- induced lipid 
peroxidation. Finally, chapter 8 summarizes and discusses the results obtained. 
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Chapter II 
ABSTRACT 
 
Background – Mitochondrial dysfunction may lead to increased oxidative stress and 
consequent changes in cell spreading. Here, we describe and validate a novel method for 
simultaneous quantification of these two parameters.  
Methods – Human skin fibroblasts were loaded with 5-(and-6)-chloromethyl-2',7'-
dichlorodihydrofluorescein (CM-H2DCF) and its oxidative conversion into CM-DCF was 
monitored as a function of time by video-rate confocal microscopy and real-time image 
averaging. Cell size was determined after binarization of the acquired images. 
Results – At the lowest practical laser output, CM-DCF formation occurred with zero order 
kinetics, indicating that [CM-H2DCF] was not rate-limiting and that the rate of [CM-DCF] 
formation (VCM-DCF) was a function of the cellular oxidant level. Analysis of fibroblasts of a 
healthy control subject and a patient with a deficiency of NADH:ubiquinone oxidoreductase, 
the first complex of the oxidative phosphorylation system, revealed a significant increase in 
cellular oxidant level in the latter cells that was, however, not accompanied by a change in 
cell spreading. Conversely, chronic treatment with 6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid (Trolox), a derivative of vitamin E, markedly decreased the oxidant level and 
cell spreading in both control and patient fibroblasts. 
Conclusions – We present a reliable method for simultaneous quantification of oxidant 
levels and cell spreading in living cells.  
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INTRODUCTION 
 
In mammalian cells, the vast majority (>90%) of reactive oxygen species (ROS) is produced 
as a consequence of electron transport through the mitochondrial electron transport chain 
(ETC; (14,68). The primary ROS species formed by the ETC is superoxide (O2-), with major 
production sites at CI and CIII (144). Superoxide can react with nitric oxide (NO) to form 
extremely reactive peroxinitrite (ONOO-). The latter reactive nitrogen species (RNS) exists in 
fast dynamic equilibrium with its conjugated acid ONOOH. In the absence of carbon dioxide, 
ONOO-/ONOOH decays to harmless nitrate (NO3-), reactive nitrogen dioxide (NO2), and the 
highly reactive hydroxyl radical (OH.); (56). 
Under normophysiological conditions, several enzymatic and non-enzymatic systems exist 
that protect the cell from the detrimental effects of oxidants. Antioxidant enzymes include 
catalases, superoxide dismutases (SODs), peroxiredoxins and glutathione peroxidases. 
Thus, once formed, the majority of superoxide is dismutated to hydrogen peroxide (H2O2) by 
the combined activity of mitochondrial MnSOD and cytosolic CuZnSOD. Hydrogen peroxide 
is subsequently decomposed to water and oxygen by the action of catalase and various 
peroxidases. In the presence of iron(II), however, H2O2 can be converted into OH. by the 
Fenton reaction. If this reaction is not properly counterbalanced by ferritin and/or heme 
oxygenase (HOx), OH. can induce serious damage to lipids, proteins, carbohydrates and 
DNA (209). The major non-enzymatic defense systems consist of membrane-bound vitamin 
E, vitamin C (ascorbic acid), and glutathione (GSH; L-γ-glutamyl-L-cysteinyl-glycine; (56)). In 
general, these antioxidants act by terminating a chain reaction of oxidizing events (270). 
Oxidative stress occurs when the generation of oxidants is not appropriately 
counterbalanced by the cell’s antioxidant systems (14,65,265,296). This imbalance will 
change the cellular redox environment, thereby activating specific redox-sensitive signaling 
pathways (65,265). Evidence has been provided that these pathways, among others, 
regulate mitochondrial biogenesis (146,171,172), cellular antioxidant capacity (204,296), 
Ca2+ homeostasis (28) and cell adhesion and spreading (13,23,51,239,294). The oxidative 
conversion of 2',7'-dichlorodihydrofluorescein (H2DCF) into 2',7'-dichlorofluorescein (DCF) 
has been widely applied to measure oxidant levels in both cell free systems and living cells 
(51,87,178,239,262). Here, we describe the establishment of a reliable protocol for 
simultaneous quantification of oxidant levels and cell spreading based on video-rate confocal 
microscopy of cells loaded with 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein (CM-
H2DCF). This protocol was subsequently used to assess the effects of a deficiency of the 
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first and largest multi-subunit complex of the mitochondrial oxidative phosphorylation 
system, NADH:ubiquinone oxidoreductase, on the oxidant levels and spreading of cultured 
skin fibroblasts derived from a patient with a pathological mutation in one of the nuclear-
encoded subunits of this enzyme. It was found that oxidant levels were increased but cell 
spreading was normal in patient fibroblasts. 
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MATERIALS AND METHODS 
 
Cell culture – Fibroblasts were derived from a skin biopsy of a healthy control subject 
(culture number #5120) and a patient with isolated complex I (CI) deficiency (culture number 
#5170) following informed parental consent and according to the relevant Institutional 
Review Boards. The deficiency was confirmed in both muscle tissue and cultured skin 
fibroblasts and screening for the presence of DNA alterations in each of the known nuclear-
encoded CI genes revealed a mutation in the NDUFS2 subunit (155). The patient was 
negative with respect to mtDNA alterations previously known to cause CI deficiency. 
Fibroblasts were cultured in medium M199 containing 5 mg/l Tween 20, 10% (v/v) fetal calf 
serum, 100 IU/ml penicillin and 100 IU/ml streptomycin (Invitrogen, Breda, The Netherlands). 
For confocal imaging, cells were seeded on glass coverslips (Ø 22 mm) and cultured to 
~70% confluence in a humidified atmosphere (95% air, 5% CO2) at 37o C.  
 
Video-rate confocal imaging of CM-DCF fluorescence – Cytosolic oxidant levels were 
quantified with 5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate (CM-
H2DCFDA; Molecular Probes). Stock solutions (1 mM) were prepared in DMSO, saturated 
with N2 gas to prevent oxidation, and stored at -20° C. Fibroblasts were incubated for 10 min 
at 37° C in a HEPES-Tris (HT) medium (132 mM NaCl, 4.2 mM KCl, 1 mM CaCl2, 1 mM 
MgCl2, 5.5 mM D-glucose and 10 mM HEPES, pH 7.4) containing 1 µM CM-H2DCFDA. After 
thorough washing to remove non-hydrolysed dye, coverslips were mounted in an incubation 
chamber placed on the stage of an inverted microscope (Nikon Diaphot, Tokyo, Japan) 
attached to an Oz confocal microscope (Noran Instruments, Middleton, WI, USA). Cells were 
placed in HT-medium and measurements were performed at 20° C in the dark. In the axial 
direction, human skin fibroblasts fitted fully within 3 consecutive 1 µm thick optical sections. 
This demonstrates that the height of the fibroblasts is ≤ 3 µm. Therefore, to prevent 
exclusion of mitochondrial structures from the image in the axial direction, no confocal slit 
was used. This equals an axial section thickness of 10 µm. The light from an Argon ion laser 
(488 nm; Omnichrome, Chino, CA, USA) was delivered to the cells via a x40 oil immersion 
planapochromat objective (NA 1.4; Nikon). Fluorescence emission light was directed through 
a 500 nm LP barrier filter (Chroma Technology Corp., Brattleboro, VT, USA) and quantified 
using a photomultiplier tube at 8-bit resolution (Hamamatsu Photonics, Bridgewater, NJ, 
USA). Hardware and image acquisition were controlled by Intervision software running under 
IRIX 6.2 on an Indy workstation (Silicon Graphics Inc., Mountain View, CA, USA) equipped 
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with 512 Mb memory. Images (512x480 pixels) were collected at 30 Hz with a pixel dwell-
time of 100 ns.  
 
Data analysis – Image analysis was performed using Image Pro Plus 5.1 (Media 
Cybernetics, Silver Spring, MD, USA) as described in the Results section. Numerical results 
were visualized using Origin Pro 7.5 (Originlabs, Northampton, MA, USA) and values from 
multiple experiments were expressed as means ± SE (standard error). Statistical 
significance (Bonferroni corrected) was assessed using Student’s t-test. During linear 
regression analysis, the degree of bivariate correlation between sets of data was analyzed 
by calculating Pearson’s R. This parameter expresses the proportion of total variation that is 
explained by the regression. If R is ±1, the total variation in the fit can be explained in terms 
of the regression curve (58). For R>0 the correlation is positive, for R<0 the correlation is 
negative. Similarly, R2 was used as a measure of the goodness of the fit during non-linear 
regression (Levenberg-Marquardt method).  
 
Chemicals – Cell culture materials were obtained from Gibco (Gaithersburg, MD, USA). All 
other reagents were from Sigma (St. Louis, MO, USA). 
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RESULTS 
 
Visualization of CM-DCF fluorescence by video-rate confocal microscopy – DCF (2',7'-
dichlorofluorescein) has been shown to be prone to passive leakage across the plasma 
membrane (124,257). Therefore, we here used a DCF variant with chloromethyl groups 
(CM-DCF), which greatly reduce passive dye leakage (93). Skin fibroblasts were incubated 
for 10 min at 37° C in HT medium containing 1 µM CM-H2DCFDA. During this period, the 
acetate groups are cleaved off by intracellular esterases, yielding non-fluorescent CM-
H2DCF, which is then oxidized by intracellular oxidants to form the highly fluorescent product 
CM-DCF (5-(and-6)-chloromethyl-2',7'-dichlorofluorescein). At the end of the loading period, 
cells were thoroughly washed to remove non-hydrolysed CM-H2DCFDA. CM-DCF 
fluorescence was monitored by video-rate confocal microscopy and real-time image 
averaging. Excitation was at 488 nm and emission light was directed through a 500 nm long-
pass barrier filter onto the photomultiplier tube (29). For maximal sensitivity, images were 
acquired using an objective with a high numerical aperture (1.4). Black level and brightness 
settings were adjusted to achieve an optimal dynamic range of grey values within the 
recorded image. Images were routinely captured at 10 s intervals. At each time point, 30 
images (512x480 pixels) were acquired at 30 Hz and averaged in real time to increase the 
signal-to-noise ratio (138). The latter setting resulted in a pixel dwell-time of 100 ns. All 
measurements were performed in the dark and excitation light was fully shielded between 
images using a hardware shutter. This experimental approach permitted acquisition of high 
quality images at minimal laser intensities. CM-DCF fluorescence was observed throughout 
the cell but was clearly higher in the nucleoplasm (Fig. 1A; inset). This might be due to a 
higher viscosity of the nuclear compartment, which enhances the excitation efficiency of CM-
DCF (134). 
 
CM-DCF fluorescence increases as a function of laser intensity – Previous reports have 
shown that laser light stimulates CM-DCF formation (29,32,87,162,257). To assess the 
relative importance of this photo-oxidation process, CM-H2DCF-loaded fibroblasts were 
excited at increasing laser intensities and CM-DCF fluorescence was recorded. For 
quantitative evaluation of the changes in CM-DCF fluorescence intensity, regions of interest 
(ROIs), encompassing either the whole cell (dotted lines) or an intracellular region of 
maximum size (solid lines), were defined (Fig. 1A). For each ROI, fluorescence emission 
intensity was expressed as average greylevel value per pixel. Before further analysis, each 
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trace was corrected for background by subtracting the fluorescence obtained from an 
extracellular ROI (marked ‘B’). At laser intensities ≤ 6% (subcellular ROIs) and ≤ 7% (whole 
cell ROIs), CM-DCF fluorescence increased linearly with time (R>0.99, p<0.0001). The rate 
of fluorescence increase (VCM-DCF) clearly depended on the laser intensity (Fig. 1B) and was 
proportional for both the whole cell and the intracellular region (Fig. 1C). Based on these 
findings, we used the lowest practical laser intensity of 4%, equaling a laser output at the 
laser head of 34 µW, in the remainder of the study.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Effect of laser power on CM-DCF formation – (A) The inset shows a confocal image of human skin 
fibroblasts incubated with CM-H2DCFDA for 10 min. The image was contrast-optimized to reveal cellular 
structures. Dotted lines indicate whole cell regions of interest (ROIs; marked 1, 2 and 3). Ovals correspond to 
intracellular ROIs and a background ROI (marked ‘B’). The scale bar indicates 15 µm. The graph shows the time 
course of the background-corrected CM-DCF fluorescence as a function of laser power for the whole cell 
(continuous lines) and subcellular ROIs (dotted lines). (B) Average rate of CM-DCF fluorescence increase (VCM-
DCF) for whole cell (black bars) and subcellular ROIs. (C) Relationship between whole cell (x-axis) and subcellular 
(y-axis) VCM-DCF as a function of laser power. All data points obtained for 4% , 5% and 6% laser intensity were on 
a straight line that passed through the origin (intercept=-2.1E-4±0.0002; R=0.999, p=0.003). (D) CM-DCF 
fluorescence change as a function of time at 4% laser intensity. The upper traces represent subcellular ROIs, the 
lower trace corresponds to an extracellular ROI. A linear fit (straight line) was calculated to the first 11 data points 
for each cell (grey box). Linearity was observed during the first 200 s of recording. After this period, both intra- 
and extracellular signals increased supra-linearly. For all linear fits, R>0.99 and p<0.0001. The slope of the line 
fitted to the background signal did not differ from zero (slope=-6.9E-5±1.1E-4). 
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CM-DCF fluorescence increases linearly during low laser intensity illumination – We next 
investigated the linearity of the increase in CM-DCF fluorescence during prolonged 
illumination at the lowest practical laser intensity (4%). For each of the traces shown in 
figure 1D, a linear fit was made to the first 11 data points indicated with ‘fit region’ (R>0.99 
and p<0.0001). The figure shows that linearity was observed for maximally 200 s, indicating 
that the slope of the fit to the first 20 data points can be taken as a reliable measure of VCM-
DCF. At longer times, both the intracellular and background fluorescence started to deviate 
from linearity. In view of these results, we decided to routinely use a recording time of less 
than 200 s for quantitative analysis of intracellular CM-DCF signals. 
 
CM-DCF fluorescence increases faster in the presence of hydrogen peroxide – Previous 
work using epidermal keratinocytes and skin fibroblasts revealed that CM-DCF fluorescence 
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increased more rapidly in the presence of H2O2 (109,129). To assess whether linearity was 
maintained under these conditions, fibroblasts were acutely treated with 100 µM H2O2. 
Figure 2B shows that this treatment stepwise increased the fluorescence signal to a new 
and higher level. Thereafter, the signal continued to increase linearly (R>0.99, p<0.0001) but 
at a 3-fold faster rate than before application of the oxidant (Fig. 2C). Importantly, this result 
demonstrates that our method is quantitative at least up to oxidant levels that cause a 3-fold 
increase in VCM-DCF. Of note, the cell size remained unaltered in the course of the experiment 
(Fig. 2A). 
 
Figure 2: Linearity of CM-DCF formation and effect of hydrogen peroxide – (A) Confocal images of control 
human skin fibroblasts following incubation with CM-H2DCFDA. Ovals indicate seven intracellular ROIs, used for 
analysis. The indicated times correspond to the trace in panel B. The scale bar indicates 15 µm. (B) Effect of 
acute hydrogen peroxide application (H2O2; 100 µM) on the background-corrected CM-DCF signal for the 
individual ROIs. Linearity was observed for both the pre- and post-H2O2 traces. For all linear fits, R>0.95 and 
p<0.0001. (C) Average rate of CM-DCF formation (VCM-DCF) calculated for the cells in panel B. This rate was more 
than three-fold increased by H2O2 (p<0.001).   
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The rate of CM-DCF formation is increased in patient fibroblasts – Next, we determined 
whether VCM-DCF was altered in fibroblasts of a patient with isolated CI deficiency. Fibroblasts 
were loaded with 1 µM CM-H2DCFDA for exactly 10 min at 37° C, thoroughly washed, and 
subjected to confocal analysis of CM-DCF fluorescence. CM-DCF fluorescence was 
quantified using an intracellular ROI of maximum size. Analysis of the first image shows that, 
relative to control, CM-DCF fluorescence was 2.5-fold increased in patient fibroblasts (Fig. 
3A). Essentially the same result was obtained when VCM-DCF was measured over de next 200 
s at a capture rate of one image every 10 seconds (Fig. 3B). 
 
Figure 3: Trolox normalizes increased cellular oxidant levels in CI deficient patient fibroblasts – (A) Effect 
of chronic Trolox treatment (0.5 mM, 96 h) on the CM-DCF signal obtained from the first image taken (expressed 
as % of vehicle-treated control measured on the same day) in control fibroblasts (CT) and cells of a patient 
(#5170) with isolated CI deficiency. (B) Effect of Trolox on the rate of CM-DCF formation (expressed as % of 
control) in control (CT) and patient (#5170) fibroblasts, calculated from a sequence of images captured at 0.1 Hz 
over a period of 200 s. Average values were obtained from N=18 cells (CT), N=25 cells (CT+Trolox), N=17 cells 
(#5170) and N=19 cells (#5170+Trolox) measured during two independent experiments. In this figure a* and b* 
indicate significant differences (p<0.05) with column a and b, respectively.  
 
The rate of CM-DCF formation is decreased upon chronic antioxidant treatment – The above 
result is compatible with an imbalance between oxidant production and detoxification in 
patient fibroblasts. To augment cellular antioxidant levels, cells were cultured in the 
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continuous presence of the antioxidant 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic 
acid or Trolox (0.5 mM, 96 h). Analysis of the first image demonstrates that Trolox 
completely normalized the increase in CM-DCF fluorescence in patient fibroblasts (Fig. 3A). 
Again, essentially the same result was obtained when assessing VCM-DCF over a measuring 
period of 200 s (Fig. 3B). In contrast to the first-image measurement, the time-sequence 
measurement revealed a significant decrease in VCM-DCF in control fibroblasts following 
antioxidant treatment. Importantly, all time courses were linear for 200 s (R>0.95 and 
p<0.0001).  
 
Cell spreading is unaltered in isolated complex I deficiency – It has been shown that 
increased cellular oxidant levels induce enlargement and flattening of human diploid 
fibroblasts (294). Conversely, oxidant scavenging was demonstrated to inhibit spreading of 
NIH-3T3 fibroblasts (51). To assess whether in CI deficient patient fibroblast the increase in 
cellular oxidant levels was accompanied by an increased cell spreading, we developed a 
protocol for computer-assisted quantification of the latter parameter from CM-DCF-stained 
cells (Fig. 4). Starting from the last ‘RAW’ image of a time-sequence measurement (Figs. 
4A and 4F; image A), which has the most optimal signal-to-noise-ratio, we first produced an 
image with an even higher contrast by evenly redistributing the intensity histogram around 
the centre of the intensity scale using a bell contrast optimization (Figs. 4B and 4F; image 
B). Next, the image was linearly contrast-stretched (Fig. 4G) to obtain the highest possible 
dynamic range (Fig. 4C). The latter image was then binarized by thresholding to discriminate 
cellular pixels from background pixels (Fig. 4D). Finally, remaining background noise pixels 
were removed by a single 3x3 median filter with a strength of 1 (Fig. 4E). As a consequence 
of the latter operation, the number of black (marked ‘0’) and white pixels (‘255’) in the image 
increased and decreased, respectively (Fig. 4H). Given their very flat morphology (138), 
counting the total number of white pixels in the image is a good estimate of the degree of 
fibroblast spreading. In this study, we used a x40 objective and no additional software zoom. 
Therefore, the pixel size equaled 0.188 µm (138). By multiplying the pixel size by the 
number of pixels per cell, it was found that control and patient fibroblasts did not significantly 
differ in their degree of spreading (total white pixel areas of 2440±470 µm2 and 
2127±417µm2 for control and patient fibroblasts, respectively) (Fig. 4I). These values are in 
good agreement with our previous results obtained with R123-stained fibroblasts (2266±125 
µm2; 138).  
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Cell size is reduced upon chronic antioxidant treatment – Chronic treatment with the vitamin 
E-derived antioxidant Trolox (0.5 mM, 96 h) significantly reduced the spreading of control 
and patient fibroblasts by 40% and 27%, respectively (Fig. 4I).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Cell size is not different between control and patient fibroblasts but significantly decreased by 
Trolox treatment – (A) Confocal image of control human skin fibroblasts following incubation with CM-
H2DCFDA. (B) Image depicted in panel A after a bell contrast stretch. (C) Image in panel B after a linear contrast 
stretch. (D) Image in panel C after thresholding. (E) Image in panel D after median filtering. (F) Intensity 
histogram for images A and B. (G) Intensity histogram of image C. (H) Intensity histogram for the black 
(greylevel=0) and white (greylevel=256) pixels in images D (open bars) and E (black bars). (I) Reduction in cell 
spreading induced by chronic Trolox treatment (0.5 mM, 96 h) in control (CT) and patient (#5170) fibroblasts. 
Averages were calculated for N=27 cells (CT), N=34 cells (CT+Trolox), N=26 cells (#5170) and N=26 cells 
#5170+Trolox) measured during four independent experiments. In this figure a* indicates a significant difference 
(p<0.05) with column a.  
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DISCUSSION 
 
Increased cellular oxidant levels have been implicated in cell spreading (13,23,51,239,294). 
Here, we present a novel protocol for simultaneous quantification of oxidant levels and cell 
spreading using CM-DCF (5-(and-6)-chloromethyl-2',7'-dichlorofluorescein). Because 
dysfunction of mitochondria has been associated with increased oxidant levels 
(14,68,136,209,247) we compared both parameters between healthy control fibroblasts and 
cells from a patient with isolated CI deficiency. Following method validation, we observed 
that control and patient displayed similar spreading but that the latter displayed significantly 
increased oxidant levels. Both parameters were significantly reduced upon chronic treatment 
with the antioxidant Trolox. 
 
The rate of CM-DCF formation is a function of laser intensity – We observed that VCM-DCF 
increased as a function of laser intensity. It has been suggested that photo-oxidation of CM-
DCF might involve singlet oxygen (1O2), a highly oxidizing species that can be generated by 
irradiation with visible (λ>300 nm) laser light (138). However, previous work has shown that 
1O2 does not directly stimulate CM-DCF formation but induces the formation of a 
semiquinone radical (CM-DCF.-), which reacts with O2 to form O2- (29,87). This radical is 
dismutated by SOD to H2O2 (138), which then stimulates the formation CM-DCF (see 
above). Our findings show that the relative contribution of the photo-oxidation process was 
minimal at the lowest practical laser intensity of 4%, equaling a laser output of 34 µW. To 
maximize the sensitivity of fluorescence detection at this low laser intensity, we used a long-
pass instead of a band-pass emission filter. Furthermore, we applied optimal black level and 
brightness settings, whereas the signal-to-noise ratio was improved by real-time image 
averaging (138). 
 
Intracellular formation of CM-DCF follows a zero order reaction mechanism – Using the 
lowest practical laser intensity, we observed that CM-DCF fluorescence increased linearly 
with time for maximally 200 s. This means that during this time the oxidative conversion of 
CM-H2DCF to CM-DCF proceeded according to a zero order reaction (235), written as the 
equation: 0][][ DCFCMtVDCFCM DCFCMt −+⋅=− − . In this equation, VCM-DCF is independent 
of [CM-H2DCF] and therefore solely determined by the steady-state oxidant level (178). The 
zero order model predicts that VCM-DCF increases as a function of [CM-DCF]0, determined 
from the first image taken at 10 min after the onset of loading and following thorough 
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washing to remove non-hydrolysed dye. Indeed, comparison of figures 3A and 3B shows 
that VCM-DCF changed proportionally with [CM-DCF]0 in both control and patient fibroblasts. 
Similarly, both parameters increased to the same extent upon addition of H2O2 (Fig. 2). 
Beyond a measuring time of 200 s, however, the increase in CM-DCF fluorescence started 
to deviate from linearity. This may suggest that CM-DCF, once formed in sufficient 
quantities, stimulates the conversion of CM-H2DCF into CM-DCF. Alternatively, cellular 
oxidant levels might increase upon prolonged laser illumination thereby accelerating the 
formation of CM-DCF. Taken together, our results demonstrate that normalization of the CM-
DCF time trace (i.e. dividing by [CM-DCF]0) is not appropriate since this would lead to 
underestimation of VCM-DCF at higher [CM-DCF]0. In addition, they show that the rate of CM-
DCF formation (VCM-DCF) is constant and therefore solely determined by the level of cellular 
oxidants.  
 
Oxidative formation of CM-DCF in living cells – Acute application of H2O2 readily increased 
VCM-DCF in human skin fibroblasts. This is in agreement with earlier findings in these cells and 
human epidermal keratinocytes (109,129). In a cell-free system, however, H2O2 but also 
superoxide (O2-), Fe(III), glutathione peroxidase and cytochrome c were found to be unable 
to convert H2DCF into its fluorescent product (99). On the other hand, DCF formation was 
readily stimulated in the presence of horseradish peroxidase, Fe(II), catalase, Cu/Zn-SOD, 
xanthine oxidase, peroxynitrite (ONOO-) and nitric oxide (NO) (99,124,190). Together, these 
results are compatible with the idea that intact cells contain catalysts, like transition metal 
ions, heme peroxidases and/or CuZnSOD that promote the H2O2-induced oxidation of the 
H2DCF. Indeed, overexpression of CuZnSOD was demonstrated to enhance H2O2-induced 
DCF formation in human epidermal keratinocytes and murine macrophages (129). 
Therefore, we conclude that the formation of CM-DCF in cellular systems can best be 
considered as a marker of oxidant levels rather than as a direct reporter of a specific 
ROS/RNS species. 
 
Oxidant levels are increased in patient cells and reduced by Trolox – [CM-DCF]0, determined 
from the first image, appeared significantly higher in patient fibroblasts as compared to 
control fibroblasts, indicating a higher VCM-DCF (Fig. 3A). Indeed, VCM-DCF, determined from 
the whole sequence of images, was higher in patient cells (Fig. 3B). These findings 
demonstrate that the higher value of VCM-DCF observed in patient cells is not due to photo-
oxidation. Therefore, it can be concluded that oxidant levels are significantly increased in 
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complex I deficient patient fibroblasts, reflecting an imbalance between their production and 
detoxification (14,65,265,296). To augment their antioxidant capacity, cells were cultured in 
the presence of the vitamin E derivative Trolox. This treatment fully normalized [CM-DCF]0 
and VCM-DCF in patient fibroblasts and lowered these parameters in control fibroblasts. Trolox 
is a phenolic antioxidant with a chromane structure similar to vitamin E but without the 
polyisoprenoid hydrophobic tail (259). It has been described for vitamin E that its antioxidant 
action is exerted through the phenolic hydroxyl group, which readily donates its hydrogen to, 
for instance, polyunsaturated fatty acid peroxyl radicals (PUFAOO.), thereby forming a stable 
lipid species (212). In this reaction, vitamin E is converted into a relatively unreactive free 
radical, because the unpaired electron is delocalized into the aromatic ring. In vitro evidence 
suggests that the Trolox radical then can be regenerated by ascorbate, resulting in the 
formation of an ascorbyl radical (212). However, the lipophylicity (log P) of Trolox (3.23) is 3-
fold less that that of vitamin E (9.60; (259)). Therefore, Trolox is probably less efficient in the 
detoxification of PUFAOO..  
 
Cell spreading is similar in control and patient cells and reduced by Trolox – Evidence in the 
literature shows that exogenous oxidants induce flattening and enlarge the size of human 
embryonic lung-derived diploid fibroblasts (294). Similarly, oxidants appear to be required for 
the integrin-mediated adhesion and spreading of NIH-3T3 fibroblasts (51). In the latter study, 
treatment with the antioxidant N-acetyl-cysteine (NAC) delayed cell attachment and reduced 
cell spreading. Although CI-deficient patient cells displayed 3-fold higher oxidant levels, we 
observed no difference in cell spreading between control and patient cells. In contrast, 
Trolox treatment lowered oxidant levels and decreased cell spreading for both control and 
patient fibroblasts. Evidence in the literature suggests that Trolox treatment diminishes cell 
proliferation (222), implying a link between Trolox, antioxidant levels, degree of cell 
spreading and cell cycle phase. In summary, our results suggest involvement of oxidants in 
the regulation of cell spreading in Trolox-treated, but not untreated, cells. This discrepancy 
might be caused by hitherto unknown non-oxidant (signaling) activity of Trolox, as described 
for vitamin E (232).  
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ABSTRACT 
  
Isolated deficiency of mitochondrial complex I (NADH:ubiquinone oxidoreductase) is 
associated with a wide variety of clinical phenotypes such as Leigh syndrome, 
encephalomyopathy and cardiomyopathy for which currently no treatment strategy is 
available. To gain insight into the cellular and molecular basis of this deficiency we combined 
live cell imaging and blue native gel electrophoresis followed by Western blotting and in-gel 
activity measurement to assess the relationship between cellular reactive oxygen species 
(ROS) level and complex I amount and activity in skin fibroblast cell lines of three healthy 
control subjects and six children with disease causing mutations in nuclear complex I genes. 
Compared to control cell lines, patient fibroblasts displayed a markedly higher ROS level and 
a variable decrease in complex I amount and in-gel activity. When normalized to one of the 
controls, the ratio between amount and activity was 1 for the two other controls and to a 
variable extent below 1 for the patients, indicating a defect in both expression and intrinsic 
catalytic activity of the complex. In all cell lines, control as well as patient, the ROS level was 
dramatically reduced following chronic treatment with the water-soluble vitamin E analogue 
Trolox, revealing its activity as an antioxidant. In each case, this effect of Trolox was 
accompanied by a substantial increase in the amount of complex I. But, whereas the ratio 
between the increase in amount and the increase in activity did not differ from 1 for the 
controls, it varied from 0.1 to 0.8 for the patients. Our data provide experimental evidence 
that chronic antioxidant treatment may be beneficial to those complex I deficient patients that 
display a relatively mild decrease in intrinsic activity of the complex.  
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INTRODUCTION 
 
The mitochondrial oxidative phosphorylation (OXPHOS) system consists of five multi-protein 
complexes (I-V) and is essential for the production of the vast majority of cellular ATP and 
various other mitochondrial activities including organelle fusion, Ca2+ uptake and metabolite 
exchange (24,168,246). Deficiency of the OXPHOS system is associated with a wide range 
of neuromuscular, cardiac, and endocrine disorders and, more recently, has also been 
implicated in age-related diseases and various forms of cancer (242,291,302). Although 
OXPHOS deficiency can occur at any given age, the onset is usually within the first 2 years 
of life. In 40% of the early-onset cases, the decrease in OXPHOS activity is associated with 
an isolated (25%) or combined (15%) deficiency of complex I (246). Human complex I 
(NADH:ubiquinone oxidoreductase; EC 1.6.5.3) consists of 7 mitochondrial DNA-encoded 
(mtDNA) and 38 nuclear DNA-encoded (nDNA) subunits (45). In the majority of early-onset 
patients, complex I deficiency (OMIM 252010) is caused by mutations in nuclear-encoded 
subunits (22,40,120,130). Additionally, disease causing mutations have been found in the 
nuclear-encoded complex I assembly factor B17.2L (185). Recent work has shown that 
disease causing mutations may reduce the assembly/stability of the complex I holocomplex, 
resulting in reduced rates of NADH oxidation (116,271). However, other evidence suggests 
that such mutations may also primarily decrease the intrinsic catalytic activity of the 
holocomplex (127). 
At present, the pathophysiological mechanisms linking defects in complex I genes to cellular 
dysfunction and disease are poorly understood. Mutations in nDNA-encoded complex I 
subunits can alter mitochondrial shape and induce aberrations in mitochondrial and cellular 
Ca2+ and ATP handling (139,281,283). Furthermore, it is widely accepted that normal 
OXPHOS function is accompanied by the generation of superoxide and derived reactive 
oxygen species (ROS) and evidence has been provided that the production of these 
oxidants is increased in isolated complex I deficiency (116,137,160,204,266,277).  
Other evidence suggests that these oxidants, if not adequately neutralized by the cell’s 
antioxidant mechanisms, can act as important mediators of oxidative injury. Thus, specific 
proteins of adult bovine submitochondrial particle complexes were found to exhibit a basal 
level of oxidative damage (52).  
It was proposed that steady leakage of electrons from the electron transport chain and 
ensuing formation of superoxide causes increasing damage to specific OXPHOS complexes 
ultimately leading to dysfunction of the OXPHOS system. More recently, in-vitro assays with 
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the flavoprotein fraction of bovine complex I revealed that NADH-induced superoxide 
production can cause specific oxidative modifications of the 51-kDa (NDUFV1) subunit, 
resulting in a decrease in electron transfer activity (47). In another study, using isolated 
perfused rat hearts following ischemia reperfusion, increases in complex I-mediated ROS 
production were found to be accompanied by thiol modifications of matrix-facing complex I 
subunits (266). Finally, recent work revealed that increases in mitochondrial ROS production 
can lead to accelerated degradation of newly synthesized mitochondrial proteins (17). It was 
suggested that consequent down-regulation of the most sensitive OXPHOS complexes may 
further increase mitochondrial superoxide production, which is compatible with the 
progressive nature of complex I deficiency.  
In accordance with the above findings, antioxidants were found to improve OXPHOS 
function in superoxide dismutase 2 null mice (102). Furthermore, chronic antioxidant 
treatment was shown to increase CV activity and ATP synthesis in cybrids containing the 
mtDNA of patients with the T8993G mtDNA mutation associated with impaired oxidative 
phosphorylation in NARP (neuropathy, ataxia and retinitis pigmentosa) and MILS (maternally 
inherited Leigh’s syndrome) (166). Likewise, chronic oral administration of high 
concentrations of vitamin E was found to prevent the loss of mitochondrial function and 
reduce protein and lipid oxidation in brain and liver of aging mice (180). These beneficial 
effects were paralleled by an increased lifespan, better neurological performance and higher 
exploratory activity. Regarding human complex I deficiency, patients have been found to 
respond differentially to antioxidant treatment (e.g. ref. 193).  
Together, these findings indicate that superoxide and derived ROS may play an important 
role in the pathogenesis of disorders associated with defects of the OXPHOS system. Here, 
we combined live cell imaging microscopy and blue native gel electrophoresis followed by 
Western blotting and in-gel activity measurement to assess the relationship between cellular 
ROS levels and complex I expression and activity in nuclear-inherited isolated complex I 
deficiency. The data presented provide evidence that the amount and cellular activity of 
complex I are under regulatory control of the cell’s oxidative balance. Furthermore, they 
show that cellular ROS levels are significantly increased in nuclear-inherited isolated 
complex I deficiency and that this increase is associated with a decrease in complex I 
amount. Most importantly, they demonstrate that apart from the amount also the intrinsic 
activity of complex I may be significantly decreased in these patients. Finally, our finding that 
chronic antioxidant treatment increases the amount of complex I provides an experimental 
basis for using antioxidants to treat complex I deficient patients. Here it should be noted, 
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however, that such treatment may only be beneficial to patients that have a predominant 
complex I expression rather than an intrinsic catalytic defect.  
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MATERIALS AND METHODS 
 
Patient skin fibroblasts – Fibroblasts were obtained from skin biopsies of three healthy 
subjects and six complex I deficient children in the age range of 0-5 years following informed 
parental consent and according to the relevant Institutional Review Boards (245). The 
deficiency was confirmed in both muscle tissue and cultured skin fibroblasts. Patients were 
screened for the presence of DNA alterations in each of the known nuclear-encoded 
complex I genes and found to carry mutations in either the NDUFS1 (#6173), NDUFS2 
(#5170), NDUFS7 (#5175), NDUFS8 (#6603) or NDUFV1 (#5866, #5171) gene (Table 1). 
All patients were shown to be negative with respect to mitochondrial DNA alterations 
associated with complex I deficiency. Fibroblasts were cultured in medium 199 with Earle’s 
salt supplemented with 10% (v/v) fetal calf serum, 100 IU/ml penicillin and 100 IU/ml 
streptomycin in a humidified atmosphere of 95% air and 5% CO2 at 37o C. Cell cycle 
analysis revealed no differences between the various cell lines (139). 
 
Table 1. Control and patient fibroblasts 
 
CELL LINE$
 
MUTATED 
SUBUNIT MUTATION
@ CLINICAL 
PHENOTYPE% REFERENCE 
    
CT1 (#5120) None None n.a. [283] 
CT2 (#5119) None None n.a. [139] 
CT3 (#5118) None None n.a. [139] 
P1 (#6603) NDUFS8 R94C L/LL [139] 
P2 (#6173) NDUFS1 R557X/D618N L/LD [283] 
P3 (#5170) NDUFS2 R228Q HCEM [155] 
P4 (#5866) NDUFV1 R59X/T423M MLM/LL [234] 
P5 (#5175) NDUFS7 V122M L/LL [268] 
P6 (#5171) NDUFV1 R59X/T423M MLM/LL [234] 
 
$CT and P indicate control and patient cell lines, respectively. Numbers indicate the designation of the cell lines 
within the Nijmegen Centre for Mitochondrial Disorders (NCMD). @Mutations are given at the protein level. 
%Clinical phenotype: L/LD, Leigh syndrome and leukodystrophy; L/LL, Leigh syndrome and Leigh-like syndrome; 
MLM, macrocephaly, leukodystrophy and myoclonic epilepsy; HCEM, hypertrophic cardiomyopathy and 
encephalomyopathy. Abbreviations: n.a., not appropriate.  
 
Quantification of cellular reactive oxygen species level – Cellular reactive oxygen species 
levels were quantified as described previously (137). Briefly, fibroblasts were incubated in 
HEPES-Tris medium (132 mM NaCl, 4.2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5.5 mM D-
glucose and 10 mM HEPES, pH 7.4) containing 1 µM 5-(and-6)-chloromethyl-2',7'-
dichlorodihydrofluorescein diacetate (CM-H2DCFDA; Molecular Probes) for 10 min at 37o C. 
During this period, the acetate groups are cleaved by intracellular esterases yielding 
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dichlorodihydrofluorescein (CM-H2DCF), which is then oxidized by oxidants to form highly 
fluorescent dichlorofluorescein (CM-DCF). After loading, the cells were thoroughly washed 
and transferred to the stage of an Oz confocal microscope (Noran Instruments, Middleton, 
WI, USA). Routinely, CM-DCF fluorescence was monitored during 200 s at a 10 s-interval. 
After background correction, the rate of CM-DCF fluorescence increase during the first 150 s 
was determined as a measure of the cellular ROS level. On each measuring day, the 
average rate obtained with #5120 control fibroblasts was set at 100%, to which all values 
were related. All recordings were carried out at minimal laser intensity using identical 
hardware settings. 
 
Blue native PAGE, Western blot analysis and in-gel activity measurement – Cultured skin 
fibroblasts were harvested by trypsinization, washed with ice-cold phosphate-buffered saline 
(PBS; Braun, Melsungen, Germany) and resuspended (approx. 2.106 cells) in 100 µl ice-cold 
PBS. For preparation of a mitochondria-enriched fraction, cells were incubated with 2 mg/ml 
digitonin (Biosciences Inc., La Jolla, CA, USA) in a final volume of 200 µl for 10 min on ice. 
Next, 1 ml ice-cold PBS was added followed by centrifugation (5 min; 10,000g; 4o C). 
Mitochondrial pellets were washed twice with 1 ml ice-cold PBS and stored overnight (-20o 
C). Pellets were solubilized in 100 µl ACBT buffer (Fluka, Steinheim, Germany) containing 
1.5 M aminocaproic acid and 75 mM Bis-Tris/HCl (pH 7.0). To extract mitochondrial protein 
complexes, 20 µl 10% (w/v) β-lauryl maltoside was added and the solution was incubated for 
10 min on ice. After centrifugation (30 min; 10,000g; 4o C), 10 µl of BN sample buffer (Biorad 
Laboratories, Hercules, CA, USA) was added to the supernatant. Blue native PAGE, 
Western blotting using a monoclonal antibody against the NDUFA9 (39-kDa) subunit of 
complex I (Molecular Probes) at a dilution of 1:1000, and in-gel activity measurement were 
performed as described previously (182). For quantitative analysis, gels were loaded with 
exactly 10 µg of mitochondrial protein. 
 
Data analysis – After Western blotting, luminescent signals were quantitatively analyzed by 
exposing illumination films to the blots for different periods of time (5-180 s). Films that 
displayed sub-maximal, non-saturated, signals were scanned using a G690 Imaging 
Densitometer (Biorad). From these scans, the integrated optical density of each band was 
determined and background corrected.  
 
 41
 
 
Chapter III 
The resulting numerical values were normalized to those obtained with control cells on the 
same blot. For quantitative analysis of in-gel activity, gels were scanned directly. Numerical 
results were visualized using Origin Pro 7.5 (OriginLab Corp., Northampton, MA, USA) and 
presented as the mean ± SEM. Statistical differences were determined using either a two-
population or one-population Student’s t-test (Bonferroni corrected).  
 
Chemicals – Culture materials were obtained from Invitrogen (Breda, The Netherlands), all 
other reagents were from Sigma-Aldrich (St. Louis, MO, USA). 
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RESULTS 
 
Cellular ROS levels are decreased by the water-soluble vitamin E derivative Trolox – To 
quantify cellular ROS levels, healthy control fibroblasts (#5120) were loaded with non-
fluorescent CM-H2DCFDA (5-(and-6)-chloromethyl-2',7'-dichlorodihydrofluorescein diacetate; 
1 µM) for 10 min, thoroughly washed to remove excess CM-H2DCFDA, and monitored for 
the conversion of intracellularly trapped CM-H2DCF into fluorescent CM-DCF. Video-imaging 
microscopy revealed that CM-DCF fluorescence was uniformly distributed throughout the 
cell (Fig. 1A) and increased linearly with time (Fig. 1B; open symbols). Importantly, this 
linearity indicates that that the amount of CM-H2DCF is not rate-limiting (137). Acute 
application of Trolox (6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid) 
instantaneously decreased the rate of CM-DCF formation by ~50% (Fig. 1B; filled symbols 
and inset).  
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Fig. 1: Effect of acute and chronic Trolox treatment on cellular ROS levels. (A) Fluorescent images of 
control fibroblasts (#5120) at the indicated time points after removal of non-hydrolyzed CM-H2DCFDA, showing 
the intracellular conversion of non-fluorescent CM-H2DCF into fluorescent CM-DCF. Fluorescence at time zero 
originates from CM-DCF produced during the loading period. The white circle represents the region of interest 
used for quantitative analysis. (B) Effect of acute application of Trolox on the rate of CM-H2DCF oxidation in 
control fibroblasts. Trolox (0.5 mM) was added at the indicated time point (black bar). Lines indicate a linear fit to 
the time course before (open symbols; slope=0.00181±3.4.10-5, R=0.99, p<0.0001) and after (filled symbols; 
slope=8.5.10-4±5.2.10-5, R=0.98, p<0.0001) addition of Trolox. The inset shows that Trolox decreased the rate of 
CM-DCF formation by 50% (N=5 cells). (C) Rate of CM-DCF formation in control cells cultured in the absence 
(open bar; N=19 cells) and presence (black bar; N=16 cells) of 0.5 mM Trolox for 96 h. (D) Rate of CM-DCF 
formation following acute application of 1 mM hydrogen peroxide (H2O2) to the untreated (open bar; N=19 cells) 
and Trolox-treated (black bar; N=16 cells) cells.  
 
 
 
 
 
 
 
 
 
 
 
We showed before that acute application of exogenous hydrogen peroxide (H2O2) readily 
increased the rate of CM-DCF formation in human skin fibroblasts (137). To assess the 
effect of Trolox on the H2O2-induced increase in the rate of CM-DCF formation, healthy 
control cells were cultured in the presence of Trolox (0.5 mM) for 96 h, loaded with CM-
H2DCF, and subsequently treated with 1 mM H2O2. In the absence of H2O2, the rate of CM-
DCF formation was significantly lower in Trolox-treated cells (Fig. 1C). Subsequent addition 
of H2O2 increased the rate of CM-DCF formation 23- and 12-fold in vehicle- and Trolox-
treated cells, respectively (Fig. 1D). These findings demonstrate the effectiveness of Trolox 
as an antioxidant in human skin fibroblasts.  
 
Trolox normalizes increased cellular ROS levels in complex I deficient patient fibroblasts – 
The rate of CM-DCF fluorescence increase did not significantly differ between the three 
control cell lines (100±2%, 100±11% and 125±13% for #5120 (412 cells), #5119, (48 cells), 
and #5118, (61 cells), respectively). In all patient cell lines analyzed, the rate of CM-DCF 
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formation was significantly higher than in each of the controls (Fig. 2; open bars). Chronic 
treatment with Trolox (0.5 mM) for 96 h significantly decreased the rate of CM-DCF 
formation in both healthy control cells and complex I deficient cells (filled bars). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2: Effect of Trolox on cellular ROS levels in human fibroblasts. Patient fibroblasts displayed cellular 
ROS levels that were significantly increased as compared to control (open bars) and efficiently reduced by 
chronic Trolox treatment (0.5 mM, 96 h; closed bars). Note that chronic Trolox also decreased the cellular ROS 
level in control cell line #5120. The data presented are from individual cells measured on 2-6 days. On each 
measuring day, the mean value obtained with vehicle-treated #5120 control cells was set at 100%, to which all 
values obtained that day including those obtained with the #5120 control cells themselves were related. Depicted 
are the mean ± SEM of 236 (#5120; bar a), 117 (#6603; bar b), 87 (#6173; bar c), 124 (#5170; bar d), 76 (#5175; 
bar e) and 78 (#5171; bar f) vehicle-treated cells and 159 (#5120), 31 (#6603), 56 (#6173), 62 (#5170), 47 
(#5175) and 32 (#5171) Trolox-treated cells. *Significantly different from the indicated vehicle-treated condition 
(p<0.05).  
 
Amount and activity of complex I are variably decreased in complex I deficient patient 
fibroblasts – To assess the cellular and molecular basis of the decrease in complex I activity 
in complex I deficient fibroblasts, we performed blue native PAGE followed by Western-blot 
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analysis (WB) and in-gel activity measurement (IGA) (271,272). First, the linearity of the IGA 
assay was determined in a dilution experiment using a mitochondrial fraction of control 
#5120 (Fig. 3A). For normalization, the integrated optical densities of the bands obtained 
with 10 µg of sample protein were set at 100%.  
 
Fig. 3: Effect of Trolox on complex I 
amount and activity in control 
fibroblasts. Mitochondrial protein 
complexes were separated by blue 
native PAGE followed by Western blot 
detection (WB) of complex I assemblies 
and measurement of their in-gel activity 
(IGA). Complex I assemblies were 
visualized using a monoclonal antibody 
against the 39-kDa (NDUFA9) subunit. 
(A) To determine the relationship 
between the signal on the Western blot 
(WB) and the signal on the activity gel 
(IGA), a dilution series was prepared 
from a mitochondria-enriched fraction of 
control cell line #5120. The amount of 
protein is indicated above each lane. (B) 
Chronic Trolox treatment (0.5 mM, 96 h) 
increased the expression and activity of 
fully assembled complex I in control 
fibroblasts. For quantitative comparison, 
gels were loaded with exactly 10 µg of 
sample protein. The blots and gels 
shown in this panel are representative 
of 8 (#5120), 1 (#5119) and 2 (#5118) 
independent experiments. Of note, each 
blot and each gel depicted in this figure 
is contrast optimized for better 
visualization of the effect of Trolox, 
which precludes direct comparison by eye. (C) Relationship between the integrated optical densities of the WB 
signals and corresponding IGA signals for the dilution series in panel A (grey symbols) and vehicle- (open 
symbols) and Trolox-treated (black symbols) control cell lines in panel B. For each blot and each gel, the 
integrated optical density obtained with 10 µg of sample protein of control cell line #5120 was set at 100%, to 
which all other values were related. The continuous line indicates a linear fit to the dilution data (R=0.998, 
slope=1.01±0.03, intercept=-2.32±2.81%, p<0.0001). The fitted line was statistically identical to the line y=x. 
Corresponding data points are connected by a dotted line.  
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Plotting of the normalized IGA values as a function of the normalized WB values revealed a 
linear relationship with a slope of 1.01±0.03 (R=0.998, p<0.0001) (Fig. 3C, grey symbols). In 
the remainder of this study, blue native PAGE gels were routinely loaded with exactly 10 µg 
of sample protein and the integrated optical densities obtained with mitochondria-enriched 
fractions of control and patient cell lines were expressed relative to that of control #5120 
present on the same gel. Importantly, exposure times of the blots were chosen such that 
saturation of the illumination films was prevented. Figure 3B (left lanes indicated with a 
minus sign) shows that all three control cell lines expressed only the fully assembled, 
catalytically active complex. Of note, the blots and gels depicted in this figure are contrast 
optimized for better visualization of the effect of Trolox and can therefore not be directly 
compared by eye. Densitometric analysis revealed a y=x relationship (slope of 0.92±0.06, 
R=0.98, p<0.0001) between IGA values and corresponding WB values, indicating that the 
activity per complex is the same for the control cell lines (Fig. 3C, open symbols).  
 
Analysis of the patient cell lines showed the presence of a catalytically active complex, the 
size of which did not differ from control (Fig. 4A, left lanes indicated with a minus sign). In 
three patient cell lines (#6173, #5171, #5866), also a second complex of lower molecular 
weight was observed. In contrast to the active complex, this subcomplex appeared inactive 
in the IGA assay. Figure 4B (open symbols) shows that in all patient cell lines the amount of 
active complex was significantly lower than control (#5120). Furthermore, this figure shows 
that in all patient cell lines the activity of this complex was less than expected on the basis of 
its amount (i.e. all data points were below the line obtained with the control cell lines).  
 
Trolox increases the amount and activity of complex I in control and patient fibroblasts – 
Chronic treatment with Trolox markedly increased complex I amount and activity in control 
fibroblasts (Fig. 3B, right lanes indicated with a plus sign). The regression line for the Trolox-
treated control cells (Fig. 3C, black symbols) had a slope of 0.86±0.11 (R=0.93, p<0.0001), 
which was not significantly different from the line of identity, indicating that the intrinsic 
activity of the wild-type complexes was not altered. Similarly to control fibroblasts, all patient 
fibroblasts displayed an increase in active complex and, for three cell lines (#6173, #5171, 
and #5866), also in partially assembled subcomplex (Fig. 4A, right lanes indicated with a 
plus sign). 
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Fig. 4: Effect of Trolox on complex I 
amount and activity in patient 
fibroblasts. (A) Chronic Trolox treatment 
(0.5 mM, 96 h) increased the amount (WB) 
and activity (IGA) of complex I in patient 
fibroblasts. Experimental details are as 
described in the caption of figure 3. The 
blots and gels shown in this panel are 
representative of 1 (#6173), 1 (#5170), 2 
(#6603), 2 (#5171), 3 (#5866) and 4 
(#5175) independent experiments, are 
contrast optimized for presentation 
purposes and can therefore not be directly 
compared by eye. (B) Relationship 
between the between the integrated 
optical densities of the WB signals and 
corresponding IGA signals, expressed as 
percentage of control #5120, for vehicle- 
(open symbols) and Trolox-treated (closed 
symbols) patient cell lines. All patient 
values are below the line of identity (dotted 
line) observed for the control cell lines (see, 
Fig. 3C). (C) Ratio between the Trolox-
induced increase in complex I activity and 
the corresponding increase in complex I 
amount (∆activity/∆amount) as a measure 
of the intrinsic catalytic activity of the 
complex in control cell lines (closed bars) 
and patient cell lines (open bars). The 
average ratio over all experiments 
obtained with control cell line #5120 was 
set at 100% (dotted line), to which all 
values including those of control cell line 
#5120 itself were related. The data 
presented are from 8 (#5120), 1 (#5119), 2 
(#5118), 1 (#6173), 2 (#6603), 1 (#5170), 
3 (#5866), 2 (#5171), and 4 (#5175) 
independent experiments. Error bars 
represent standard deviation (n>2 
experiments) or difference between 
duplicate values (n=2).  
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Control experiments with isolated heart mitochondria demonstrated that acute exposure to 
Trolox (0.5 mM, 15 min) did not alter the amount and/or in-gel activity of the active complex 
(not shown). The importance of this finding is that it makes it highly unlikely that Trolox 
exerts its effect by stabilizing the complex during β-lauryl maltoside extraction and 
subsequent native electrophoretic separation and/or increasing its in-gel activity. Calculation 
of the ratio between the Trolox-induced increase in complex I activity (∆activity) and the 
corresponding increase in complex I amount (∆amount) as a measure of the intrinsic 
catalytic activity of the complex, revealed that compared to control #5120, for which the 
average ratio was set at 100%, all patients displayed a catalytic defect, which was smallest 
in patient cell line #5175 and largest in patient cell line #6173 (Fig. 4C). Comparison of 
figures 4B and 4C furthermore shows that patient cell lines with the largest intrinsic catalytic 
defect (#6173, #6603, #5170) display the lowest amount of active complex, whereas patient 
cell lines with a higher intrinsic catalytic activity show also a higher expression of this 
complex.  
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DISCUSSION 
 
Pathogenic mutations in nuclear-encoded subunits of the first and largest complex of the 
OXPHOS system lead to a reduction in total cellular activity of this enzyme and are 
associated with a broad spectrum of clinical manifestations that occur directly after birth or 
during early childhood (242,246,291,302). Here we analyzed cultured skin fibroblasts of six 
children with disease causing mutations in nuclear complex I genes and show that they 
expressed a catalytically active complex, the size of which did not differ from control, but the 
amount and intrinsic catalytic activity of which were decreased to a variable degree. 
Extrapolation of the results obtained in this study to the whole population of isolated complex 
I deficient patients means that some patients may have primarily a relatively mild expression 
problem (#5175 of this study), other patients may have a relatively mild expression problem 
combined with a relatively mild intrinsic catalytic problem (#5171 and #5866 of this study), 
and again other patients may have a severe expression problem and a severe intrinsic 
catalytic problem (#6173, #6603 and #5170 of this study). By far the most important 
consequence of our findings is that therapeutic strategies aimed at improving the expression 
of complex I in nuclear-inherited complex I deficiency are only meaningful if the fully 
assembled complex has a substantial residual activity. Thus, the data obtained with Trolox 
may provide an experimental basis for antioxidant treatment of complex I deficient patients in 
which primarily the expression of complex I is reduced rather than the activity per complex. 
In this context, our results may explain the observation that complex I deficient patients 
respond differentially to antioxidant treatment (193). 
The present study demonstrates that blue native gel electrophoresis in combination with 
Western blotting and in-gel activity measurement is a powerful tool to establish the relative 
contribution of an expression defect and an intrinsic catalytic defect to the decrease in total 
cellular complex I activity in isolated human complex I deficiency. All three control cell lines 
harbored the fully assembled, catalytically active complex and a line of identity was observed 
between the amount and activity when expressed relative to the values obtained with control 
cell line #5120, indicating that the intrinsic catalytic activity was the same for the three 
control cell lines. Chronic Trolox treatment significantly increased both parameters and also 
in this case the obtained data points lie on the line of identity. The latter result indicates that 
Trolox does not alter the intrinsic catalytic activity of the complex and, thus, primarily acts by 
increasing its expression. All six patient cell lines expressed significantly less active complex 
than the control. Importantly, control experiments revealed that this reduction in amount of 
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active complex was not due to experimental procedures because Western blot analysis of 
mitochondrial enriched fractions confirmed that all six patient cell lines contained significantly 
less 39 kDa subunit than control (in press). In agreement with our results, the NDUFS1-
Q522K mutation has only recently been published to be associated with a marked reduction 
in complex I amount and activity and a significant increase in mitochondrial superoxide and 
derived ROS levels (116). Most importantly, these patient cells showed an enhanced 
mitochondrial susceptibility to ROS damage. Here, we made use of the ability of Trolox to 
increase the amount of active complex I to identify patient cell lines with an intrinsic catalytic 
defect and to determine the severity of this defect. In all but one case (#5175), chronic 
Trolox treatment increased the in-gel activity (expressed relative to the value obtained with 
control cell line #5120) with a smaller factor than the amount of active complex (expressed 
relative to the value obtained with control cell line #5120), clearly demonstrating the 
presence of a catalytic defect. Three of the patient cell lines displayed an additional, 
catalytically inactive complex, the size of which was markedly smaller than that of the active 
complex. Chronic Trolox treatment also increased the amount of this subcomplex. At present, 
it is not clear whether this subcomplex constitutes an assembly intermediate or a breakdown 
product.  
Thus far, only few studies have addressed the effect of pathogenic mutations on the intrinsic 
catalytic activity of complex I. Two of the mutations studied here, NDUFS2-R228Q (#5170) 
and NDUFS7-V122M (#5175), have been analyzed in great detail in the yeast Yarrowia 
lipolytica (3,127). In contrast to the present findings, these mutations did not reduce the 
complex I content in the yeast. Moreover, the NDUFS2-R228Q mutation did not alter the 
intrinsic catalytic activity of the complex, whereas in the case of the NDUFS7-V122M 
mutation the intrinsic catalytic activity was virtually halved. In another study, however, using 
the fungus Neurospora crassa, the latter mutation had no major effect on the catalytic 
activity of complex I (67). The same observation was reached with the NDUFV1-T423M 
mutation and the authors concluded that diminished formation and or stability of the complex 
are the major factors in cellular complex I deficiency. Both groups used essentially the same 
analysis methods, suggesting that the observed discrepancies are due to the use of different 
model systems. In the present study we used the original patient cell lines and yet again 
obtained other results with these mutations. Taken together, these findings stress the 
importance of the model system that is chosen for the analysis of pathogenic mutations. 
All five mutated subunits investigated here constitute part of the minimal form or “core” of the 
complex, which furthermore contains the nuclear-encoded NDUFV2 and NDUFS3 subunits 
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and the seven mitochondrial-encoded subunits (35). NADH is oxidized at the NDUFV1 
subunit and the high-energy electrons freed during this reaction are delivered via flavine 
mononucleotide, which is non-covalently bound to this subunit, onto a chain of iron-sulfur 
clusters, of which the last one, which is contained in the NDUFS7 subunit, donates the 
electrons to ubiquinone. Because all five subunits investigated in this study contain one or 
more iron-sulfur clusters, it remains to be established whether the variable decreases in 
intrinsic catalytic activity are due to a more or lesser efficient transport of electrons through 
the mutated forms of these subunits.  
Another intriguing question deals with the origin of the ROS. Are they derived from 
superoxide generated by abnormal functioning complexes or are they produced by other 
enzyme systems as a consequence of increased NADH and/or ambient oxygen levels (2). A 
further question that needs to be resolved is whether the decrease in complex I amount 
results from the use of imperfectly fitting building blocks, which might slow down the 
assembly process or accelerate the breakdown process, or whether it is a consequence of, 
for instance, ROS damage. The data obtained with Trolox suggest that at least part of the 
decrease in complex I amount can be explained by an increase in cellular ROS. 
 
Evidence that complex I expression may be controlled by the cell’s oxidative balance – 
Trolox is a phenolic antioxidant with a chromane structure similar to vitamin E but without the 
hydrophobic polyisoprenoid tail of the latter (259). Vitamin E exerts its antioxidant action 
through the phenolic hydroxyl group, which readily donates its hydrogen to, for instance, 
polyunsaturated fatty acid peroxyl radicals, thereby forming a stable lipid species (212). In 
this reaction, vitamin E is converted into a relatively unreactive free radical. In vitro evidence 
suggests that this vitamin E radical can be regenerated by ascorbate, resulting in the 
formation of an ascorbyl radical (212). Chronic Trolox treatment significantly increased the 
amount of fully assembled, catalytically active complex I in healthy control fibroblasts, which 
may suggest that total cellular complex I activity is controlled by the cell’s oxidative balance 
primarily through regulation of its amount. Using bovine heart submitochondrial particles, it 
was shown that the decrease in complex I activity induced by peroxidation of cardiolipin was 
reversed upon addition of exogenous cardiolipin, indicating an effect of peroxidized 
cardiolipin on the activity per complex rather than on its amount (195). It has been 
demonstrated that depletion of cardiolipin also causes an increase in ROS production (49), 
possibly leading to oxidative damage of complex I (17,47,52). Similarly, enhanced ROS 
generation was found to be associated with thiol modifications in several matrix-facing 
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subunits of complex I and a reduction in complex I-linked respiration (266). It remains to be 
established whether Trolox acts by directly reversing ROS damage in patient fibroblasts. 
Recent work has shown that overexpression of Mitofusin-2 (Mfn2) increased not only the 
complexity of the mitochondrial network but also the expression of complex I subunits, 
suggesting a link between mitochondrial morphology and complex I expression (203). An 
interesting option might therefore be that Trolox acts through a change in mitochondrial 
network morphology to alter complex I expression.  
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ABSTRACT 
  
Genetic defects in mitochondrial oxidative phosphorylation (OXPHOS) are most frequently 
observed in a small subgroup of the 38 nuclear-encoded subunits that comprise the first and 
largest complex (CI; NADH:ubiquinone oxidoreductase) of the electron transport chain. 
Malfunction of this enzyme is associated with a wide array of clinical symptoms and is 
established by measurement of the rotenone-sensitive oxidation of NADH in the presence of 
coenzyme Q1 in both a crude homogenate from skeletal muscle and a mitochondria-
enriched fraction from cultured skin fibroblasts. Using this diagnostic assay, we and others 
have found that mitochondria-enriched fractions from patient fibroblasts carrying a mutation 
in the NDUFS4 gene, display a significant residual CI activity, whereas, in sharp contrast, 
blue native analysis of these fractions followed by in-gel activity measurement reveals only 
an inactive subcomplex of ~830 kDa. To exclude that this discrepancy is due to a lack of 
sensitivity of the in-gel activity assay, we here treated NDUFS4 mutant fibroblasts with the 
water-soluble analog of vitamin E, Trolox, shown before to markedly increase the amount 
and activity of CI, and determined the activity of this complex in both assays. The data 
presented demonstrate that Trolox significantly increased the activity of CI in the diagnostic 
assay, without causing the appearance of any active complex on the blue native gel. Based 
on these findings it is concluded that the NDUFS4 subunit, which belongs to the so-called 
supernumerary subunits, primarily stabilizes the active complex. Moreover, our data provide 
experimental proof that the administration of analogues of vitamin E might be beneficial for 
the treatment of CI deficient patients with a mutation in the NDUFS4 gene. 
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INTRODUCTION 
 
Complex I (NADH:ubiquinone oxidoreductase; EC 1.6.5.3.) of the oxidative phosphorylation 
(OXPHOS) system catalyses the transfer of electrons from NADH to ubiquinone and uses 
part of their energy to translocate protons across the inner mitochondrial membrane (103). 
Mammalian complex I (CI) consists of 45 subunits together having a molecular weight of 
close to 1 MDa. Seven of these subunits are products of the mitochondrial genome, whereas 
the remainder is encoded by the nuclear genome (44,45,83). The core of the complex, which 
can perform all bioenergetic functions, comprises the seven subunits encoded by the 
mitochondrial genome and seven of the subunits encoded by the nuclear genome namely 
the NDUFS1 (75-kDa), NDUFV1 (51-kDa), NDUFS2 (49-kDa), NDUFS3 (30-kDa), NDUFV2 
(24-kDa), NDUFS7 (PSST) and NDUFS8 (TYKY) subunit (104). The remaining 31 subunits 
encoded by the nuclear genome are the so-called supernumerary subunits, involved in 
stabilization and/or assembly of the complex.  
Malfunction of CI (OMIM 252010) is the most frequently encountered defect of the OXPHOS 
system and is associated with a wide variety of clinical signs and symptoms (246). The 
enzymatic diagnosis involves the measurement of the rotenone-sensitive oxidation of NADH 
in the presence of coenzyme Q1 under Vmax conditions in both a crude homogenate of 
skeletal muscle and a mitochondria enriched fraction from cultured skin fibroblasts (245). As 
far as the nuclear genome is concerned, disease-causing mutations have been identified in 
all seven core subunits (20,21,22,156,157,234,268), three of the supernumerary subunits 
(NDUFS4, NDUFS6 and NDUFA1 (40,74,130), and the CI-specific chaperone B17.2L (185). 
Live cell imaging of cultured skin fibroblasts revealed that these mutations were associated 
with alterations in mitochondrial length and degree of branching (138), decreased Ca2+-
stimulated mitochondrial ATP production (281,283) and increased superoxide and derived 
reactive oxygen species (ROS) levels (116,277,277,278). Furthermore, blue native analysis 
of mitochondria-enriched fractions followed by Western blotting and in-gel activity 
measurement demonstrated that in all mutant fibroblasts the amount of active CI was 
significantly decreased (130,185,199,223,271,278,279). Using the same analysis technique, 
we recently showed that chronic treatment with the water-soluble analog of vitamin E, Trolox, 
caused a significant increase in the amount of fully assembled CI in both healthy control 
fibroblasts and fibroblasts of patients with a mutation in either the NDUFS1, NDUFS2, 
NDUFS8, NDUFS7, or NDUFV1gene (278). Importantly, in the patient cell lines, this 
increase in CI amount was paralleled by lower than proportional increase in CI activity, 
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indicating that the reduction in cellular CI activity is due to a decrease in both the amount 
and the intrinsic catalytic activity of the complex. 
Unexpectedly, blue native analysis of mitochondria-enriched preparations from cultured skin 
fibroblasts of patients with a mutation in the NDUFS4 gene revealed only an inactive 
subcomplex of ~830 kDa (223,271), whereas the same preparations displayed a marked 
rotenone-sensitive NADH:ubiquinone oxidoreductase activity in the spectrophotometric 
assay (40,223,271). To exclude that this discrepancy is due to a lack of sensitivity of the in-
gel activity measurement, we here treated NDUFS4 mutant fibroblasts with Trolox and 
determined the activity of CI in both assays. It was found that Trolox markedly increased the 
rotenone-sensitive NADH:ubiquinone oxidoreductase capacity, without causing, however, 
the appearance of any active complex on the blue native gel. Based on these results we 
conclude that the NDUFS4 subunit primarily stabilizes the active complex.  
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MATERIALS AND METHODS 
 
Patient skin fibroblasts – Fibroblasts were obtained from skin biopsies of a healthy subject 
and five CI deficient children in the age range of 0-5 years following informed parental 
consent and according to relevant institutional review boards (245). Pathogenic mutations 
were identified in the NDUFS4 subunit of patients #4608 (K158fs; (40)), #4827 (R106X; (40)), 
#5260 (R106X; (40) and #5737 (VPEEHI67/VEKSIstop; (unpublished)) and in the NDUFS8 
subunit of patient #6603 (R94C; (unpublished)). Fibroblasts were cultured in medium 199 
with Earle’s salt supplemented with 10% (v/v) fetal calf serum, 100 IU/ml penicillin and 100 
IU/ml streptomycin in a humidified atmosphere of 95% air and 5% CO2 at 37o C.  
 
Enzyme activity measurement – Rotenone-sensitive NADH:ubiquinone oxidoreductase 
activity was measured in a mitochondria-enriched fraction from cultured skin fibroblasts as 
described previously (245). Values are expressed as mU/mg protein.  
 
Blue native PAGE, Western blot analysis and in-gel activity measurement – Quantitative 
measurement of CI expression and in-gel activity was performed as described previously 
(277). Briefly, cultured skin fibroblasts were harvested by trypsinization, washed with ice-cold 
phosphate-buffered saline (PBS) and resuspended (approx. 2·106 cells) in 100 µl ice-cold 
PBS. For preparation of a mitochondria-enriched fraction, cells were incubated with 2 mg/ml 
digitonin (Biosciences Inc., La Jolla, CA, USA) in a final volume of 200 µl for 10 min on ice. 
Next, 1 ml ice-cold PBS was added followed by centrifugation (5 min; 10,000g; 4° C). 
Mitochondrial pellets were washed twice with 1 ml ice-cold PBS and stored overnight (-20° 
C). Pellets were solubilized in 100 µl ACBT buffer (Fluka, Steinheim, Germany) containing 
1.5 M aminocaproic acid and 75 mM Bis-Tris/HCl (pH 7.0). To extract mitochondrial protein 
complexes, 20 µl 10% (w/v) β-lauryl maltoside was added and the solution was incubated for 
10 min on ice. After centrifugation (30 min; 10,000g; 4° C), 10 µl of Blue native sample buffer 
(Biorad Laboratories, Hercules, CA, USA) was added to the supernatant. Polyacrylamide 
gels were loaded with exactly 20 µg of mitochondrial protein and subjected to blue native 
electrophoresis. In-gel activity measurement was performed as described previously (182). 
For quantitative analysis of the amount of complex, gels were blotted onto PVDF 
membranes and immunodecorated with primary antibodies against the NDUFA9 (39-kDa) 
subunit of CI and the 70-kDa subunit of CII (Molecular Probes) at a dilution of 1:1000 and 
1:10000, respectively. This step was followed by incubation with IRDye 800CW-conjugated 
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goat polyclonal anti-mouse IgG (Li-cor Biosciences, Lincoln, USA) at a dilution of 1:10000 as 
a secondary antibody. Finally, blots were dried and quantified using the Odyssey Infrared 
Imaging System (Li-cor Biosciences). 
  
Quantification of reactive oxygen species (ROS) levels – Quantitative determination of 
cellular ROS levels was performed as described previously (137,278,279). Briefly, fibroblasts, 
grown to ~70% confluence on glass coverslips (Ø 24 mm), were incubated in a HEPES-Tris 
medium (132 mM NaCl, 4.2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5.5 mM D-glucose and 10 
mM HEPES, pH 7.4) containing 1 µM CM-H2DCFDA for 10 min at 37 °C. After thorough 
washing to remove non-hydrolyzed CM-H2DCFDA, the increase in CM-DCF fluorescence 
intensity was monitored as a function of time using a video-rate confocal microscope (Oz; 
Noran Instruments, Middleton, WI, USA) attached to an inverted microscope (Nikon, Diaphot, 
Tokyo, Japan) equipped with a 40x oil immersion planapochromat objective (NA 1.4; Nikon). 
Cells were excited with light from an argon ion laser (488 nm; Omnichrome, Chino, CA, USA) 
and fluorescence emission light was directed by a 500 nm LP barrier filter (Chroma 
Technology Corp., Rockingham, VT, USA) onto a photomultiplier tube (Hamamatsu 
Photonics, Bridgewater, NJ, USA). After background correction, the rate of CM-DCF 
formation was calculated from the slope of the line fitted to the fluorescence intensity versus 
time. In each experiment, the average value obtained with healthy fibroblasts was set at 
100%, to which all other values were related. 
 
Quantification of cellular NAD(P)H levels – For measurement of cellular NAD(P)H levels, 
fibroblasts were seeded on glass coverslips (Ø 24 mm) and cultured to ~70% confluence. 
Immediately prior to measurement, fibroblasts were transferred to HEPES-Tris medium and 
coverslips were mounted in an incubation chamber placed on the stage of an inverted 
microscope (Axiovert 200 M, Carl Zeiss, Jena, Germany) equipped with a Zeiss 40x/1.3 NA 
Plan NeoFluar objective. The cells were excited at 360 nm using a monochromator 
(Polychrome IV, TILL Photonics, Gräfelfing, Germany). Fluorescence emission light was 
directed by a 415DCLP dichroic mirror (Omega Optical Inc., Brattleboro, VT, USA) through a 
510WB40 emission filter (Omega Optical Inc.) onto a CoolSNAP HQ monochrome CCD-
camera (Roper Scientific, Vianen, The Netherlands). The imaging setup was controlled by 
Metafluor 6.0 software (Molecular Devices Corporation, Downingtown, PA, USA). Routinely, 
10 fields of view were analyzed per coverslip using an image capturing time of 100 
milliseconds. The mean fluorescence intensity was determined in an intracellular region of 
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interest and, for purpose of background correction, an extracellular region of identical size. 
Quantitative image analysis was performed with Metamorph 6.1 (Molecular Devices 
Corporation). In each experiment, the average value obtained with healthy fibroblasts was 
set at 100%, to which all other values were related.  
 
Data analysis – Processing and analysis of fluorescence images and densitometer scans 
was performed with Image Pro Plus 5.1 (Media Cybernetics, San Diego, CA, USA) and 
Metamorph 6.1 (Molecular Devices Corporation). Numerical results were visualized using 
Origin Pro 7.5 (OriginLab Corp., Northampton, MA, USA) and are expressed as means ± SE. 
Statistical differences between average values were determined using an independent two-
population Student’s t-test (Bonferroni corrected). P-values <0.05 were considered 
significant.  
 
Chemicals – Culture materials were obtained from Invitrogen (Breda, The Netherlands). All 
other reagents were from Sigma-Aldrich (St. Louis, MO, USA). 
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RESULTS 
 
Previously, we and others have reported that mitochondria-enriched fractions from cultured 
skin fibroblasts of patients with a mutation in the NDUFS4 gene contained an inactive 
subcomplex of CI when separated on a blue native polyacrylamide (BNP) gel (223,271). 
Remarkably, however, the same fractions were found to exhibit a significant rotenone-
sensitive NADH:ubiquinone oxidoreductase capacity when analyzed in a spectrophotometric 
assay (40). A plausible explanation for these disparate results might be that the in-gel 
activity assay lacks sufficient sensitivity. To address this possibility, we here assessed the 
effect of chronic treatment of cultured skin fibroblasts with Trolox, a water-soluble analog of 
vitamin E, on the oxidative capacity of CI as determined in the above two assays. We 
showed before that this maneuver resulted in an increase in the amount and, as a 
consequence, in-gel activity of the fully assembled complex in cultured skin fibroblasts of 
both healthy control subjects and patients with a mutation in either the NDUFS1, NDUFS2, 
NDUFS7, NDUFS8 or NDUFV1 gene (278). Importantly, parallel measurements revealed a 
marked decrease in cellular ROS levels, suggesting a regulatory role for cellular oxidants in 
the expression of the fully assembled and catalytically active complex.  
 
Mutations in the NDUFS4 gene cause variable expression of an inactive CI subcomplex – 
Figure 1 confirms previous findings that fibroblasts of patients with a mutation in the 
NDUFS4 gene do not express detectable amounts of the fully assembled (upper panel) and 
catalytically active (middle panel) complex (band a). Instead, they expressed variable 
amounts (upper panel) of a catalytically inactive (middle panel) CI subcomplex with a 
molecular weight of approximately 830 kDa (band b). For comparison, we analyzed 
fibroblasts of a patient with a mutation in the NDUFS8 gene (lane 6). The latter cells clearly 
expressed the fully assembled and catalytically active complex, albeit at a very low level. 
Comparison of the band intensities obtained with this patient and the four NDUFS4 patients 
already indicates that the absence of any in-gel activity in the latter patients is not likely to be 
due to a lack of sensitivity of this assay. 
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Figure 1: Blue native gel analysis of CI amount and activity in a mitochondria-enriched fraction of 
NDUFS4 mutant fibroblasts - Mitochondria-enriched fractions from cultured skin fibroblasts of a healthy subject 
(lane 1), four patients with a mutation in the NDUFS4 gene (lanes 2-5) and one patient with a mutation in the 
NDUFS8 gene (lane 6) were subjected to blue native PAGE followed by either Western blotting using specific 
antibodies against the NDUFA9 subunit of CI (αCI-39; upper lane) and the 70-kDa subunit of CII (αCII-70; lower 
panel) or in-gel activity measurement (IGA; middle panel). All four NDUFS4 preparations showed a single 
inactive subcomplex of ~830 kDa. Note that the relatively small amount of fully assembled CI obtained with the 
mitochondria-enriched fraction of the NDUFS8 mutant fibroblasts gave a clear band on the activity gel (lane 6; 
upper and middle panel, respectively). Cell line codes are as follows: #5120 (healthy control fibroblasts), #4608 
(NDUFS4-K158fs), #4827 (NDUFS4-R106X), #5737 (NDUFS4-VPEEHI67/VEKSIstop), #5260 (NDUFS4-R106X) 
and #6603 (NDUFS8-R94C). a, fully assembled complex. b, inactive subcomplex.   
 
Trolox normalizes cellular ROS levels in fibroblasts of patients with a mutation in the 
NDUFS4 gene – Figure 2 (open bars) shows that cellular ROS levels were significantly 
increased in cultured fibroblasts of the NDUFS4 patients. In this respect, these patient 
fibroblasts do not differ from those with mutations in other nuclear CI genes (see also, 279). 
Moreover, in accordance with this result, we recently showed that fibroblasts of all five 
NDUFS4 patients at our disposal displayed a significantly increased cellular superoxide level 
(277). Here, we show that chronic treatment of these patient cell lines with 0.5 mM Trolox for 
72 h caused a marked reduction in cellular ROS levels (Fig. 2, closed bars). This finding 
clearly demonstrates the effectiveness of this antioxidant in fibroblasts of NDUFS4 patients. 
As reported before, Trolox also reduced these levels in healthy control cells (278). 
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Figure 2: Effect of chronic Trolox treatment on ROS levels in NDUFS4 mutant fibroblasts - Cultured skin 
fibroblasts, chronically treated with either vehicle (open bars) or 0.5 mM Trolox (closed bars) for 72 h, were 
loaded with CM-H2DCFDA, thoroughly washed to remove non-hydrolyzed dye, and monitored for the rate of 
fluorescence increase as a measure of intracellular ROS levels by video-rate confocal microscopy. In each 
experiment, the average rate of CM-DCF fluorescence increase obtained with vehicle-treated healthy control 
fibroblasts  (#5120) was set at 100%, to which all other values were related. Note that chronic Trolox-treatment 
also decreased intracellular ROS levels in healthy control cells. The values depicted are from three independent 
measurements performed on three different days and represent the mean ± SE of 412 (#5120), 160 (#5260) and 
98 (#5737) vehicle-treated cells and 236 (#5120), 160 (#5260) and 98 (#5737) Trolox-treated cells. a, 
significantly different from vehicle-treated healthy control fibroblasts. b, significantly different from corresponding 
vehicle-treated fibroblasts. Cell line codes are as follows: #5120 (healthy control fibroblasts), #5260 (NDUFS4-
R106X) and #5737 (NDUFS4-VPEEHI67/VEKSIstop). 
 
Trolox increases the rotenone-sensitive CI capacity in a mitochondria-enriched fraction 
without causing the appearance of an active complex on a BNP gel – Table 1 shows that the 
rotenone-sensitive NADH:oxidoreductase capacity as determined in a mitochondria-enriched 
fraction is still 20% of control in cultured skin fibroblasts of patients with a mutation in the 
NDUFS4 gene. Chronic treatment of these patient cells with Trolox significantly increased 
the rotenone-sensitive NADH:oxidoreductase capacity in this assay. In sharp contrast, 
however, this maneuver did not result in the appearance of an active form of CI on a blue 
native gel (Fig. 3). The experiment was performed in triplicate and in all three cases the 
amount of inactive subcomplex tended to be increased in the Trolox-treated cells. 
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Table 1. Effect of Trolox and rotenone on NADH:ubiquinone oxidoreductase activity and 
NAD(P)H fluorescence 
 
Cell line$
 
NADH:ubiquinone oxidoreductase 
activity (mU/mg)# 
 
NAD(P)H autofluorescence
(% of vehicle-treated healthy control)&
 VEHICLE TROLOX VEHICLE ROTENONE 
 
Healthy control 
(#5120) 
 
22±3 (n=5) 29±5 (n=5) 100±2 (n=143) 132±8b (n=22) 
 
NDUFS4-R106X 
(#5260) 
 
4.1±1a (n=5) 10±1b (n=5) 132±4a  (n=114) 179±24a,b (n=19) 
 
NDUFS4-
VPEEHI67/VEKSIstop 
(#5737) 
 
3.7±1a  (n=6) 7.1±1b (n=6) 127±6a  (n=70) 176±10a,b (n=22) 
$Numbers indicate the designation of the cell lines within the Nijmegen Centre for Mitochondrial Disorders 
(NCMD). #Values depicted are mean ± SEM expressed as mU/mg protein of vehicle- or Trolox-treated (0.5 mM, 
72h) cells; numbers between brackets represent the number of assays. &Values depicted are mean ± SEM 
expressed as percentage of vehicle-treated control; values between brackets represent the numbers of cells 
measured on at least 3 days. Statistics: asignificantly different from vehicle-treated healthy control, bsignificantly 
different from the corresponding vehicle-treated cells.   
 
Patient fibroblasts with a mutation in the NDUFS4 gene display a significant rotenone-
sensitive NADH-oxidizing activity – To support our conclusion that fibroblasts of NDUFS4 
patients express a functionally active CI, we determined the effect of short-term rotenone 
treatment (1 µM, 2 min) on cellular NAD(P)H autofluorescence. Table 1 shows that 
NAD(P)H autofluorescence was significantly increased in untreated patient fibroblasts. This 
result is in agreement with the reduction in rotenone-sensitive NADH:oxidoreductase 
capacity observed in the spectrophotometric assay. Most importantly, however, the table 
shows that short-term rotenone treatment resulted in a marked increase in NAD(P)H 
autofluorescence in the patient cell lines, indicating the presence of a substantial rotenone-
sensitive NADH-oxidizing capacity. Also in this case, NAD(P)H autofluorescence was 
significantly higher in patient fibroblasts as compared to healthy fibroblasts. The latter result 
may be indicative for an altered energy metabolism in response to the CI deficient condition. 
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Figure 3: Effect of chronic Trolox treatment on CI amount and activity in a mitochondria-enriched fraction 
of NDUFS4 mutant fibroblasts - Mitochondria-enriched fractions from cultured skin fibroblasts, chronically 
treated with either vehicle (-) or 0.5 mM Trolox (+) for 72 h, were subjected to blue native PAGE followed by 
either Western blotting (upper lanes) or in-gel activity measurement (lower lanes) as described in the caption to 
figure 1. Note that Trolox readily increases the amount and activity of the fully assembled complex (band a) in 
healthy control fibroblasts, without causing the appearance of any active band in NDUFS4 mutant fibroblasts. 
The data presented are representative for three individual experiments. Cell line codes are as follows: #5120 
(healthy control fibroblasts), #5260 (NDUFS4-R106X) and #5737 (NDUFS4-VPEEHI67/VEKSIstop). a, fully 
assembled active complex. b, inactive subcomplex.   
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DISCUSSION 
 
The major conclusion of this study is that patient fibroblasts with a mutation in the NDUFS4 
gene contain an active form of CI that is, however, relatively labile as compared to that of 
healthy control cells. Evidence comes from the current finding that chronic treatment of 
NDUFS4 mutant fibroblasts with the vitamin E analogue Trolox markedly increased the 
rotenone-sensitive NADH:ubiquinone oxidoreductase capacity in a mitochondria-enriched 
fraction without causing the appearance of any active complex on a blue native gel. 
Furthermore, in agreement with the above conclusion, live cell imaging of these fibroblasts 
revealed a substantial rotenone-sensitive NADH consumption. Importantly, our data provide 
experimental proof that the administration of vitamin E analogues may be beneficial for the 
treatment of CI deficient patients with a mutation in the NDUFS4 gene. 
The present study sheds light on puzzling data obtained by us and others regarding the 
presence of an active form of CI in patients with a mutation in the NDUFS4 gene. Previous 
studies by Papa and co-workers failed to detect any NDUFS4 protein on a whole cell 
Western blot from cultured skin fibroblasts of patients with a five base-pair duplication 
(K158fs; (273); #4608 of this study), leading to a 14-amino acid C-terminal extension, or a 
base-pair deletion (W97X; (39)) or non-sense mutation (W15X; (199)), both resulting in a 
premature stop codon (223). Intriguingly, in the case of the first two patients, mitochondria-
enriched fractions were found to display a significant rotenone-sensitive NADH:ubiquinone 
oxidoreductase capacity (40,223). However, contradictory results were obtained with the 
third patient. Our group found a low but detectable activity (40), whereas Papa and co-
workers found no activity at all (116,199,223). In addition to the fibroblast cell line with the 
five base-pair duplication (#4608), we here investigated fibroblast cell lines of three more 
patients with a mutation in the NDUFS4 gene. Two unrelated patients had the same non-
sense mutation (R106X; #4827 (39) and #5260 (40)), whereas the third patient carried a 
deletion/frameshift mutation (VPEEHI67/VEKSIstop; #5737 (unpublished)). All three 
mutations result in premature translation termination and, thus, to the probable absence of 
any NDUFS4 protein (see above). Whereas the original studies already showed that 
mitochondria-enriched fractions of patient cell lines #4827 (39) and #5260 (40) exhibited a 
significant rotenone-sensitive NADH:ubiquinone oxidoreductase capacity, we here show that 
this was also the case for the patient with the deletion/frameshift mutation (#5737). Moreover, 
we show that intact fibroblasts of these patients displayed a marked rotenone-sensitive 
NADH consumption. Taken together, these findings are in agreement with the idea that 
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patient fibroblasts with a mutation in the NDUFS4 gene fail to express this subunit but 
nevertheless display a significant CI activity.  
Blue native gel electrophoresis followed by Western blotting and in-gel activity measurement 
is a widely used tool in the analysis of CI deficiency. In agreement with previous results by 
us and others (223,271), we were unable to detect any active form of CI on a blue native gel 
of mitochondria-enriched preparations from NDUFS4 mutant fibroblasts. One can argue that 
the absence of any detectable in-gel activity is due to a lack of sensitivity of this analysis 
technique. However, we here show that doubling of the rotenone-sensitive 
NADH:ubiquinone oxidoreductase capacity by chronic treatment of patient cell lines #5260 
and #5737 with the vitamin E analogue Trolox did not result in the appearance of any active 
form of CI on the gel. Moreover, inclusion of a patient with a mutation in the NDUFS8 gene, 
revealed that even at very low levels of CI expression, in-gel activity was readily detectable 
(see also, 278). Taken together, these findings are compatible with the idea that patients 
with a mutation in the NDUFS4 gene contain an active form of CI that is, however, relatively 
labile and falls apart during blue native gel electrophoresis. This then suggests that the 
NDUFS4 subunit may function primarily to stabilize CI. Additional evidence for a stabilizing 
role comes from earlier findings that mutations in this subunit not only decrease the activity 
of CI but also that of CIII (39). Thus far, evidence has been provided that CI is stabilized by 
the complex-specific chaperones B17.2L (185) and NDUFAF1 (286).  
Using an antibody against the NDUFA9 subunit, all four preparations were found to contain 
an inactive subcomplex with a molecular weight of approximately 830 kDa. In agreement 
with this result, Scacco et al. reported the presence of an inactive subcomplex of similar size 
for two other NDUFS4 patients (223). At present, it is unclear whether the inactive form of CI, 
detected on a blue native gel from NDUFS4 mutant fibroblasts, represents an assembly 
intermediate or a breakdown product. Scacco et al. observed that this subcomplex was still 
associated with the inner mitochondrial membrane (223). Ugalde et al. showed that in 
addition to the NDUFA9 subunit this subcomplex contained the NDUFS3 and NDUFS5 
subunit (271), whereas Scacco et al. demonstrated the additional presence of the NDUFS7, 
NDUFB6 and NDUFA6 subunit (223). Intriguingly, an inactive subcomplex of similar size 
was observed on a blue native gel of patients with mutations in either the NDUFS1 gene 
(116,278), NDUFV1 gene (185,278) or NDUFS6 gene (130), but not the NDUFS2, NDUFS7 
or NDUFS8 gene (278). In-gel activity measurements revealed that NDUFS1 and NDUFV1 
mutant fibroblasts (278), but not NDUFS4 mutant fibroblasts (this study), contained in 
addition to the inactive subcomplex also the active complex. Importantly, Iuso et al. 
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demonstrated that the inactive subcomplex of patient fibroblasts with a mutation in the 
NDUFS1 gene showed no immunostaining with polyclonal antibodies directed against either 
the N-terminus or the phosphorylated C-terminus of the NDUFS4 subunit (116). Similarly, 
Ogilvie et al. observed that the inactive subcomplex of NDUFV1 mutant fibroblasts contained 
no NDUFS4 subunit (185). These results are compatible with the idea that the presence of 
the NDUFS4 subunit is required for the stabilization of the fully assembled complex. Ogilvie 
et al. showed that the assembly factor B17.2L associated with the subcomplex and not with 
the fully assembled complex in fibroblasts of patients with a mutation in either the NDUFV1 
gene or the NDUFS4 gene (185), indicating that the absence of the NDUFS4 subunit does 
not interfere with the binding of this assembly factor.  
Using an anti-NDUFS1 antibody, Papa and co-workers co-immunoprecipitated the NDUFV2 
subunit from NDUFS4 mutant fibroblasts, suggesting that both subunits are present in the 
same subcomplex (194). The fact that the NDUFS4 subunit is absent in the inactive 
subcomplex of NDUFV1 (185) and NDUFS1 (116) mutant fibroblasts (185), may suggest 
that it is associated with the NDUFS1/NDUFV2 containing subcomplex. Detailed analysis of 
the composition of this subcomplex will show whether it represents the NADH 
dehydrogenase module (284). According to our hypothesis, this module then associates with 
the remainder of the complex, containing at least the NDUFA9, NDUFS3, NDUFS5, 
NDUFS7, NDUFB6 and NDUFA6 subunit (223,271), in an NDUFS4-dependent manner.  
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ABSTRACT 
 
Deficiency of NADH:ubiquinone oxidoreductase or complex I (CI) is the most common cause 
of disorders of the oxidative phosphorylation system in humans. Using life cell imaging and 
blue-native electrophoresis we quantitatively compared superoxide production and CI 
amount and activity in cultured skin fibroblasts of 7 healthy control subjects and 21 children 
with inherited isolated CI deficiency. Thirteen children had a disease causing mutation in one 
of the nuclear-encoded CI subunits, whereas in the remainder the genetic cause of the 
disease is not yet established. Superoxide production was significantly increased in all but 
two of the patient cell lines. An inverse relationship with the amount and residual activity of 
CI was observed. In agreement with this finding, rotenone, a potent inhibitor of CI activity, 
dose-dependently increased superoxide production in healthy control cells. Also in this case 
an inverse relationship with the residual activity of CI was observed. In sharp contrast, 
however, rotenone did not decrease the amount of CI. The data presented show that 
superoxide production is increased in inherited CI deficiency and that this increase is 
primarily a consequence of the reduction in cellular CI activity and not of a further leakage of 
electrons from mutationally malformed complexes. 
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INTRODUCTION 
 
The mitochondrial oxidative phosphorylation (OXPHOS) system consists of five multiprotein 
complexes: NADH:ubiquinone oxidoreductase (complex I or CI), succinate-dehydrogenase-
ubiquinone oxidoreductase (CII), ubiquinol:cytochrome c oxidoreductase (CIII), cytochrome c 
oxidase (CIV) and F0F1-ATP synthase (CV) (246). The first four complexes (CI-CIV), 
together with two electron carriers (coenzyme Q10 and cytochrome c), constitute the 
respiratory chain that utilizes the energy of NADH and succinate, oxidized at CI and CII, 
respectively, to translocate protons from the mitochondrial matrix into the intermembrane 
space. The latter results in a negative potential (∆ψ) across the inner mitochondrial 
membrane, which is crucial for the maintenance of mitochondrial integrity (68).  
Dysfunction of the OXPHOS system is associated with a wide array of clinical 
manifestations, ranging from single lesions in Leber’s hereditary optic neuropathy or 
maternally-inherited nonsyndromic deafness to more widespread lesions including 
myopathies, encephalomyopathies, cardiopathies, or complex multisystem syndromes 
(62,242,274,302). Inherited disorders of the OXPHOS system are observed once every 
10,000 live births and the most frequently occurring enzymatic deficiency is found in CI (EC 
1.6.5.3), which catalyzes the transfer of electrons from NADH to coenzyme Q10. In human 
heart, this complex consists of at least 45 different subunits, together having a molecular 
weight close to 1 MDa (45). With the aid of differential extraction techniques, CI can be 
subdivided into a flavoprotein (FP), iron-sulfur protein (IP) and hydrophobic protein (HP) 
fraction. The catalytic core of the complex comprises 14 evolutionary conserved subunits, 2 
of which reside in the FP fraction, 5 in the IP fraction and 7 in the HP fraction (81). In 
humans, these core subunits are encoded by the nuclear NDUFV1 and NDUFV2 genes, the 
nuclear NDUFS1, NDUFS2, NDUFS3, NDUFS7 and NDUFS8 genes and the mitochondrial 
ND1-ND6 and ND4L genes. Thus far, disease causing mutations have been identified in all 
14 core subunits (246) and, as far as the nuclear genome is concerned, in genes encoding 
supernumerary subunits NDUFS4 (246) and NDUFS6 (130) and assembly factor B17.2L 
(185). 
The pathophysiological mechanisms linking defects in CI genes to cellular dysfunction and 
disease are only partially understood. To obtain insight into these mechanisms, we use skin 
fibroblasts of patients with inherited isolated CI deficiency and study the biogenesis of CI and 
cytopathological consequences of its dysfunction. Native gel electrophoresis and in-gel 
activity assays revealed that mutations in CI subunits (NDUFS2, NDUFS4, NDUFS7 and 
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NDUFS8) markedly reduced the expression of the fully assembled, catalytically active 
complex (271). At the cell physiological level, this reduction was found to be associated with 
disturbed mitochondrial Ca2+ handling and ensuing ATP production during hormone 
stimulation (281,283).  
Partial inhibition of CI activity by chronic treatment with rotenone significantly increased 
superoxide production and lipid peroxidation in cultured skin fibroblasts of healthy control 
subjects (136). Similarly, the formation of superoxide-derived hydroxyl radicals and lipid 
peroxidation products was found to be increased in fibroblasts of three patients with a 
reduced rotenone-sensitive NADH-cytochrome c reductase (CI and CIII) activity (160). At 
pathological concentrations, superoxide and its derived reactive oxygen species are 
hazardous for the cell. At physiological concentrations, however, they play important roles in 
a variety of signaling processes (65). In fibroblasts of healthy control subjects we observed 
that the increase in superoxide production induced by chronic rotenone treatment was 
associated with a marked increase in mitochondrial length and degree of branching (136). 
Moreover, in patient fibroblasts we found that this parameter was linearly correlated with the 
residual activity of CI (139). Based on these observations, we hypothesized that the increase 
in mitochondrial length and degree of branching constitutes an adaptive response to protect 
against the consequences of CI deficiency. In agreement with this idea, recent evidence 
showed that a more complex mitochondrial network, induced by manipulating mitochondrial 
fusion, protected against radical-induced mitochondrial depolarization possibly by allowing a 
more effective sharing of intra-mitochondrial antioxidants (181). 
To obtain a quantitative understanding of the relationship between CI deficiency and 
superoxide production, we here compare superoxide production and amount and activity of 
CI between cultured skin fibroblasts of 7 healthy control subjects and 21 children with 
inherited isolated CI deficiency. The data presented show that superoxide production is 
increased in virtually all patient cell lines but to a variable degree and that the extent of 
increase is inversely proportional to the amount and activity of CI. 
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MATERIALS AND METHODS 
 
Patient skin fibroblasts – Fibroblasts were derived from skin biopsies of 21 CI deficient 
children in the age range of 0-5 years, 2 age-matched healthy children and 5 healthy adults 
following informed consent and according to relevant institutional review boards (Smeitink et 
al., 2001). Table 1 shows that superoxide production did not differ between adult (CT1-CT5) 
and age-matched (CT6 and CT7) control cell lines. For 11 patients the biochemical analysis, 
mutations and clinical phenotypes were described before (P1, P2 (234); P4-P6 (155); P7, 
P8, P9, P11 (40); P12 (268)), for 3 patients (P3, P10, P13) these data are not yet reported, 
whereas for the remaining 8 patients the mutations are hitherto unknown (P14-P21 (271). 
Fibroblasts were cultured in medium 199 with Earle’s salt supplemented with 10% (v/v) fetal 
calf serum, 100 IU/ml penicillin and 100 IU/ml streptomycin in a humidified atmosphere of 
95% air and 5% CO2 at 37o C. Measurements were performed within 5 passages after the 
start of the culture. The passage number at the onset of the culture is given in Table 1.  
 
Enzyme activity measurements – Activities of NADH:ubiquinone oxidoreductase (CI; EC: 
1.6.5.3) and cytochrome c oxidase (CIV; EC: 1.9.3.1) were determined in a mitochondrial 
enriched fraction of cultured fibroblasts as described previously (119). The activity of CI was 
normalized against that of CIV and expressed as percentage of lowest control (110 mU/U 
CIV (119,245).  
 
Quantification of superoxide production – Fibroblasts were incubated in HEPES-Tris medium 
(132 mM NaCl, 4.2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5.5 mM D-glucose and 10 mM 
HEPES, pH 7.4), containing 10 µM hydroethidine (HEt; Molecular Probes, Leiden, The 
Netherlands) for 10 minutes at 37o C. HEt is a lipophylic, uncharged compound that readily 
enters the cell where it reacts with superoxide to form two positively charged products, 2-
hydroxyethidium and ethidium, both of which emit red fluorescence (304). The reaction was 
stopped by thorough washing of the cells with PBS to remove excess HEt. For quantitative 
analysis of the fluorescent HEt oxidation products, coverslips were mounted in an incubation 
chamber placed on the stage of an inverted microscope (Axiovert 200 M, Carl Zeiss, Jena, 
Germany) equipped with a Zeiss 40x/1.3 NA fluor objective. The cells were excited at 490 
nm using a monochromator (Polychrome IV, TILL Photonics, Gräfelfing, Germany). 
Fluorescence emission light was directed by a 525DRLP dichroic mirror (Omega Optical 
Inc., Brattleboro, VT, USA) through a 565ALP emission filter (Omega) onto a CoolSNAP HQ 
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monochrome CCD-camera (Roper Scientific, Vianen, The Netherlands). Hardware was 
controlled with Metafluor 6.0 software (Universal Imaging Corporation, Downingtown, PA, 
USA). Routinely, 10 fields of view were analyzed per coverslip using an acquisition time of 
100 milliseconds. 
 
Blue-native electrophoresis – Cultured skin fibroblasts were harvested by trypsinization, 
washed, and resuspended (approx. 2·106 cells) in 100 µl ice-cold PBS. For isolation of 
mitochondria, cells were incubated with 2 mg/ml digitonin (Biosciences Inc., La Jolla, CA, 
USA) in a final volume of 200 µl for 10 min on ice. Next, 1 ml ice-cold PBS was added 
followed by centrifugation (5 min; 10,000g; 4° C). Mitochondrial pellets were washed twice 
with 1 ml ice-cold PBS and stored overnight (-20° C). Pellets were solubilized in 100 µl 
ACBT buffer (Fluka, Steinheim, Germany) containing 1.5 M aminocaproic acid and 75 mM 
Bis-Tris/HCl (pH 7.0). To extract mitochondrial protein complexes, 20 µl 10% (w/v) β-lauryl 
maltoside was added and the solution was incubated for 10 min on ice. After centrifugation 
(30 min; 10,000g; 4° C), 10 µl of blue native sample buffer (Biorad Laboratories, Hercules, 
CA, USA) was added to the supernatant. Blue native PAGE (BNP) and Western blotting, 
using monoclonal antibodies with human reactivity against the NDUFA9 (39-kDa) subunit of 
CI (Molecular Probes) and the 70-kDa subunit of CII (Molecular probes) at a dilution of 
1:1000, was performed as described previously (182). For quantitative analysis gels were 
loaded with exactly 40 µg of mitochondrial protein. After Western blotting, luminescent 
signals were quantitatively analyzed by exposing illumination films to the blots for different 
periods of time (5-180 s). Non-saturating films were scanned using a G690 Imaging 
Densitometer (Biorad). From these scans, the integrated optical density of each band was 
determined and background corrected. The resulting numerical values were normalized to 
those obtained with control cells on the same blot.  
 
Data analysis – Processing and analysis of fluorescence images and densitometer scans 
was performed with Image Pro Plus 5.1 (Media Cybernetics, San Diego, CA, USA) and 
Metamorph 6.1 (Universal Imaging Corporation, Downingtown, PA, USA). Numerical results 
were visualized using Origin Pro 7.5 (OriginLab Corp., Northampton, MA, USA) and 
presented as the mean ± SEM. During linear regression analysis, the degree of bivariate 
correlation between sets of data was analyzed by calculating Pearson’s R. This parameter 
expresses the proportion of total variation that is explained by the regression. If R is ±1, the 
total variation in the fit can be explained in terms of the regression curve (58). For R>0 the 
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correlation is positive, for R<0 the correlation is negative. Statistical differences between 
average values were determined using an independent two-population Student’s t-test 
(Bonferroni corrected). P-values <0.05 were considered significant.  
 
Chemicals – Culture materials were obtained from Invitrogen (Breda, The Netherlands), all 
other reagents were from Sigma-Aldrich (St. Louis, MO, USA). 
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RESULTS 
 
Quantitative measurement of superoxide production in human skin fibroblasts -  In this study 
we assessed superoxide production in living cells using hydroethidine (HEt), a membrane-
permeable derivative of ethidium bromide that is specifically converted by superoxide into 2-
hydroxyethidium and ethidium (304,305). Both products are positively charged and emit red 
fluorescence when excited at 490 nm. Human skin fibroblasts were grown to ~70% 
confluence, treated with 10 µM HEt for 10 min and thoroughly washed to remove non-
oxidized HEt. Next, video-imaging microscopy was used for subcellular quantification of the 
fluorescent oxidation products formed during the 10-min incubation period with HEt. We 
reported before that the fluorescent products formed during the oxidation of HEt 
accumulated predominantly in the nucleus and a widespread network of tubular structures 
located within the cytosol (136). Figure 1A shows that in both compartments the average 
fluorescence intensity remained stable for at least 200 s, indicating that non-oxidized HEt 
was effectively removed during the washing step and that its oxidation products did not 
translocate during the ensuing recording period. In addition, this result demonstrates that the 
fluorescent products were resistant to photo-bleaching. Figure 1A furthermore shows that 
dissipation of the mitochondrial membrane potential by FCCP (p-trifluoromethoxy carbonyl 
cyanide phenyl hydrazone) leads to a rapid decrease in tubular fluorescence. This result 
identifies the tubular structures as active mitochondria in which positively charged HEt 
oxidation products are retained in a membrane potential-dependent manner. The FCCP-
induced decrease in tubular fluorescence was mirrored by a concomitant increase in nuclear 
fluorescence, indicating the translocation of HEt oxidation products from the mitochondria to 
the nucleus. The results obtained with FCCP demonstrate that HEt oxidation products can 
easily pass mitochondrial membranes. Therefore, it is not possible to make a statement 
concerning the exact site(s) of primary HEt oxidation.   
 
Chronic rotenone treatment dose-dependently increases superoxide production in human 
skin fibroblasts – To mimic the pathological condition of chronic CI deficiency, control 
fibroblasts were cultured in the presence of different concentrations of rotenone for 72 h 
(136). At concentrations at or below 1 nM, this specific inhibitor of CI had no effect on the 
amount of fluorescent oxidation products that accumulated in the mitochondrial compartment 
during the 10-min incubation period with HEt (Fig. 1B, closed circles). At higher 
concentrations, however, the drug dose-dependently increased this amount. For the entire 
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range of rotenone concentrations, mitochondrial and nuclear fluorescence were linearly 
correlated (R=0.98, p<0.0001). The increase in mitochondrial fluorescence was virtually 
mirrored by the decrease in residual CI activity (Fig. 1B, open circles), determined in a 
mitochondrial enriched fraction of cultured fibroblasts (data from 136). Half-maximal 
concentrations were 110 nM and 20 nM, respectively. These findings show that in human 
skin fibroblasts drug-induced reduction in CI activity is accompanied by increasing 
production of cellular superoxide.   
Figure 1: Effect of chronic rotenone 
treatment on subcellular superoxide 
production, residual CI activity and 
cellular CI expression in human skin 
fibroblasts – (A) FCCP-induced 
redistribution of HEt oxidation products 
between mitochondria and nucleus. 
Fibroblasts (CT1, Table 1) were incubated 
with 10 µM hydroethidine (HEt) for 10 min at 
37o C, thoroughly washed and visualized 
using fluorescence microscopy. FCCP was 
added at the designated time (arrow). 
Fluorescence signals were obtained from the 
indicated compartments and background 
corrected. (B) Dose-dependency of the effect 
of chronic rotenone treatment on the 
accumulation of HEt oxidation products in the 
indicated compartment (closed symbols) and 
the residual CI activity (open symbols). 
Fibroblasts were pretreated with vehicle or 
the indicated concentration of rotenone 
(closed symbols) for 72 h. Residual CI 
activity (right y-axis) and fluorescence 
intensity (left y-axis) are expressed as 
percentage of vehicle-treated control. The 
data presented are the average ± SEM of 3 
independent measurements. (C) Effect of 
chronic rotenone treatment on CI expression. 
Mitochondrial enriched fractions of vehicle- 
and rotenone-treated cells were subjected to 
blue-native electrophoresis and Western blotting. Intensities of the CI and CII bands were determined by 
densitometry and expressed as percentage of vehicle-treated control. The data presented are the average ± 
SEM of three independent experiments. *, significantly different from control.   
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Superoxide production is increased in patient skin fibroblasts – The amount of fluorescent 
oxidation products that accumulated in the mitochondrial compartment during the 10-min 
incubation with HEt did not significantly differ between fibroblasts of seven healthy control 
subjects (Table 1, CT1-CT7). Compared to control, however, mitochondrial accumulation of 
HEt oxidation products was significantly increased in all but two patient cell lines (P2 and 
P20). As for healthy control fibroblasts treated with various concentrations of rotenone, 
mitochondrial and nuclear fluorescence were linearly correlated for the whole cohort of 
patient cell lines (R=0.98, p<0.0001). Linear regression analysis furthermore revealed an 
inverse relationship between mitochondrial fluorescence and residual CI activity (Fig. 2, R=-
0.83, p<0.0001). In all patient cell lines, acute treatment with rotenone (during the 10-min 
incubation with HEt) caused a further increase in fluorescence intensity (Table 1), 
demonstrating the presence of a functional rotenone binding site. 
 
Figure 2: Inverse relationship between 
superoxide production and residual CI 
activity in fibroblasts of patients with 
isolated CI deficiency – Measurement of 
superoxide production was performed as 
described in the caption to figure 1. 
Fluorescence intensity in the indicated 
compartment (left y-axis) is expressed as 
percentage of vehicle-treated control (CT). 
Mean values, number of cells analyzed 
and patient numbers are depicted in 
Table 1. Closed and open symbols 
represent patient cell lines with a known 
(13 patients) and hitherto unknown (8 
patients) mutation, respectively. Linear 
regression analysis reveals an inverse 
correlation between superoxide 
production and residual CI activity for the 
whole cohort of patient cell lines. 
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Fully assembled CI is decreased in patient skin fibroblasts – We reported before that the 
amount of fully assembled CI is markedly reduced in patient fibroblasts with mutations in 
nuclear-encoded CI subunits (271). Figure 3, depicts assembly data of a subgroup of 13 
patients, 7 with a known mutation (Table 1, P1-P5 and P12-P13) and 6 with a hitherto 
unknown mutation (Table 1, P14-P16 and P18-P20), and shows that in all but one (P20) of 
them the amount of fully assembled CI was lower than control. Except cell line P20, the cell 
lines of the other patients with a hitherto unknown mutation (open symbols) did not differ 
from those with a known mutation (closed symbols). Linear regression analysis revealed that 
for the whole cohort of patient cell lines this parameter was negatively related to the cell’s 
superoxide production (R=-0.62, p=0.017) and positively to its residual CI activity (R=0.89, 
p<0.0001).  
 
Figure 3: Inverse relationship 
between superoxide production 
and fully assembled CI in 
fibroblasts of patients with 
isolated CI deficiency – (A) 
Measurement of superoxide 
production and analysis of fully 
assembled CI was performed as 
described in the caption to figure 1. 
Linear regression analysis reveals an 
inverse correlation between 
superoxide production and amount of 
fully assembled CI for 7 patient cell 
lines with a known (black symbols) 
and 6 with a hitherto unknown (open 
symbols) mutation. Assembly data 
are from 9 (CT), 1 (P5, P14, P15, 
P16, P18, P19, P20), 2 (P1, P2, P3, 
P13), 4 (P4) and 5 (P12) 
independent experiments. Mean 
fluorescence intensities (± SEM), 
number of cells analyzed and patient 
numbers are depicted in Table 1. (B) 
The Western blot shows the 
decrease in fully assembled CI in one 
of the patient cells lines (P4). 
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   Table 1. Characteristics of the complex I deficient fibroblast cell lines 
$Numbers indicate the designation of the cell lines within the re for Mitochondrial Disorders ( nd P indi  patient  cell lines, respectively LA: 
Fatal infantile lactic acidosis, HCEM: Hypertrophic cardiomyopathy and encephalomyopathy, L/LD: Leigh syndrome and leukodystrophy, L/LL: Leigh syndrome and Leigh-like syndrome, 
MLM: Macrocephaly, leukodystrophy and myoclonic epilepsy, UEM: Unspecified encephalomyopathy. 
Nijmegen Cent NCMD). CT a cate control and . %FI
CELL LINE 
$
AFFECTED SUBUNIT 
AND MUTATION 
CLINICAL 
PHENOTYPE% PN
φ CI ACTIVITY# SUPEROXIDE PRODUCTION&
       Nucleus Mitochondria
       Untreated Rotenone Untreated Rotenone
CT1 (#5120)† None n.a. 17 113 100±1 (n=526) 237±3 (n=516) 100±1 172±2 
CT2 (#5119)† None   n.a. 17 105 112±3 (n=89) 237±8 (n=89) 102±2 156±6 
CT3 (#5118)† None   n.a. 21 103 102±2 (n=126) 229±5 (n=127) 98±3 172±5 
CT4 (#4996)† None n.a. 10* n.d. 112±3 (n=95) 283±9 (n=89) 100±3 182±5 
CT5 (#223V)† None n.a. 8* 103 112±3 (n=94) 286±6 (n=90) 99±3 175±4 
CT6 (#5117)‡ None     n.a. 15 223 99±4 (n=92)  n.d. 92±3 n.d.
CT7 (#5503)‡ None       n.a. 6* 20 91±3 (n=98) n.d. 93±3 n.d.
         
P1    (#5171) NDUFV1-R59X/T423M MLM/LL 18 73 214±7 (n=84) 405±10 (n=87) 186±6 281±7 
P2    (#5866)  NDUFV1-R59X/T423M MLM/LL 18 64 117±4 (n=61) 244±8 (n=58) 110±3 167±8 
P3    (#6173) NDUFS1-D618N/R577X L/LD 13* 31 207±5 (n=83) 271±8 (n=71) 176±4 205±6 
P4    (#5170) NDUFS2-R228Q  HCEM 11* 39 229±7 (n=66) 331±12 (n=69) 205±8 243±8 
P5    (#5067) NDUFS2-P229Q   HCEM 10* 36 331±10 (n=100) 528±15 (n=108) 264±9 356±10 
P6    (#4605) NDUFS2-S413P   HCEM 15* 40 301±21 (n=40) 378±18 (n=47) 218±13 272±17 
P7    (#5077) NDUFS4-W97X   L/LL 23* 59 170±4 (n=100) 339±11 (n=95) 142±4 232±7 
P8    (#5260) NDUFS4-R106X  L/LL 12 36 196±10 (n=64) 293±8 (n=68) 174±8 203±6 
P9    (#4827) NDUFS4-R106X  L/LL 7* 58 238±8 (n=93) 398±13 (n=93) 196±6 252±9 
P10  (#5737) NDUFS4-VPEEHI67/VEKSIstop   L/LL 12 53 150±4 (n=92) 228±6 (n=87) 131±4 166±5 
P11  (#4608) NDUFS4-K158fs L/LL 18*  75 207±5 (n=106) 377±9 (n=102) 195±6 270±7 
P12  (#5175) NDUFS7-V122M   L/LL 15* 68 161±4 (n=94) 322±9 (n=95) 151±5 209±7 
P13  (#6603) NDUFS8-R94C    L/LL 15 18 263±7 (n=147) 375±9 (n=126) 222±7 267±8 
P14  (#4611)    Unknown L/LL 14* 36 395±27 (n=36) 581±39 (n=40) 265±19 330±28 
P15  (#5409)     Unknown FILA 6* 45 265±11 (n=104) 425±22 (n=65) 262±11 340±20 
P16  (#4591)     Unknown UEM 6* 39 189±5 (n=79) 377±15 (n=60) 159±5 234±11 
P17  (#4554)     Unknown L/LL 6* 42 175±6 (n=60) 286±11 (n=56) 145±7 192±8 
P18  (#4590)     Unknown FILA 8* 60 217±7 (n=70) 401±13 (n=59) 204±7 315±15 
P19  (#4606)     Unknown FILA 6* 63 197±9 (n=42) 302±18 (n=45) 177±10 237±14 
P20  (#4617)    Unknown L/LL 3* 85 127±5 (n=56) 217±6 (n=64) 131±6 174±7 
P21  (#5671)     Unknown L/LL 10 27 331±18 (n=38) 402±22 (n=34) 241±15 282±16 
φPN: passage number, an asterisk indicates the passage number after arrival at the 
Nijmegen Center for Mitochondrial disorders. #CI activity is measured in mitochondrial enriched fractions and expressed as % of lowest control. &Mean (± SEM) nuclear and mitochondrial 
fluorescence intensity expressed as percentage of untreated control #5120 (CT1) for the number of cells between brackets. Each cell line was tested on at least two days. Values in bold 
are below lowest control value (CI activity) or significantly different (p<0.05) from highest control (CT2; superoxide production). Rotenone indicates acute treatment with 100 nM rotenone 
during HEt incubation (10 min, 37o C). †Cells obtained from healthy adults. ‡Cells obtained from healthy age-matched children. Abbreviations: n.a., not appropriate, n.d., not determined. 
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DISCUSSION 
 
Malfunction of the OXPHOS system causes a wide range of neuromuscular, cardiac, and 
endocrine disorders and, more recently, has also been implicated in age-related diseases 
and various forms of cancer (242,291,302). In 40% of the cases of inherited OXPHOS 
disease, the deficiency is associated with an isolated (25%) or combined (15%) defect in CI, 
the first and largest complex of the OXPHOS system (246). At present, however, there is 
only very limited information about the cytopathological effects of a disease-causing 
reduction in CI activity. Here, we quantitatively assessed superoxide production in living skin 
fibroblasts of a large cohort of 21 patients with inherited isolated CI deficiency, 13 of which 
with an established mutation in one of the nuclear-encoded CI subunits and 8 in which the 
disease causing mutation still has to be established, and demonstrate an inverse 
relationship with the amount and residual activity of this complex. The same inverse 
relationship between superoxide production and CI activity was observed in healthy 
fibroblasts treated with increasing concentrations of rotenone. In the latter case, however, 
the amount of CI increased rather than decreased, indicating that superoxide production can 
increase in the absence of any mutated subunit. Based on the latter finding we conclude that 
in isolated human CI deficiency increased cellular superoxide production is primarily a 
consequence of decreased cellular CI activity and not of further electron leakage due to the 
presence of a mutated subunit. 
In healthy cells, the vast majority (>90%) of reactive oxygen species is produced as a 
consequence of oxidative phosphorylation (14,68). Work on isolated mitochondrial 
preparations suggests that CI and CIII are the major contributors to superoxide production 
(14,68,209). In addition, CII can contribute by donating electrons to CI via reverse electron 
flow (144,154). As far as CI is concerned, single electron reduction of oxygen can occur at 
the FMN binding site, the iron-sulfur clusters and/or the Q-binding site 
(12,47,84,144,154,186). Evidence has been provided that superoxide produced by CI is 
released into the mitochondrial matrix, whereas that produced by CIII enters both the matrix 
and the intermembrane space (144). It has been demonstrated that reverse electron flow 
can be effectively blocked by CI inhibitors, leading to a reduction in superoxide production. 
Here we show that in all patient cell lines acute addition of rotenone increased rather than 
decreased the amount of HEt oxidation products, indicating that reverse electron flow is not 
the underlying cause of increased superoxide production in isolated human CI deficiency. 
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In addition to CI and CIII, the tricarboxylic acid cycle enzyme α-ketoglutarate dehydrogenase 
can produce significant amounts of superoxide, especially under conditions that the NADH 
level in the matrix is increased (267). Moreover, other organelles, such as the endoplasmic 
reticulum and peroxisomes, may contribute to the production of superoxide (reviewed in 
(108)). Because HEt oxidation products can easily pass mitochondrial membranes, the 
method used here to measure cellular superoxide production does not allow to make a 
statement concerning the exact site(s) of HEt oxidation. Whatever the case may be, the 
present finding that chronic rotenone decreased the activity of CI and increased the amount 
of HEt oxidation products with virtually the same potency indicates that a reduction in 
mitochondrial CI activity is associated with an increase in cellular superoxide production. 
Importantly, because the inhibitor increased rather than decreased the amount of fully 
assembled CI, it can be concluded that the observed increase in superoxide production was 
not due to misassembly of the complex. 
The same correlation between cellular superoxide production and residual CI activity was 
observed within our large cohort of CI deficient patient cell lines. In this case, however, the 
decrease in residual activity was quantitatively correlated with a decrease in fully assembled 
CI. In agreement with our results, the NDUFS1-Q522K mutation has recently been published 
to be associated with a marked reduction in CI amount and activity and a significant increase 
in mitochondrial superoxide and derived reactive oxygen species (116). Taken together, the 
present findings may provide first insight into the mechanism of superoxide production in 
human CI deficiency in that they suggest that decreasing numbers of active complexes 
produce increasing amounts of superoxide not because of the presence of a mutated 
subunit but as a consequence of a decrease in cellular CI activity. The alternative 
explanation that increasing numbers of partially assembled complexes are responsible for 
the observed increase in superoxide production is not supported by the present finding that 
chronic rotenone treatment increased rather than decreased the amount of fully assembled 
CI. 
The cohort of patient cell lines used in this study included 13 cell lines with established 
mutations in nuclear-encoded CI subunits (see, Table 1). All 6 affected subunits are 
predicted to constitute part of the matrix-protruding arm of CI (35). Five of them, NDUFV1 
(51-kDa), NDUFS1 (75-kDa), NDUFS2 (49-kDa), NDUFS7 (PSST) and NDUFS8 (TYKY), 
belong to the group of 14 “central” subunits that are sufficient to perform all bioenergetic 
functions of the complex, whereas the remaining one, NDUFS4 (AQDQ), belongs to the 
large group of accessory proteins. Except for NDUFS2, the other 4 “central” subunits carry 
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iron-sulfur clusters responsible for electron transport from NDUFV1, where NADH is 
oxidized, to NDUFS7, where ubiquinone is reduced. With the exception of 5 cell lines 
carrying a mutation in NDUFS4 (see below), 7 (P6 was not analyzed) of the other 8 cell lines 
displayed a fully assembled complex on a blue-native gel, the amount of which was 
decreased to a variable degree. Irrespective of the affected subunit, this amount was 
quantitatively correlated with the cell’s residual CI activity, indicating that primarily the 
expression of the fully assembled complex rather than its intrinsic activity is altered. This 
conclusion is in agreement with our proposal that the increase in cellular superoxide 
production is not a direct consequence of further electron leakage from complexes 
containing a mutated subunit, but of the decrease in cellular CI activity. Importantly, when 
patient cells were acutely treated with rotenone, superoxide production was even further 
increased. This indicates that the rotenone-binding site, which is part of the coenzyme Q 
binding site (14,188), is intact in these CI deficient patients. 
Regarding the 5 patient cell lines carrying a mutation in NDUFS4, they all showed a 
rotenone-sensitive CI activity when assayed in a mitochondrial enriched fraction. On the 
other hand, all 5 cell lines showed only an inactive subcomplex on a blue-native gel. 
Previous work revealed the complete absence of any NDUFS4 in patient cell lines P7 and 
P11 (223). Together with the information that the other 3 patient cell lines of the present 
study are either homozygous for a premature stop codon (P8 and P9) or carry a premature 
stop codon and a frameshift (P10) and, therefore, do not express any NDUFS4, these 
results indicate that in the absence of NDUFS4 catalytically active complexes are formed, 
which are, however, relatively unstable and fall apart during blue-native electrophoresis. 
Analysis of the amount of subcomplex as a measure of the amount of catalytically active 
complex in the mitochondrial enriched fraction then shows that also in these patient cells 
significantly less catalytically active complex is formed. In contrast to the present study, it 
was recently shown that fibroblasts of a patient with a nonsense mutation in the first exon of 
the NDUFS4 gene (NDUFS4-W15X) produced normal amounts of superoxide (116). 
Similarly, the present study demonstrates that superoxide production can be increased (P1) 
or normal (P2) in fibroblasts of two CI deficient brothers. Both cell lines showed the same 
decrease in fully assembled CI and residual CI activity. These findings indicate that 
additional factors, such as detoxifying enzymes and nonenzymatic antioxidants, play a role 
in determining net superoxide production. The involvement of such factors is also evident 
from the large variation in superoxide production at any given residual CI activity (Fig. 2).   
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Finally, our results partially agree with earlier work showing that superoxide generation was 
increased in 5 CI deficient patients, whereas it was not different from control or even lower 
than control in another 8 patients (204). Moreover, in contrast to the latter study, we found 
no correlation between the rate of superoxide production and clinical phenotype (depicted in 
Table 1). At present, we have no explanation for these discrepancies. Major differences are 
the use of living fibroblasts rather than frozen-thawed mitochondria and the use of HEt 
instead of the chemiluminescent probe lucigenin. Both studies had only two clinical 
phenotypes in common, Leigh’s Disease (LD) and Fatal Infantile Lactic Acidosis (FILA). In 
both studies, the LD patients showed an increase in superoxide, whereas the two FILA 
patients investigated in the earlier study showed either a decrease or no change in 
superoxide production. Our study did not include patients displaying Cardiomyopathy with 
Cataracts and Hepatomegaly with Renal Tubulopathy, shown in the previous study to have a 
decreased and normal rate of superoxide production, respectively. Obviously, evaluation of 
these latter clinical phenotypes is required to be confident that under all conditions of 
isolated CI deficiency a decrease in CI activity is associated with an increase in cellular 
superoxide production.      
In accordance with the above findings, antioxidants were found to improve OXPHOS 
function in superoxide dismutase 2 null mice (102) and fibroblasts of Parkinson’s disease 
patients (296). Furthermore, chronic antioxidant treatment was shown to increase CV activity 
and ATP synthesis in cybrids containing the mtDNA of patients with the T8993G mtDNA 
mutation associated with impaired oxidative phosphorylation in NARP (neuropathy, ataxia 
and retinitis pigmentosa) and MILS (maternally inherited Leigh’s syndrome) (166). Likewise, 
chronic oral administration of high concentrations of vitamin E was found to prevent the loss 
of mitochondrial function and reduce protein and lipid oxidation in brain and liver of aging 
mice (180). These beneficial effects were paralleled by an increased lifespan, better 
neurological performance and higher exploratory activity. Regarding human CI deficiency, 
patients have been found to respond differentially to antioxidant treatment (e.g. ref. (193)). 
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ABSTRACT 
 
Isolated complex I (CI) deficiency is the most common enzymatic defect of the oxidative 
phosphorylation system, causing a wide range of clinical phenotypes including 
macrocephaly with progressive leukodystrophy, nonspecific encephalopathy, 
(cardio)myopathy, liver disease, Leigh and Leigh-like syndrome, Leber hereditary optic 
neuropathy, and some forms of Parkinson disease. We previously reported that cellular 
superoxide levels are significantly increased in skin fibroblasts of all but one patient (P2 of 
this study) with nuclear-inherited CI deficiency. Using video-rate confocal microscopy of cells 
loaded with CM-H2DCF, we here show a similar increase in superoxide-derived ROS levels. 
Despite this increase, video microscopy of cells expressing mitochondria-targeted reduction-
oxidation sensitive GFP1 (roGFP1) showed no detectable changes in mitochondrial and/or 
cytosolic thiol redox state. Similarly, neither the glutathione (GSH) nor the glutathione 
disulfide (GSSG) content differed significantly between patient and healthy control cells. 
Finally, video-rate confocal microscopy of cells loaded with C11-BODIPY581/591 demonstrated 
that the extent of lipid peroxidation, regarded as a readout of oxidant damage, was not 
altered in patient fibroblasts. Our results indicate that cultured skin fibroblasts of patients with 
nuclear-inherited CI deficiency maintain a normal thiol redox state, which is the predominant 
determinant of the cellular redox environment, even though oxidant levels are markedly 
increased.  
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INTRODUCTION 
 
NADH:ubiquinone oxidoreductase or complex I (CI; EC 1.6.5.3.) is the main entry point of 
metabolic electrons into the mitochondrial electron transport system and its proper function 
is essential for the adequate production of ATP. In accordance with this function, defects in 
CI have been found to be associated with a wide range of human disorders including early 
onset, fatal clinical phenotypes such as Leigh and Leigh-like syndrome, encephalomyopathy 
and cardiomyopathy (246). In mammals, CI consists of 38 nuclear-encoded and seven 
mitochondrial-encoded subunits, together having a molecular weight close to 1 MDa 
(44,45,83). As far as the nuclear genome is concerned, disease-causing mutations have 
been identified in nine CI subunits (22,40,120,130) and the CI assembly factor B17.2L (185). 
At the cellular level, these disease-causing mutations were demonstrated to decrease the 
amount of catalytically active complex (271). Live cell studies revealed that this decrease in 
CI-specific NADH-oxidizing capacity was associated with disturbed Ca2+ and ATP handling 
(281,283), increased superoxide and derived reactive oxygen species (ROS) levels 
(116,279) and altered mitochondrial morphology (139). In healthy cells, the large majority of 
ROS are generated as a consequence of oxidative phosphorylation (OXPHOS; (14,68)). It 
has been suggested that these OXPHOS-derived ROS play an important signaling role in 
gearing mitochondrial and cellular physiology for one another (80,153). Of pathological 
relevance, however, disturbances of the delicate balance between ROS production and ROS 
scavenging, may lead to cellular injury and, eventually, death (117,209). 
The cell’s redox environment is crucial in integrating multiple metabolic, signaling and 
transcriptional processes (153). Because of the high intracellular glutathione concentration 
(1-11 mM), the glutathione disulfide (GSSG)-glutathione (GSH) redox couple is widely 
believed to be the major determinant of the cell’s redox environment (226,297). Glutathione 
can either directly react with ROS or function as electron donor for peroxidases (111,297).  
In the present study, we used organelle-targeted variants of the reduction-oxidation sensitive 
green fluorescent protein 1 (roGFP1; (64,95)) to determine the subcellular redox 
environment in cultured skin fibroblasts of 10 patients with disease-causing mutations in 
nuclear-encoded CI subunits. It was found that, despite a large increase in superoxide and 
derived ROS levels, the subcellular redox environment was not detectably altered as 
compared to healthy control. In agreement with this result, no significant changes in total 
cellular glutathione content, GSSG to GSH ratio and extent of lipid peroxidation were 
observed.  
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MATERIALS AND METHODS 
 
Patient skin fibroblasts – Fibroblasts were derived from skin biopsies of ten patients in the 
age range of 0-5 years (P1-P10) in whom an isolated NADH:ubiquinone oxidoreductase 
deficiency was confirmed in both muscle tissue and cultured fibroblasts and ten healthy 
subjects, five adults (CT1-CT5) and five age-matched children (CT6-CT10), following 
informed consent and according to relevant institutional review boards (table 1). Genetic 
characterization revealed disease-causing mutations in either the NDUFV1 (P1-P2), 
NDUFS1 (P3), NDUFS2 (P4-P5), NDUFS4 (P6-P8), NDUFS7 (P9) or NDUFS8 (P10) gene 
of CI (120). None of the patients harbored mitochondrial DNA mutations previously 
associated with CI deficiency. Measurement of CI activity was performed in a mitochondrial-
enriched fraction obtained from cultured skin fibroblasts as described previously (245). The 
activity of the complex was normalized against that of complex IV (cytochrome c oxidase), 
which was measured in the same fraction, and expressed as percentage of lowest control 
(110 mU/U cytochrome c oxidase; (245)). Fibroblasts were cultured in medium 199 with 
Earle’s salt supplemented with 10% (v/v) fetal calf serum, 100 IU/ml penicillin and 100 IU/ml 
streptomycin in a humidified atmosphere of 95% air and 5% CO2 at 37o C. Initial passage 
numbers are given in Verkaart et al., 2007 and measurements were performed within 5 
passages. Cell cycle analysis revealed no differences between the various cell lines (139). 
 
Quantification of intracellular superoxide and derived reactive oxygen species levels – 
Quantitative determination of intracellular superoxide and derived reactive oxygen species 
levels was performed as described previously (136,137,277). For measurement of 
intracellular superoxide levels, fibroblasts, grown to ~70% confluence on glass coverslips (Ø 
24 mm), were incubated in a HEPES-Tris medium (132 mM NaCl, 4.2 mM KCl, 1 mM CaCl2, 
1 mM MgCl2, 5.5 mM D-glucose and 10 mM HEPES, pH 7.4) containing 10 µM 
hydroethydine (HEt) for exactly 10 min at 37° C. During this period, non-fluorescent HEt 
enters the cell, where it is converted by superoxide into two fluorescent products, 2-
hydroxyethidium and ethidium. After thorough washing to remove non-oxidized HEt, 
coverslips were mounted in an incubation chamber placed on the stage of an inverted 
microscope (Axiovert 200 M, Carl Zeiss, Jena, Germany) equipped with a Zeiss 40x/1.3 NA 
Plan NeoFluar objective. Cells were excited at 490 nm using a monochromator (Polychrome 
IV, TILL Photonics, Gräfelfing, Germany) and fluorescence emission light was directed by a 
525DRLP dichroic mirror (Omega Optical Inc., Brattleboro, VT, USA) through a 565ALP 
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emission filter (Omega Optical Inc.) onto a CoolSNAP HQ monochrome CCD-camera 
(Roper Scientific, Vianen, The Netherlands). The imaging setup was controlled by Metafluor 
6.0 software (Molecular Devices Corporation, Downingtown, PA, USA). Routinely, 10 fields 
of view were analyzed per coverslip using an image capturing time of 100 milliseconds. The 
mean fluorescence intensity was determined in an intracellular region of interest and, for 
purpose of background correction, an extracellular region of identical size. Quantitative 
image analysis was performed with Metamorph 6.0 (Molecular Devices Corporation). In each 
experiment, the average value obtained with healthy fibroblasts was set at 100%, to which 
all other values were related.  
For measurement of superoxide-derived reactive oxygen species levels, fibroblasts were 
incubated in HEPES-Tris medium containing 1 µM CM-H2DCFDA for 10 min at 37° C. 
During this period, the acetate groups are cleaved off by the action of intracellular esterases 
yielding CM-H2DCF (dichlorodihydrofluorescein), which is successively oxidized by cytosolic 
reactive oxygen species to form the highly fluorescent product CM-DCF 
(dichlorofluorescein). After thorough washing to remove non-hydrolyzed CM-H2DCFDA, the 
increase in CM-DCF fluorescence intensity was monitored as a function of time using a 
video-rate confocal microscope (Oz; Noran Instruments, Middleton, WI, USA) attached to an 
inverted microscope (Nikon, Diaphot, Tokyo, Japan) equipped with a 40x oil immersion 
planapochromat objective (NA 1.4; Nikon). Cells were excited with light from an argon ion 
laser (488 nm; Omnichrome, Chino, CA, USA) and fluorescence emission light was directed 
by a 500 nm LP barrier filter (Chroma Technology Corp., Rockingham, VT, USA) onto a 
photomultiplier tube (Hamamatsu Photonics, Bridgewater, NJ, USA). After background 
correction, the rate of CM-DCF formation was calculated from the slope of the line fitted to 
the fluorescence intensity versus time. In each experiment, the average value obtained with 
healthy fibroblasts was set at 100%, to which all other values were related.  
 
Quantification of cytosolic and mitochondrial redox environment – cDNA’s encoding roGFP1 
and mitochondria-targeted roGFP1 (64,95) were digested from a pEGFP-N1 vector 
backbone using EcoRI/XbaI and NdeI/XbaI, respectively. For expression in mammalian 
cells, inserts were ligated into a modified pFastbacdual transfer vector (283). RoGFP1 
contains surface-exposed cysteine residues that form disulfide bonds upon oxidation. The 
fluorescence emission ratio after excitation at 400 nm (oxidized state) and 480 nm (reduced 
state) is a measure of the ambient redox potential (64,95). The ratiometric nature of the 
probe minimizes errors associated with changes in roGFP1 expression, photobleaching, and 
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variations in cell thickness (95). Moreover, roGFP1 fluorescence is pH-independent, which 
allows comparison of roGFP1 signals between the cytosolic and the more alkaline 
mitochondrial matrix (68). For roGFP1 experiments, human skin fibroblasts, seeded on glass 
coverslips (Ø 24 mm), were cultured for 24 h, infected with the appropriate baculovirus and 
cultured for another 48h. Immediately prior to fluorescence measurement, fibroblasts were 
transferred to HEPES-Tris medium and coverslips were mounted in an incubation chamber 
placed on the stage of an inverted microscope (Axiovert 200 M) equipped with a Zeiss 
40x/1.3 NA Plan NeoFluar objective. RoGFP1 was alternately excited at 400 and 480 nm 
using a monochromator (Polychrome IV) and fluorescence emission light was directed by a 
525DRLP dichroic mirror (Omega Optical Inc.) through a 535DF25 emission filter (Omega 
Optical Inc.) onto a CoolSNAP HQ monochrome CCD-camera (Roper Scientific). The 
imaging setup was controlled by Metafluor 6.0 software (Molecular Devices Corporation). 
Image capturing time was 300 ms and a pair of images was taken every 5 s. For each 
wavelength, the mean fluorescence intensity was monitored in an intracellular region and, for 
purpose of background correction, an extracellular region of identical size. After equilibration 
for 3 min, cells were successively treated with 1 mM hydrogen peroxide (100% oxidation) 
and 10 mM dithiothreitol (100% reduction). Quantitative image analysis was performed with 
Metamorph 6.0 (Molecular Devices Corporation). After background correction, the 
fluorescence emission ratio after excitation at 400 nm (oxidized state) and 480 nm (reduced 
state) was calculated and the percentage oxidation was determined. In each experiment, the 
average value with healthy fibroblasts was set at 100%, to which all other values were 
related.  
 
Determination of GSSG and GSH content in whole-cell homogenates – Preparation of cell 
extracts and measurement of cellular GSSG and GSH content were performed using HPLC 
as described previously (57). Values were expressed as nmol/mg protein. 
 
Quantification of the intracellular extent of lipid peroxidation – Measurement of the extent of 
lipid peroxidation was performed as described before (136). Briefly, fibroblasts, grown to 
~70% confluence on glass coverslips, were incubated in HEPES-Tris medium containing 4 
µM C11-BODIPY581/591 for 30 min at 37° C. Upon oxidation, the red emitting form of the dye 
(595 nm) is converted into a green emitting form (520 nm). After thorough washing, cells 
were excited at 488 nm and images were collected using the video-rate confocal 
microscope. Green and red fluorescence emission signals were separated using a 560 DM 
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dichroic mirror and appropriate band-pass filters (535D20 and 580LP; Chroma). In each 
experiment, the average of the green to red fluorescence emission ratios obtained with 
healthy fibroblasts was set at 100%, to which all other values were related.  
 
Data analysis and statistics – Numerical results were visualized using Origin Pro 7.5 
(Originlabs, Northampton, MA, USA) and are expressed as means ± SE. Statistical 
differences between average values were determined using an independent two-population 
Student’s t-test (Bonferroni corrected). P-values <0.05 were considered significant.  
 
Chemicals – Culture materials and fluorescent probes were obtained from Invitrogen (Breda, 
The Netherlands). All other reagents were from Sigma (Zwijndrecht, the Netherlands). 
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RESULTS  
 
Reactive oxygen species (ROS) levels are increased in patient fibroblasts – Mitochondria-
enriched fractions from cultured skin fibroblasts of patients with isolated CI deficiency exhibit 
a rotenone-sensitive NADH oxidizing capacity that is lower than the lowest control value 
(table 1). In intact fibroblasts, this condition was found to be associated with a significant 
increase in superoxide level in all but two cell lines of 21 patients (277). To assess whether 
this increase is accompanied by a change in cytosolic ROS levels, we here loaded 
fibroblasts with CM-H2DCF and monitored its oxidation into fluorescent CM-DCF (137). 
Table 1 shows that all but one (P2) of the 10 patient cell lines tested exhibited a significant 
increase in CM-DCF fluorescence. The table furthermore shows that the fibroblasts of P2 
also failed to show an increase in superoxide level.   
 
Total cellular glutathione content and GSSG to GSH ratio are not detectably altered in 
patient fibroblasts – The results obtained thus far show that the large majority of patient cell 
lines exhibit a marked increase in oxidant levels. This leaves the question of whether and, if 
so, how the cellular redox environment is altered under these conditions. An important 
determinant of this environment is the glutathione disulfide (GSSG)-glutathione (GSH) 
couple (226). To establish whether CI deficiency affects the redox state of this couple, we 
determined the GSSG and GSH content in whole-cell homogenates of 10 healthy and 10 
patient fibroblast cell lines using high performance liquid chromatography. Table 2 shows 
that on average neither the GSSG nor GSH content differed significantly between fibroblasts 
of healthy subjects and CI deficient patients (p values of 0.55 and 0.36, respectively). 
Similarly, the ratio of GSSG to GSH did not differ between healthy and patient fibroblasts 
(p=0.12). Together, these results indicate that the overall cellular redox environment is not 
detectably altered in human CI deficiency.    
  
Quantification of the subcellular redox environment using organelle-targeted roGFP1 – To 
investigate the possibility that the subcellular redox environment is altered in human CI 
deficiency, healthy and patient fibroblasts were transduced with recombinant baculoviruses 
containing the DNA for roGFP1, a redox-sensitive variant of the green fluorescent protein. 
RoGFP1 was either expressed in the cytosol (cyt-roGFP1) or targeted exclusively to the 
mitochondrial matrix (mit-roGFP1). Both proteins were readily expressed and their 
fluorescence was determined in circular regions marked ‘m’ (Fig. 1A) and ‘c’ (Fig. 1B), 
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respectively. For background correction, a cell-free region of similar size (marked ‘b’) was 
used. Figure 1C depicts the ratio of the fluorescence emission intensities after excitation at 
400 and 480 nm as a function of time.  
 
Figure 1: Quantitative measurement subcellular thiol redox state with roGFP1 - (A) Fluorescence image 
(400 nm excitation) of a typical control fibroblast (table 1; CT1) transiently expressing the mitochondria-targeted 
variant of roGFP1 (mit-roGFP1). (B) The same following transient expression of the cytosolic variant of roGFP1 
(cyt-roGFP1). Circles represent regions of interest used for quantitative measurement of thiol redox state in 
mitochondrial matrix (m), cytosolic compartment (c) and cell free region used for background correction (b). (C) 
Quantification of the subcellular thiol redox state using 1 mM H2O2 (maximal oxidation) and 10 mM DTT (maximal 
reduction). After background correction, the 400/480 nm fluorescence excitation intensity was calculated. The 
traces presented depict the average of 42 and 23 cells for mit-roGFP1 and cyt-roGFP1, respectively. Note that 
roGFP1 is more oxidized in the mitochondrial matrix. 
 
To establish the extent of roGFP1 oxidation, ratio signals were calibrated by successive 
treatment with 1 mM hydrogen peroxide (H2O2) and 10 mM dithiothreitol (DTT) to fully 
oxidize (100% oxidation) and reduce (0% oxidation) the probe, respectively (95). H2O2 
gradually increased the fluorescence emission ratio to a maximum reached within 350 s, 
whereas subsequent addition of DTT rapidly reduced this ratio to below pre-H2O2 levels. 
Higher concentrations of H2O2 and DTT caused no further change in fluorescence emission 
ratio, indicating that the probe was maximally oxidized and reduced, respectively. Figure 1C 
shows that for healthy fibroblasts (table 1; CT1), the extent of roGFP1 oxidation was higher 
in the mitochondrial matrix than in the cytosol.  
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Chronic rotenone treatment slightly oxidizes the subcellular redox environment in healthy 
fibroblasts – We previously showed that chronic rotenone treatment dose-dependently 
reduced the activity of CI in healthy fibroblasts (136). To determine whether CI deficiency 
could, in principle, alter the subcellular redox environment, healthy fibroblasts (table 1; CT1) 
were treated with 100 nM rotenone for 72 h. This treatment slightly but significantly (p<0.05) 
increased the extent of mit-roGFP1 and cyt-roGFP1 oxidation (Figs. 2A and 2B, 
respectively). Experiments performed in parallel revealed that chronic rotenone treatment 
also increased the superoxide level (Fig. 2C), whereas, in sharp contrast, it did not affect 
cytosolic ROS levels (Fig. 2D). These results demonstrate that a chronic reduction in CI 
activity, despite causing a substantial rise in superoxide level, only slightly oxidizes the 
subcellular redox environment in healthy fibroblasts. 
 
RoGFP1 oxidation is not altered in patient fibroblasts – To establish whether CI deficiency is 
associated with a change in subcellular redox environment, fibroblasts of 10 healthy subjects 
and 10 patients were transduced with mit-roGFP1 and cyt-roGFP1 and analyzed as 
described above. In all cases, mit-roGFP1 was significantly more oxidized than cyt-roGFP1 
(table 2). Unexpectedly, however, no significant differences in mitochondrial and/or cytosolic 
roGFP1 oxidation were observed between healthy and CI deficient cell lines. This result 
shows that CI deficiency is not associated with detectable changes in subcellular redox 
environment. 
 
RoGFP1 oxidation is markedly increased in BSO-treated healthy fibroblasts – To assess the 
relevance of the GSSG/GSH couple in preserving the subcellular redox environment, healthy 
fibroblasts (table 1; CT1) were cultured in the presence of 12.5 µM L-buthionine-(S,R)-
sulphoximine (BSO) for 72 h. BSO is a potent inhibitor of γ-glutamylcysteine synthetase, the 
rate limiting enzyme in the synthesis of GSH (89), and it has been demonstrated that chronic 
treatment with this drug effectively depletes GSH (4,77). BSO dramatically increased the 
extent of roGFP1 oxidation in both mitochondrial matrix (Fig. 2A) and cytosolic compartment 
(Fig. 2B). Moreover, it caused a marked decrease in superoxide level (Fig. 2C) and, in 
sharp contrast, a substantial increase in ROS levels (Fig. 2D). These findings demonstrate 
that the GSSG/GSH couple is essential in preserving the subcellular redox environment in 
human skin fibroblasts. 
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Figure 2: Effect of chronic rotenone and BSO treatment on subcellular thiol redox state and cellular 
levels of superoxide and derived reactive oxygen species (ROS) - (A) CT1 fibroblasts transiently expressing 
mit-roGFP1 were treated with either rotenone (100 nM) or BSO (12.5 µM) for 72 h. After background correction, 
the 400/480 nm fluorescence excitation intensity was calculated and expressed as percentage oxidized. (B) The 
same for CT1 fibroblasts transiently expressing cyt-roGFP1. (C) CT1 cells chronically treated with either rotenone 
or BSO were incubated with 10 µM hydroethidine (HEt) for 10 min at 37o C, thoroughly washed to remove non-
oxidized dye and subsequently analyzed using digital imaging microscopy for quantification of the fluorescent 
oxidation products formed during the 10-min incubation period with HEt. The fluorescence emission intensity 
obtained with vehicle-treated CT1 cells is set at 100%, to which all other values are related. (D) CT1 cells 
chronically treated with either rotenone or BSO were incubated with 1 µM CM-H2DCFDA for 10 min at 37 °C, 
thoroughly washed to remove non-hydrolyzed dye and subsequently subjected to video-rate confocal microscopy 
for quantitative analysis of superoxide-derived ROS levels. The rate of fluorescence increase obtained with 
vehicle-treated CT1 cells is set at 100%, to which all other values are related. Numerals indicate the number of 
cells analyzed. *, significantly different from vehicle-treated control (P<0.05).    
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The extent of lipid peroxidation is not altered in patient fibroblasts – We previously showed 
that chronic rotenone treatment (100 nM, 72 h) significantly increased the extent of lipid 
peroxidation in healthy fibroblasts and that this effect of the inhibitor was abolished by the 
mitochondria-targeted antioxidant mitoquinone (136). Here, we used the same measuring 
protocol but could not detect any difference in the extent of lipid peroxidation between 
patient cell lines and cell lines of healthy subjects (table 1).  
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Table 1. Cellular oxidant levels and degree of lipid peroxidation in patient and control fibroblasts 
CELL LINE$ AFFECTED SUBUNIT 
AND MUTATION‡
CI ACTIVITY# CELLULAR SUPEROXIDE 
LEVEL&
SUPEROXIDE-DERIVED 
ROS 
LEVEL&
DEGREE OF LIPID 
PEROXIDATION‡ ‡
      
Average CT:  106±2.4 100±0.66 108±8.33 115±10 
CT1  (#5120) None 113 100±1 (n=526) 100±2 (n=412) 100±3 (n=99) 
CT2  (#5119) None 105 102±2 (n=89) 100±11 (n=48) 135±5 (n=112) 
CT3  (#5118) None 103 98±3 (n=126) 125±13 (n=61) 110±4 (n=108) 
CT4  (#4996) None    n.d. 100±3 (n=95) n.d. n.d.
CT5  (#223V) None    103 99±3 (n=94) n.d. n.d.
      
Average P:  49±6.3 181±14.0 223±20.8 112±4 
P1  (#5171) NDUFV1-R59X/T423M 73  186±6 (n=84) 242±19 (n=78) 92±3 (n=73) 
P2  (#5866) NDUFV1-R59X/T423M 64 110±3 (n=61) 135±12 (n=49) 123±3 (n=108) 
P3  (#6173) NDUFS1-D618N/R577X 31  176±4 (n=83) 171±13 (n=87) 109±3 (n=74) 
P4  (#5170) NDUFS2-R228Q 39  205±8 (n=66) 169±7 (n=124) 115±4 (n=101) 
P5  (#5067) NDUFS2-P229Q 36  264±9 (n=100) 351±41 (n=28) 115±5 (n=64) 
P6  (#5260) NDUFS4-R106X 36  174±8 (n=64) 187±12 (n=160) 127±4 (n=64) 
P7 (#5737) NDUFS4-VPEEHI67/VEKSIstop 53  131±4 (n=92) 202±12 (n=98) 115±4 (n=81) 
P8 (#4608) NDUFS4-K158fs 75  195±6 (n=106) 289±46 (n=29) 123±5 (n=76) 
P9 (#5175) NDUFS7-V122M 68  151±5 (n=94) 212±15 (n=76) 87±3 (n=99) 
P10 (#6603) NDUFS8-R94C 18  222±7 (n=147) 275±20 (n=117) 111±3 (n=90) 
 
$Numbers indicate the designation of the cell lines within the Nijmegen Centre for Mitochondrial Disorders (NCMD).  
CT and P indicate control and patient cell lines, respectively.   
‡Mutations are given at the protein level, the affected CI subunit indicated in bold. 
#Enzymatic activities were measured in mitochondria-enriched fractions and expressed as % of the lowest control value (110 mU/U cytochrome c oxidase).  
&Cellular superoxide levels were determined previously and are expressed as % of CT1 (Verkaart, 2007). 
‡ ‡Lipid peroxidation was determined using C11-BODIPY581/591 (Koopman, 2005) and expressed as % of CT1.  
Statistics: Values in bold are below the lowest control value (CI activity) or significantly different (p<0.05) from highest control 
(superoxide level, superoxide-derived ROS level). Values between brackets represent the number of individual cells analyzed on at least two days.  
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Table 2. Cellular thiol redox status in patient and control fibroblasts  
 
 
 
 
 
CELL LINE$ MIT-ROGFP1@ CYT-ROGFP1@ GSH+GSSG& GSSG& (OXIDIZED) GSH& (REDUCED) GSSG/GSH 
       
Average CT: 44.6±2.16 17.6±1.25 26.9±1.8   0.793±0.033 26.1±1.8 0.031±0.0020 
 
 
 
 
 
 
 
 
 
 
 
 
 
CT1   (#5120) 38±2 (n=42) 15±1 (n=23)     25.1 0.911 24.2 0.038
CT2   (#5119) 48±4 (n=24) 20±3 (n=14)     25.4 0.722 24.7 0.029
CT3   (#5118) 44±4 (n=22) 14±2 (n=11)     28.0 0.831 27.1 0.031
CT4   (#4996) 39±4 (n=21) 20±2 (n=8) 25.7 0.805 24.9 0.032 
CT5   (#223V) 45±4 (n=18) 18±4 (n=11)     25.6 0.748 24.9 0.030
CT6   (#MW21) 49±4 (n=23) 19±3 (n=18)     31.2 0.946 30.3 0.031
CT7   (#MW25) 59±4 (n=15) 25±1 (n=12)     26.9 0.749 26.2 0.029
CT8   (#MW28) 40±5 (n=11) 19±3 (n=6) 36.3 0.861 35.5 0.024 
CT9   (#MW33) 48±7 (n=11) 15±4 (n=3) 30.8 0.782 30.0 0.026 
CT10 (#MW35) 36±6 (n=9) 11±1 (n=10) 14.1 0.577 13.5 0.043 
       
Average P: 43.3±2.05 21.5±1.40    24.8±1.4 0.830±0.050 24±1.4 0.035±0.0010 
 
 
 
 
 
 
 
 
 
 
 
 
P1     (#5171) 40±3 (n=20) 19±3 (n=23) 29.2    1.014 28.2 0.036
P2     (#5866) 44±4 (n=23) 15±1 (n=13)     21.6 0.742 20.9 0.036
P3     (#6173) 49±5 (n=14) 20±2 (n=12) 23.0    0.904 22.1 0.041
P4     (#5170) 44±5 (n=19) 18±2 (n=14) 27.9    0.783 27.1 0.029
P5     (#5067) 36±3 (n=21) 27±2 (n=21)     31.7 0.986 30.7 0.032
P6     (#5260) 52±4 (n=22) 26±2 (n=13)     19.4 0.587 18.8 0.031
P7     (#5737) 54±3 (n=44) 26±2 (n=31)     19.7 0.732 19.0 0.039
P8     (#4608) 40±3 (n=28) 24±3 (n=15)     24.3 0.902 23.4 0.039
P9     (#5175) 37±3 (n=20) 16±1 (n=22)     21.9 0.630 21.3 0.030
P10   (#6603) 37±3 (n=34) 24±2 (n=29)     29.5 1.017 28.5 0.036
$Numbers indicate the designation of the cell lines within the Nijmegen Centre for Mitochondrial Disorders (NCMD).  
CT and P indicate control and patient cell lines, respectively.  
@Data reflects the % of oxidized roGFP1 in the mitochondrion (mit-roGFP1) and cytosol (cyt-roGFP1); values between brackets represent the  
number of individual cells analyzed on at least four days.  
&Expressed as nmol/mg protein, determined in two independent experiments 
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DISCUSSION 
 
In this study, we measured the thiol redox state as an important determinant of the redox 
environment in both the cytosol and mitochondrial matrix of cultured skin fibroblasts of 10 
healthy control subjects and 10 patients with an isolated CI deficiency caused by a mutation 
in one of the nuclear-encoded subunits of the complex (table 1). All but one (P2) of the 
patient cell lines displayed a marked increase in superoxide and derived ROS levels. 
Strikingly, however, neither the thiol redox state nor the extent of lipid peroxidation differed 
significantly between the healthy and patient cell lines. 
  
Cellular ROS levels are increased in inherited CI deficiency – Under normal conditions more 
than 90% of ROS is generated as a consequence of oxidative phosphorylation 
(14,68,144,175). In first instance, this involves the production of superoxide and studies with 
isolated mitochondria indicated that CI and CIII are the major sources of this oxidant 
(14,68,209). Furthermore, these studies suggested that superoxide produced by CI is 
released into the mitochondrial matrix, whereas that produced by CIII enters both the matrix 
and the intermembrane space (144). However, whether CIII contributes to the production of 
this oxidant in living cells is still debated (184). Although previous work revealed a significant 
increase in cellular superoxide level in all but one (P2) of the patient cell lines (table 1), the 
method used for its determination precluded any statement about the origin of this oxidant 
(277). In this context, experimental evidence suggests that under pathological conditions 
mitochondrial superoxide production may not be confined to CI but may in addition involve 
α-ketoglutarate dehydrogenase in the mitochondrial matrix (253,267) and monoamine 
oxidases in the outer mitochondrial membrane (5). Superoxide is rapidly converted into 
hydrogen peroxide (H2O2) by superoxide dismutases present in both the mitochondrial 
matrix (MnSOD) and cytosolic compartment (CuZnSOD). In agreement with the increase in 
superoxide level, we observed an increase in cytosolic ROS levels in all but one (P2) of the 
CI deficient cells lines (table 1). Intriguingly, patient 2 is a brother of patient 1 (P1), both 
harboring exactly the same mutation in the NDUFV1 subunit of CI. We reported before that 
fibroblast cell lines derived from these two patients show a similar decrease in fully 
assembled CI and residual CI activity (277). These findings clearly indicate that additional 
factors play an important role in determining cellular ROS levels. In accordance with this 
conclusion, fibroblasts of CI deficient patients were demonstrated to express variable 
amounts of MnSOD (204). The present results are in agreement with recent work showing a 
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marked elevation in cellular ROS levels in skin fibroblasts of a patient with a mutation in the 
NDUFS1 gene (116). In contrast to the latter study, however, we found that cellular ROS 
levels were increased in fibroblasts of three patients with a mutation in the NDUFS4 gene. 
The latter result indicates that the type of mutation in a particular subunit and/or the genetic 
background of the patient are likely to play a role in the occurrence of a net increase in 
cellular ROS levels. 
   
Cellular redox environment is not detectably altered in inherited CI deficiency – In the 
mitochondrial matrix, which is devoid of catalase, H2O2 is detoxified by glutathione 
peroxidase (GPX) (72). The reduction equivalents required for this reaction are provided by 
the GSSG/GSH redox couple. Importantly, GSH is regenerated from GSSG by glutathione 
reductase (GR) using NADPH as electron donor (125). It has been suggested that isocitrate 
dehydrogenase is a major source of NADPH in this compartment (128). In addition, NADH 
can be converted into NADPH by the action of mitochondrial transhydrogenase (221). In the 
cytosol, H2O2 is removed by the combined action of GPX and catalase. Conditions that 
increase the production of superoxide and, as a consequence, H2O2, will increase the GPX-
catalyzed formation of GSSG. Because mitochondria cannot export GSSG to the cytosol 
(189) and are limited in their ability to synthesize GSH (169), this will lead to a decrease in 
mitochondrial GSH, if not appropriately balanced by ATP-dependent uptake of GSH from the 
cytosol (164). In the cytosol, excess GSSG is exported out of the cell, which, if not 
sufficiently compensated by de novo GSH synthesis, will lead to a decrease in total cellular 
glutathione content. Here, we show that, despite a marked increase in the levels of 
superoxide and derived ROS, the total cellular glutathione content and the GSSG to GSH 
ratio are not detectably altered in a large cohort of patient cell lines as compared to a large 
cohort of healthy control cell lines. In agreement with this result, measurements with roGFP1 
revealed no significant differences in thiol redox state between patient and healthy 
fibroblasts. A similar lack of effect of increased ROS levels on the oxidation state of roGFP1 
was observed in EGF-treated NR6 cells (64). Our results disagree with a recent study 
showing a decrease in total cellular glutathione content in fibroblasts of a patient with a 
mutation in the NDUFS1 gene (116). However, the latter study included only one healthy 
control cell line and we show here that the total cellular glutathione content varied over the 
same range in both the patient and healthy control group. In agreement with our results, the 
total cellular glutathione content was found to be unaltered in fibroblasts of a patient with a 
mutation in the NDUFS4 gene.  
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Taken together, our findings show that patient fibroblasts are able to maintain the thiol redox 
state despite the increased levels of superoxide and derived ROS.  
It has been suggested that the redox state of roGFP1 is determined by the reducing capacity 
of the most important redox buffer within the cell (64). Here, we show that inhibition of GSH 
synthesis by L-buthionine-(S,R)-sulphoximine (BSO) resulted in virtually complete oxidation 
of mit- and cyt-roGFP1. This result indicates that the glutathione disulfide (GSSG)-
glutathione (GSH) couple is the most important determinant of the cellular redox 
environment (226). BSO markedly increased cytosolic ROS levels, demonstrating the 
importance of GSH in oxidant scavenging. At the same time, BSO decreased the superoxide 
level. Both findings are in agreement with the recent observation that BSO increased the 
expression of superoxide dismutases (50,79). 
Because primary human skin fibroblasts are refractory to most classical transfection 
methods, we engineered baculoviral vectors for selective expression of roGFP1 in either the 
cytosol (cyt-roGFP1) or mitochondrial matrix (mit-roGFP1; (140,283). Single cell analysis 
revealed that in both healthy and patient fibroblasts mit-roGFP1 was significantly more 
oxidized than cyt-roGFP1 (values of 44% and 20%, respectively). Similar results were 
obtained with HeLa cells (64,95; values of 33% and 18%, respectively). The finding that the 
redox environment is more oxidized in the mitochondrial matrix is in accordance with the 
observation that the vast majority of cellular ROS is produced as a consequence of oxidative 
phosphorylation (14,68,144,175).  
Our results with BSO and rotenone show that the absence of any detectable alteration in 
cellular redox environment is not due to a lack of sensitivity of roGFP1 because BSO almost 
completely oxidized this sensor, whereas rotenone, at a concentration shown before to 
inhibit the activity of CI by approximately 80% (136), only slightly but significantly increased 
the amount of oxidized roGFP1. Our findings are in agreement with results obtained with an 
in vitro model for Parkinson’s disease involving chronic treatment of human neuroblastoma 
cells with 5 nM rotenone for 4 weeks and showing a significant decrease in cellular GSH 
content (240). Although at present we have no explanation for the lack of effect of rotenone 
on cytosolic ROS levels, the results obtained with this potent CI inhibitor substantiate our 
conclusion that CI deficiency only slightly, if at all, oxidizes the subcellular redox environment 
in human skin fibroblasts.  
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Lipid peroxidation is not detectably altered in inherited CI deficiency - When the production 
of oxidants exceeds the antioxidant capacity of the cell, this may cause damage to lipids, 
proteins and DNA. Importantly, the extent of damage to a particular target depends, among 
others, on the type of oxidant involved, the location of the target versus the oxidant, the 
oxidant to target ratio and the occurrence of repair reactions. It has been demonstrated that 
inadequate detoxification of H2O2 may result in the formation of highly reactive hydroxyl 
radicals through the classic Fe2+-catalyzed Fenton reaction. As far as human CI deficiency is 
concerned, experimental evidence suggests that this condition may indeed lead to an 
increased production of this radical and consequent increase in the extent of lipid 
peroxidation (160). In accordance with these results, we demonstrated that chronic 
treatment with rotenone caused a 2-fold increase in the extent of lipid peroxidation (136). 
Contradictory to these results, however, we now show that the extent of lipid peroxidation is 
not detectably altered in patient fibroblasts. Together with our conclusion that the GSSG-
GSH couple is the most important determinant of the cellular redox environment and our 
finding that the redox state of this couple is not detectably altered in patient fibroblasts, this 
finding is compatible with previous conclusions that the presence of sufficient amounts of 
GSH can prevent the occurrence of oxidant-induced damage (105). In conclusion, the 
present study demonstrates that cellular superoxide and derived ROS levels are increased 
complex I deficient human skin fibroblasts but that this condition does not lead to oxidative 
damage because these cells are able to maintain a normal redox environment.   
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ABSTRACT 
 
Recent evidence indicates that oxidative stress is central in the pathogenesis of a wide 
variety of degenerative diseases, aging, and cancer. Oxidative stress occurs when the 
delicate balance between production and detoxification of reactive oxygen species is 
disturbed. Mammalian cells respond to this condition in several ways, among which is a 
change in mitochondrial morphology. The mechanism underlying this response is still 
elusive. Here we use rotenone, an inhibitor of complex I of the respiratory chain, which is 
thought to increase mitochondrial superoxide production, and MitoQ, a mitochondria-
targeted antioxidant, to investigate the relationship between mitochondrial superoxide 
production and morphology change in human skin fibroblasts. Video-rate confocal 
microscopy of cells pulse-loaded with the mitochondria-specific cation rhodamine 123 (200 
µM, 40 seconds) followed by automated analysis of mitochondrial morphology revealed that 
chronic rotenone treatment (100 nM, 72 hours) caused a significant increase in 
mitochondrial length and branching without changing the number of mitochondria per cell. 
Chronic rotenone treatment also caused a 2-fold increase in the extent of lipid peroxidation 
as was determined by video-rate confocal microscopy of cells loaded with the lipid 
peroxidation reporter C11-BODIPY581/591 (4 µM, 30 minutes). Finally, digital imaging 
microscopy of cells loaded with hydroethidine (10 µM, 10 minutes), which is oxidized by 
superoxide to yield fluorescent ethidium, revealed that chronic rotenone treatment caused a 
2-fold increase in the rate of superoxide production. MitoQ (10 nM, 72 hours) did not 
interfere with rotenone-induced ethidium formation but abolished rotenone-induced 
outgrowth and lipid peroxidation. These findings show that increased mitochondrial 
superoxide production as a consequence of, for instance, complex I inhibition leads to 
mitochondrial outgrowth and that MitoQ acts downstream of this oxygen radical to prevent 
alterations in mitochondrial morphology.  
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INTRODUCTION 
 
Highly aerobic cells from brain, heart, muscle, liver, kidney and endocrine tissue depend on 
the ATP-generating capacity of their mitochondria to meet energetic demands. Acute 
changes in cellular energy consumption are met through feed-back and/or feed-forward 
regulation of enzymes involved in aerobic ATP production, whereas chronic changes lead to 
alterations in mitochondrial capacity and/or architecture (11,97,173,174). Marked changes in 
structure of the cellular mitochondrial network are furthermore observed during 
differentiation, cellular senescence and apoptosis, whereas subtle rearrangements occur 
during cellular growth and division (298). 
Mitochondria generate ATP through oxidative phosphorylation (OXPHOS) and defects in this 
system lead to decreased energy production, increased formation of superoxide and derived 
reactive oxygen species such as hydrogen peroxide and the hydroxyl radical, and the 
release of death-promoting factors (231,246,290). Defects occur in a wide variety of 
degenerative diseases, aging, and cancer and primarily affect tissues that have high energy 
requirements and that are unable to adapt to conditions of reduced mitochondrial energy 
supply. Cells that can survive under such conditions such as cancer cells show a variety of 
adaptations including upregulation of glucose transport, glycolysis, and lactate formation 
(197). At the same time these cells show a marked reduction in mitochondrial content (54) 
and OXPHOS capacity (244), whereas the mitochondrial reticulum is largely perinuclear 
(251). Cancer cells that are forced to grow on galactose and glutamine readily switch from 
anaerobic to aerobic energy production (219). This adaptation is accompanied by an 
increase in OXPHOS protein, a decrease in mitochondrial matrix pH, a more oxidized matrix 
redox state, an increase in the amount of cristae but no increase in mitochondrial mass, and 
a more extended mitochondrial network. Similar observations were initially reached in 
budding yeast, where a change of substrate induced a 3-fold increase in mitochondrial 
volume (70). Qualitative and/or quantitative changes in the mitochondrial reticulum are also 
observed under pathological conditions that are caused by inherited mutations in 
mitochondrial DNA or in nuclear OXPHOS genes (37,91) and suggest a tight relationship 
between mitochondrial structure and function (59).  
Recent insights suggest that superoxide anions, formed as “by-product” of the oxidative 
phosphorylation process, may activate specific redox-sensitive signaling pathways (65). 
Evidence has been provided that these pathways control uncoupling protein-mediated 
proton conductance (34). In addition, these pathways are implicated in mitochondrial 
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biogenesis (146,171,172) and regulation of cellular antioxidant capacity (204). Failure to 
make the appropriate changes is thought to lead to increased oxygen radical production, 
which, if not properly balanced by the cell’s antioxidant mechanisms may cause structural 
and functional damage to polyunsaturated fatty acids in membrane lipids, proteins, and 
DNA. There is good evidence that increased oxygen radical formation is the cause of 
atherosclerosis and possibly also of the major neurodegenerative and chronic inflammatory 
diseases (92). Moreover, increased radical formation has been implicated in aging (75) and 
apoptosis (150). However, in the majority of diseases in which tissue damage occurs 
increased radical formation is regarded as consequence rather than as cause (92). Human 
mitochondrial complex I (NADH:ubiquinone oxidoreductase; EC: 1.6.5.3) is the largest 
multisubunit assembly of the OXPHOS system, comprising 39 nuclear encoded and seven 
mitochondrially encoded subunits (104). Malfunction of this complex is associated with a 
wide variety of clinical syndromes (246). In order to enhance our understanding of the 
pathophysiology of these diseases, with the final aim of developing new treatment strategies 
to stabilize or even cure these conditions, we study genetically characterized human 
complex I deficient fibroblast cell lines as a model for OXPHOS-system disease, knowing 
that these cells are glycolytic (216). In doing so, we recently showed that agonist-induced 
mitochondrial Ca2+ accumulation and ensuing ATP production are significantly decreased in 
skin fibroblasts derived from patients with an isolated complex I deficiency caused by 
mutations in nuclear-encoded structural subunits of the complex (283). 
Robinson and co-workers reported that mitochondrial morphology and dynamics are altered 
in skin fibroblasts from patients with mitochondrial complex I deficiency (200). Similar 
observations were reached with control fibroblasts treated with the complex I inhibitor 
rotenone (40 µM) for 5 minutes. Studies with mitochondrial membranes isolated from patient 
fibroblasts showed that NADH-stimulated mitochondrial superoxide formation is increased in 
human complex I deficiency and that 10 µM rotenone readily increases formation of this 
radical in control membranes (204). Together with observations that exogenous application 
of hydrogen peroxide increases mitochondrial mass in human lung fibroblasts (146), these 
findings suggest a causal relationship between increased mitochondrial oxygen radical 
formation and alterations in mitochondrial reticulum and dynamics in complex I deficiency. 
However, no definitive proof has yet been offered. Here we show that a sustained increase 
in mitochondrial superoxide production, brought about by chronic inhibition of complex I of 
the electron transport chain (100 nM rotenone, 72 hours), causes a marked increase in 
mitochondrial length and branching.  
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MATERIALS AND METHODS 
 
Cell culturing, NADH:ubiquinone oxidoreductase measurements and cell cycle analysis 
Fibroblasts were obtained from a skin biopsy of a healthy individual and cultured in medium 
M199 with Earle’s salt (Invitrogen, Carlsbad, CA, USA) in a humidified atmosphere of 95% 
air, 5% CO2 at 37o C. The medium contained 5 mg/l Tween 20 and was supplemented with 
10% (v/v) fetal calf serum, 100 IU/ml penicillin and 100 µg/ml streptomycin (Invitrogen). The 
activities of NADH:ubiquinone oxidoreductase (complex I), cytochrome c oxidase (complex 
IV) and citrate synthase (CS) were measured in a mitochondria-enriched fraction as 
described previously (245). For fluorescence microscopy, fibroblasts were seeded on glass 
coverslips (Ø 22 mm) and cultured to ~70% confluence. For cell cycle assessment, cells 
were trypsinized and stored on ice. After staining with propidium iodide, cell suspensions 
were analyzed using flow cytometry (275).  
 
Quantitative analysis of mitochondrial morphology by video-rate laser-scanning confocal 
microscopy - Stock solutions of the lipophilic cation rhodamine 123 (R123), Mitotracker 
Green FM (MG), and Mitotracker Red CMXRos (MR; all from Molecular Probes, Leiden, NL) 
were freshly prepared in dimethylsulfoxide (DMSO) prior to each measurement. Fibroblasts 
were incubated in culture medium containing 200 µM (R123) or 5 µM (MR and MG) of the 
dye for 40 seconds (R123), 3 minutes (MR), or 20 minutes (MG) at 20o C. After loading cells 
were thoroughly washed with Hepes-Tris medium (132 mM NaCl, 4.2 mM KCl, 1 mM CaCl2, 
1 mM MgCl2, 5.5 mM D-glucose and 10 mM Hepes, pH 7.4). For confocal imaging, 
coverslips were mounted in an incubation chamber placed on the stage of an inverted 
microscope (Nikon Diaphot, Tokyo, Japan), attached to an Oz confocal microscope (Noran 
Instruments, Middleton, WI, USA). Measurements were performed at 20o C. The light from 
an Argon ion laser (488 nm; Omnichrome, Chino, CA, USA) was delivered to the cells via a 
x40 oil immersion planapochromat objective (NA 1.4; Nikon). For all dyes, fluorescence 
emission light was directed through a 500 nm LP barrier filter (Chroma Technology Corp., 
Brattleboro, VT, USA) and quantified using a photomultiplier tube (Hamamatsu Photonics, 
Bridgewater, NJ, USA). Given the flat morphology of the fibroblasts (size <3 µm in the axial 
direction) slit settings were chosen in such a way that axially, each cell was entirely present 
within the confocal volume (135). This prevented exclusion of mitochondrial structures from 
the image and guaranteed an optimal fluorescence signal at minimal laser intensity. 
Hardware and image acquisition were controlled by Intervision software (Version 1.5, Noran 
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Instruments) running under IRIX 6.2 on an Indy workstation (Silicon Graphics Inc., Mountain 
View, CA, USA) equipped with 512 Mb memory. Before image acquisition, brightness and 
contrast settings were optimized using a custom-made look up table that colored the upper 
and lower ten greylevels red and blue, respectively. Images (512x480 pixels) were collected 
at 30 Hz with a pixel dwell time of 100 ns. To reduce random noise, images were averaged 
in real-time using the running average algorithm of the Intervision Acquisition software with a 
window size of 32. This acquisition protocol, in combination with the low mitochondrial 
mobility at 20o C, effectively prevented distortion of the image by mitochondrial movement. 
Images were recorded from a cross-shaped area transecting the center of the coverslip and 
converted to TIFF-format using a Silicon Graphics O2 workstation running IRIX 6.5. 
Quantitative analysis of mitochondrial morphology was performed using Image Pro Plus 4.5 
(Media Cybernetics, Silver Spring, MD, USA) as described in the Results section.  
 
Quantitative analysis of mitochondrial superoxide production by digital-imaging microscopy - 
Fibroblasts were incubated in Hepes-Tris medium containing 10 µM hydroethidine (HEt; 
Molecular Probes) for 10 minutes at 37o C. HEt is an uncharged compound that readily 
enters the cell. Within the cell, it reacts with superoxide to form the fluorescent and positively 
charged product ethidium (Et; 69). The reaction was stopped by thorough washing of the 
cells with PBS to remove excess HEt. For quantitative analysis of Et, coverslips were 
mounted in an incubation chamber placed on the stage of an inverted microscope (Axiovert 
200 M, Carl Zeiss, Jena, Germany) equipped with a Zeiss 40x/1.3 NA F Fluar objective. 
Ethidium was excited at 490 nm using a monochromator (Polychrome IV, TILL Photonics, 
Gräfelfing, Germany). Fluorescence emission light was directed by a 525DRLP dichroic 
mirror (Omega Optical Inc., Brattleboro, VT, USA) through a 565ALP emission filter (Omega) 
onto a CoolSNAP HQ monochrome CCD-camera (Roper Scientific, Vianen, The 
Netherlands). The image capturing time was 100 milliseconds. Routinely, 10 fields of view 
were analyzed per coverslip. Hardware was controlled with Metafluor 6.0 software (Universal 
Imaging Corporation, Downingtown, PA, USA). Quantitative image analysis was performed 
using Metamorph 6.0 (Universal Imaging Corporation) as described in the Results section. 
 
Quantitative analysis of the extent of lipid peroxidation by video-rate laser-scanning confocal 
microscopy - The extent of lipid peroxidation was quantified using the fluorescent ratio probe 
C11-BODIPY581/591 (Molecular Probes). Upon oxidation, the red emitting form of the dye (595 
nm) is converted into a green emitting form (520 nm), which results in an increase in 
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green/red emission ratio (66). Cells were incubated in Hepes-Tris medium containing 4 µM 
C11-BODIPY581/591 for 30 minutes at 37º C. After thorough washing, images were collected 
with the Oz confocal system as described above.  Green and red fluorescence emission 
signals were separated by a 560DM dichroic mirror and appropriate bandpass filters 
(535D20 and 580LP; Chroma). Quantitative image analysis was performed as described in 
the Results section.  
 
Statistics and data analysis - Numerical values were visualized using Origin Pro 6.1 
(OriginLab Corporation, Northampton, MA, USA) and values from multiple experiments were 
expressed as average ± s.e.m. Statistical significances were assessed by Student's t-test. 
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RESULTS 
 
Visualization of mitochondria in living skin fibroblasts - Successful quantitative analysis of 
mitochondrial morphology requires a visualization protocol that is compatible with off-line 
computer-assisted image analysis. The latter requirement implicates that fluorescence 
originating from mitochondria can be easily separated from background signals. In the ideal 
case this means that the recorded images contain a discrete range of greylevels solely 
associated with these organelles. To find a mitochondrial dye most compatible with this 
requirement, we stained fibroblasts with three widely used mitochondria-specific 
fluorophores: rhodamine 123 (R123, N=34 cells), Mitotracker Red CMXRos (MR, N=37) and 
Mitotracker Green FM (MG, N=42). To reduce illumination time of the fluorophores, prevent 
artifacts associated with mitochondrial movement and increase signal-to-noise ratio, 32 
images were captured during 1 second and  averaged in real time.  
All three dyes revealed extensive mitochondrial reticula as well as individual mitochondrial 
filaments (Fig. 1A-C; left panels). Next, images were segmented using three greylevel 
intervals (0-50, 51-150 and 151-255; columns below intensity scale in Fig. 1). Only for R123 
a discrete range of greylevels was exclusively associated with mitochondrial structures (Fig. 
1A; third image). When R123-stained cells were treated with 1 µM of the protonophore 
carbonylcyanide-p-trifluoromethoxy-phenylhydrazone (FCCP), the mitochondrial staining 
pattern was acutely lost thus confirming the mitochondrial localization of the dye (not 
shown). 
  
Fig. 1. Visualization of mitochondria in living human skin fibroblasts - To determine which mitochondria-
specific dye suited best for computerized image analysis cells were stained with (A) rhodamine 123 (R123), (B) 
mitotracker red CMXRos (MR), or (C) mitotracker green FM (MG). Image segmentation into three discrete 
greylevel ranges (0-50: second column, 51-150: third column and 151 to 255: fourth column) revealed that only in 
the case of R123 mitochondrial structures are present within a discrete greylevel interval required for 
computerized image analysis (panel A, third image).  
 
 
 
 
 
 
 
 112
 
 
Chapter VII 
 
Quantitative analysis of mitochondrial structure - To identify mitochondrial structures in 
images of R123-stained fibroblasts (Fig. 2A; solid line indicates cell boundary), an image-
processing algorithm was developed that consisted of three steps. First, the contrast in the 
image was optimized by reassigning the greyvalues of the pixels to cover the entire available 
range from 0 to 255 (Fig. 2B; intensity histograms before and after optimization are 
displayed in panel E). Next, a “top-hat” spatial filter was applied (Fig. 2C).  
This filter is particularly suited to isolate bright features from a dark background and consists 
of two steps:  (I) the pixel values in a certain region of the image are multiplied by a matrix h 
(or kernel) of integer filtering coefficients given by: 
   h =  
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Fig. 2 Quantitative analysis of mitochondrial morphology - For quantitative analysis, (A) raw images of 
R123-stained fibroblasts (solid line indicates the cell boundary) were first (B) contrast optimized. Next, (C) a 
spatial filter was applied to highlight mitochondrial structures. (D) The small grey particles introduced by this 
operation were removed by applying a threshold to the image. (E) Intensity distribution before (filled symbols) and 
after (open symbols) contrast optimization, calculated for the images A and B, respectively. (F) Intensity profiles 
across the lines shown in panels A and B (dotted and continuous line, respectively). (G and H) intensity profiles 
for panels C and D. Details are given in the Results section. 
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(II) the newly assigned pixel values are summed and used to replace the original intensity of 
the central pixel. This process is repeated until each pixel in the image is processed. Of 
note, the filter always uses the original intensity values of the neighborhood pixels as an 
input. We chose a dimension of the top-hat filter of 7x7 pixels because this is compatible 
with the size of the mitochondrial objects. The result in figure 2C was obtained by applying 
the top-hat filter three times using a filter-strength of 30%. The latter value indicates that 
each time the filter is applied only 30% of the difference between the pixel value after and 
before filtering is added. Finally, a threshold operation was performed to remove the distinct 
spherical objects of intermediate intensity introduced by the top-hat filter (Fig. 2D). The 
effects of the various steps of the image processing protocol are visualized in figures 2F-H, 
depicting the intensity profiles across a horizontal line transecting the cell (dotted line in 
Figs. 2A-D). The clear distinction between background (black) and mitochondrial (white) 
signals in the binary image (Figs. 2D and H) allows automated shape-analysis of 
mitochondrial structures.  
For morphological analysis two parameters (descriptors) were calculated for each 
mitochondrial object: (I) the formfactor F (perimeter2/4π·Area) and (II) the aspect ratio AR 
(ratio between the major and minor axis of the ellipse equivalent to the object). Moreover, 
(III) the total number of mitochondria per cell (Nc) was determined. Both F and AR are 
independent of image magnification, have a minimal value of one (corresponding to a perfect 
circle) and were used previously to analyze cell shape (133). Figure 3 illustrates the 
morphological meaning of F and AR. Images of R123-stained fibroblasts were contrast 
optimized (Fig. 3A) and mitochondrial structures were isolated by image processing (Fig. 
3B). Plotting AR as a function of F for all 392 mitochondria depicted in figure 3C revealed 
that AR is a measure of mitochondrial length, whereas F is a measure of both length and 
degree of branching (representative mitochondrial structures are indicated by black dots). 
For statistical analysis we routinely calculated the average values of F and AR for each 
recorded field of view.  
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Fig. 3. Morphological descriptors of 
mitochondrial shape - (A) Confocal 
image of fibroblasts stained with R123. 
(B) The same cells after image 
processing. (C) Aspect ratio (AR) plotted 
as function of formfactor (F) for the 392 
mitochondrial objects present in the 
processed image. Morphology is shown 
for mitochondria with representative 
combinations of F and AR (filled 
symbols). The three corners of the 
shaded triangle represent morphological 
extremes.  
 
 
 
 
 
 
 
 
 
 
Chronic rotenone treatment inhibits complex I activity and induces mitochondrial outgrowth 
in human skin fibroblasts - To assess a possible connection between mitochondrial stress 
and mitochondrial morphology, cells were cultured in the presence of rotenone, an 
archetypal inhibitor of complex I of the respiratory chain. Enzyme activity measurements in 
mitochondria-enriched fractions of cells chronically treated with this drug for 72 hours 
revealed a dose-dependent decrease in complex I activity (Fig. 4A, filled circles). In contrast, 
the activities of complex IV (open circles) and the Krebs cycle enzyme citrate synthase 
(squares) were not altered. Visual inspection of R123-stained cells suggested an increase in 
mitochondrial length and/or branching following rotenone treatment (Fig. 4B). Subsequent 
quantitative analysis revealed that rotenone did not alter AR or Nc, but caused a dose-
dependent increase in F, which was significant at a concentration of 100 nM (Fig. 4C; 
P<0.01). Importantly, rotenone did not change cell cycle phase. Values of G0/G1, G2/M and S 
were 86%, 4% and 10% (N=3), 91%, 5% and 5% (N=2) and 92%, 4% and 4% (N=2) for 
vehicle-treated cells and cells treated with 2.5 and 100 nM rotenone, respectively). The drug 
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did not detectably alter the mitochondrial membrane potential as indicated by the lack of 
effect on the R123 fluorescence emission intensity (Fig. 4C). Of note, the latter was 
determined in unprocessed images recorded at identical hardware settings, using the binary 
image obtained after image processing as a mask.  
 
Fig. 4. Chronic rotenone treatment 
decreases complex I activity and induces 
mitochondrial outgrowth - (A) Chronic 
treatment of human skin fibroblasts with 
rotenone (72 h) decreased complex I activity 
dose-dependently (filled circles) without 
affecting the activities of complex IV (open 
circles) and citrate synthase (squares). 
Activities were measured in a mitochondria-
enriched fraction and are expressed as milli-
unit per unit citrate synthase (mU/UCS) for 
complex I and complex IV and milli-unit per mg 
protein for citrate synthase. (B) Control 
fibroblasts treated with vehicle (containing 
0.001% v/v ethanol; left panel) and rotenone 
(100 nM, 72 hours, right panel) stained with 
R123. Mitochondria appeared to be more 
branched in rotenone-treated cells. (C) 
Quantitative analysis of mitochondrial 
morphology as a function of rotenone 
concentration. Aspect ratio (AR) and R123 
emission intensity remained unaffected, 
whereas the formfactor (F) increased dose-
dependently (significant at 100 nM rotenone). 
Experiments were performed on two days. On 
each day, the average value obtained with 
vehicle was set at 100% to which the other 
values were related. Averages are from N=30 
cells (vehicle), N=26 cells (2.5 nM rotenone), 
N=23 cells (15 nM rotenone) and N=52 cells 
(100 nM rotenone). **Significantly different from 
vehicle-treated cells (P<0.01). 
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Chronic treatment with rotenone increases superoxide production in human skin fibroblasts - 
Measurement of the effect of rotenone on oxygen radical formation in living cells has yielded 
conflicting results. Increases were observed in the human osteosarcoma-derived cell line 
143B (16), mesencephalic neurons (179) and HL-60 cells (150), whereas decreases 
occurred in hepatocytes (289), cultured mice hippocampal neurons (233) and monocytes 
and macrophages (151). In this study we used hydroethidine (HEt), a redox-sensitive probe 
that is widely used to measure mitochondrial superoxide production in living cells 
(30,31,69,305). Hydroethidine is a cell-permeant compound that is oxidized by superoxide to 
its positively charged product ethidium (Et). Digital imaging microscopy of fibroblasts loaded 
with 10 µM HEt for 10 minutes and thoroughly washed to remove non-oxidized HEt, 
revealed the presence of Et in both nucleoli and a widespread network of tubular structures 
present in the cytosolic compartment (Fig. 5A). The intensity of fluorescence emission did 
not change during 10 minutes of illumination at 0.2 Hz, as demonstrated by a linear fit with a 
slope of 4.4·10-5 ± 2.3·10-6 (P<0.001). This indicates that excess HEt was effectively 
removed, Et did not leak out of the cell and photo-bleaching and/or photo-activation did not 
occur during at least 10 minutes of image acquisition. The mitochondrial nature of the tubular 
structures was demonstrated by the immediate loss of Et fluorescence upon addition of the 
mitochondrial uncoupler FCCP (1 µM; Fig. 5B). This confirms that mitochondrial Et 
accumulation depends on mitochondrial membrane potential (30,31,69).  
Fibroblasts treated with 100 nM rotenone for 1 hour prior to the 10-min incubation period 
with HEt displayed a marked increase in Et fluorescence in both nucleoli and mitochondria 
(Fig. 5C and D). For quantification of the effect of rotenone, we determined the average 
fluorescence intensity in the nucleoplasm and a cytosolic region of equal size containing a 
high density of mitochondrial structures (Fig. 5C, circles n and m, respectively). Figure 5E 
shows that the average fluorescence intensities in both regions, determined at different 
degrees of rotenone inhibition, are linearly correlated (R=0.99; slope = 0.51 ± 0.03, P<0.05). 
This demonstrates that the nucleolar ethidium is of mitochondrial origin. The figure 
furthermore shows that the average fluorescence intensity in cells treated with 100 nM 
rotenone for 1 hour (N=35 cells) was 2-fold higher than that in vehicle-treated cells (N=37). A 
further increase to 3-fold the control value was reached with 1 µM rotenone (N=31). Cells 
chronically treated with 100 nM rotenone for 72 hours still displayed a 2-fold increase in 
average fluorescence intensity (N=32). Finally, addition of H2O2 (100 µM) did not increase Et 
fluorescence, demonstrating that HEt is not oxidized by this superoxide derivative. Taken 
together, these findings show that chronic rotenone treatment causes a rapid and persistent 
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increase in the rate of mitochondrial superoxide production in cultured human skin 
fibroblasts.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. Rotenone increases mitochondrial superoxide production - (A) Human skin fibroblasts incubated in 
the presence of HEt (10 µM) for 10 min and thoroughly washed to remove non-oxidized HEt, revealed the 
presence of Et in both nucleoli and a widespread network of tubular structures present in the cytosolic 
compartment. (B) Staining of the cytosolic tubular structures was lost immediately after addition of the 
mitochondrial uncoupler FCCP (1 µM). (C,D) Stimulatory effect of rotenone (100 nM, 1 hour) on Et accumulation 
in nucleoli (n) and mitochondrial structures (m) during 10 minutes incubation with 10 µM HEt. Vehicle-treated 
cells were incubated with 0.001% (v/v) ethanol. For quantification of the rotenone effect, the average 
fluorescence intensity was determined in the nucleoplasm and a cytosolic region of equal size containing a high 
density of mitochondrial structures (C, circles). (E) Linear relationship (slope = 0.51 ± 0.03, P<0.001) between the 
average fluorescence intensities in nucleoplasm and cytosolic region for fibroblasts exposed to vehicle (N=35 
cells), 100 nM ROT for 1 hour (N=34), 0.1 µM ROT for 1 hour (N=30), or 100 nM ROT for 72 hours (N=28). 
aSignificantly different from vehicle-treated cells (P<0.01). bSignificantly different from fibroblasts treated with 100 
nM rotenone for 1 hour (P<0.01). cSignificantly different from fibroblasts treated with 100 nM rotenone for 72 
hours (P<0.01). 
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MitoQ prevents rotenone-induced mitochondrial outgrowth without affecting rotenone-
induced superoxide formation - To investigate the mechanism underlying rotenone-induced 
mitochondrial outgrowth we applied the antioxidant mitoquinone (MitoQ; 126). MitoQ is a 
ubiquinone derivative that is mitochondria-targeted by covalent attachment to a lipophilic 
triphenylphosphonium cation through an aliphatic carbon chain. Chronic treatment of human 
fibroblasts with MitoQ for 72 hours did not alter mitochondrial morphology (Fig. 6A) or 
number (not shown). At a concentration of 10 nM, however, MitoQ abolished the effect of 
chronic rotenone treatment on mitochondrial outgrowth. Figure 6B shows that MitoQ alone 
had no effect on mitochondrial superoxide production. In addition, this figure shows that 
MitoQ did not inhibit rotenone-induced superoxide formation. These findings demonstrate 
that MitoQ acts downstream of superoxide to inhibit rotenone-induced mitochondrial 
outgrowth.  
 
MitoQ prevents the rotenone-induced increase in lipid peroxidation - To address the question 
of the specificity of MitoQ we used C11-BODIPY581/591, a lipid peroxidation reporter molecule 
that is insensitive to superoxide, nitric oxide and hydroperoxides (66), to assess the effect of 
rotenone, alone and in combination with MitoQ, on lipid peroxidation. Cells chronically 
treated with 100 nM rotenone for 72 hours and subsequently incubated in the presence of 4 
µM C11-BODIPY581/591 for 30 minutes showed a 2-fold increase in the ratio between the 
oxidized and non-oxidized form of the reporter molecule (Fig. 6C). This effect of rotenone 
was fully absent in cells co-treated with 10 nM MitoQ. MitoQ alone did not alter the relative 
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amount of oxidized C11-BODIPY581/591. These data show that lipid peroxidation is markedly 
increased in cells chronically treated with 100 nM rotenone and that this effect of rotenone is 
completely blocked by MitoQ.  
Fig. 6. MitoQ inhibits rotenone-induced 
mitochondrial outgrowth and lipid peroxidation 
but not superoxide generation - Human skin 
fibroblasts were incubated in the presence of ethanol 
(0.001% (v/v); vehicle), rotenone (100 nM), MitoQ (1 
nM, 10 nM), or the combination of both drugs for 72 
hours prior to analysis of mitochondrial morphology, 
rate of mitochondrial superoxide production and 
extent of lipid peroxidation. (A) Effect on formfactor. 
Experiments were performed on four days. On each 
day, the average value obtained with vehicle was set 
at 100% to which the other values were related. The 
values presented are the average of N=56 cells 
(vehicle; V), N=71 cells (100 nM ROT), N=84 cells (1 
nM MitoQ), N=102 cells (10 nM MitoQ), N=34 cells 
(100 nM ROT + 1 nM MitoQ) and N=87 cells (100 nM 
ROT + 10 nM MitoQ). (B) Effect on Et accumulation 
in the nucleoplasm during 10 minutes incubation with 
10 µM HEt as a measure of the rate of mitochondrial 
superoxide production. Experiments were performed 
on two days. On each day, the average fluorescence 
intensity in vehicle-treated cells was set at 100% to 
which the other values were related. The values 
presented are the average of N=60 cells (V), N=64 
cells (100 nM ROT), N=61 cells (1 nM MitoQ), N=63 
cells (10 nM MitoQ), N=77 cells (100 nM ROT + 1 nM 
MitoQ) and N=30 cells (100 nM ROT + 10 nM MitoQ). 
(C) Effect on the emission ratio of C11-BODIPY581/591 
as a measure of the extent of lipid peroxidation. Data 
are from two independent measurements. The values 
presented are the average of N=55 cells (V), N=44 
cells (100 nM ROT), N=62 cells (10 nM MitoQ) and 
N=53 cells (10 nM MitoQ + 100 nM ROT). 
**Significantly different from vehicle-treated cells 
(P<0.01) 
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DISCUSSION 
 
Human mitochondrial complex I (NADH:ubiquinone oxidoreductase) is the largest 
multisubunit assembly of the oxidative phosphorylation (OXPHOS) system. Its malfunction is 
associated with a wide variety of clinical syndromes ranging from often early lethal disorders, 
of which Leigh disease, a progressive encephalopathy, is the most frequent, to 
neurodegenerative disorders in adulthood, including Leber’s hereditary optic neuropathy and 
Parkinson’s disease. In recent years, all human nuclear structural complex I genes have 
been characterized, which allowed us to elucidate the genetic defect in 40% of a cohort of 
complex I-deficient patients in which the enzyme defect was present in at least skeletal 
muscle and cultured skin fibroblasts (246). To enhance our understanding of the 
pathophysiological consequences of complex I deficiency we study fibroblasts from 
genetically characterized patients (283). Pilot experiments employing the protocol for 
quantitative analysis of mitochondrial morphology described in this paper, revealed 
significant differences between control and patient fibroblasts (W.J.H. Koopman, H.-J. Visch, 
S. Verkaart, J.A.M. Smeitink, L.P. van den Heuvel and P.H.G.M. Willems, unpublished data). 
This prompted us to investigate the relationship between complex I activity and 
mitochondrial morphology in control human skin fibroblasts. In order to mimic the 
pathological condition as closely as possible, control fibroblasts were chronically treated with 
rotenone concentrations that decreased the activity of complex I to values similar to those 
measured in patient fibroblasts. 
The data presented show that chronic treatment of fibroblasts with 100 nM rotenone for 72 
hours decreased complex I activity by 80% and caused significant mitochondrial outgrowth. 
Importantly, the alterations in mitochondrial shape were not the result of changes in cell 
cycle phase. This is in agreement with previous studies showing that 100 nM rotenone did 
not affect cell growth and viability of human B lymphoma cells (9). The morphological 
parameters analysed were: aspect ratio (AR), which is a measure of mitochondrial length, 
and formfactor (F), which is a combined measure of mitochondrial length and degree of 
branching. Both parameters are independent of objective or zoom factor and therefore most 
suited for comparison between different microscopes and cell types. To minimize the effects 
of phototoxicity and mitochondrial movement, images were acquired at video-speed (30 Hz) 
and averaged in real time. For statistical evaluation, we calculated the average value of AR, 
F and Nc (the number of mitochondria per cell) for each field of view. These averages were 
not influenced by the small number of partially imaged mitochondria because typically 
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between 80-500 mitochondria were present per field of view. Day to day variations in AR, F 
and Nc were effectively corrected by expressing each value as a percentage of the 
corresponding control value recorded on the same day. The fact that our R123 staining 
procedure is very short (40 seconds) and image analysis can be automated allows future 
application of this protocol in the rapid screening of large numbers of mitochondrial 
structures. 
Chronic treatment with 100 nM rotenone for 72 hours caused a marked increase in 
formfactor but did not significantly alter the aspect ratio or the number of mitochondrial 
structures. These findings show that human skin fibroblasts respond to chronic complex I 
inhibition with the formation of a more complex mitochondrial reticulum. Chronic treatment 
with 15 nM rotenone tended to increase both AR and F, suggesting that the effect of 
rotenone is dose-dependent. When the concentration of rotenone was increased to 100 nM, 
however, the effect of chronic rotenone treatment on AR decreased rather than increased, 
whereas that on F increased further to reach statistical significance. Robinson and co-
workers recently reported that human skin fibroblasts displayed increased amounts of 
mitochondria in the swollen filamentous forms, nodal filaments, and ovoid forms upon acute 
(5 minutes) treatment with 40 µM rotenone (200). We did not observe such aberrations in 
mitochondrial morphology in our study, indicating that mitochondria respond completely 
differently depending on the concentration of the inhibitor and the duration of the treatment. 
Chronic treatment of fibroblasts with 5 µM rotenone caused massive cell death (data not 
shown), demonstrating the inability of these cells to cope with relatively high inhibitor 
concentrations. It should be noted, however, that the relatively low concentration of 100 nM 
rotenone used in the present study decreased the activity of complex I already by 80%. 
Moreover, acute addition of 100 nM rotenone caused an immediate increase in the rate of 
superoxide production (data not shown), indicating that the inhibitor acts instantaneously. 
These observations suggest that the cytotoxicity of the higher rotenone concentrations is not 
directly related to its inhibitory effect on complex I activity and that, therefore, results 
obtained with these concentrations should be treated with caution. 
Several studies have shown that high concentrations of rotenone or exogenously added 
H2O2 can induce apoptosis (9,60,131,150,258). In general, this induction is accompanied by 
permeabilization of the mitochondrial inner membrane, opening of the permeability transition 
pore, and dissipation of the mitochondrial membrane potential (78). It has been 
demonstrated that chronic (36 hours) rotenone treatment induces apoptosis through 
enhancing mitochondrial reactive oxygen production in HL-60 cells (150). However, the 
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lowest concentration of rotenone that gave a significant increase in percentage of apoptotic 
cells was 200 nM. In agreement with this finding the present study did not show any adverse 
effects of chronic treatment with 100 nM rotenone on cell growth and viability. On the 
contrary, rotenone-treated fibroblasts displayed an increase in complexity of the 
mitochondrial network that suggests the induction of an adaptive response. A similar 
increase was observed in cancer cells that were forced to grow on galactose and glutamine 
(219). Importantly, the latter study showed that the increase in complexity of the 
mitochondrial reticulum was accompanied by an increase in OXPHOS protein, indicating the 
adaptive nature of this response. These findings support the existence of a tight relationship 
between mitochondrial structure and function (59). 
The rotenone-induced increase in mitochondrial outgrowth was completely prevented by co-
treatment with MitoQ, a mitochondria-targeted derivative of coenzyme Q10 (121,126). Given 
its very large hydrophobicity, MitoQ is preferentially adsorbed to the matrix-facing leaflet of 
the inner mitochondrial membrane with the triphenylphosphonium moiety at the membrane 
surface at the level of the fatty acid carbonyls, and the alkyl chain and ubiquinol moiety 
inserted into the hydrophobic core of the lipid bilayer (10). The inhibitory effect of MitoQ on 
rotenone-induced mitochondrial outgrowth suggests that an increase in mitochondrial 
oxidative stress is the primary cause of this cellular response.  
MitoQ completely blocked rotenone-induced outgrowth and lipid peroxidation but had no 
effect on the rotenone-induced increase in mitochondrial superoxide formation. The latter 
finding shows that MitoQ exerts its effect downstream of this oxygen radical. It has been 
demonstrated that superoxide radicals produced upon complex I inhibition are released into 
the mitochondrial matrix (43,255). The rotenone-induced increase in superoxide production 
found here might very well be at the basis of the rotenone-induced increase in H2O2 
production observed in previous studies (16,150,258). The observation that exogenous 
application of H2O2 increases mitochondrial mass in human lung fibroblasts (146), indeed 
suggests the involvement of matrix manganese superoxide dismutase in the mechanism of 
action of rotenone. Recent work concerning the mechanism by which superoxide activates 
mitochondrial uncoupling proteins has suggested that superoxide releases ferrous iron from 
iron-sulfur center-containing enzymes, which reacts with hydrogen peroxide, produced by 
the action of manganese superoxide dismutase, to form the hydroxyl radical. This radical 
then extracts a hydrogen atom from an unsaturated fatty acyl chain of a phospholipid to 
generate carbon-centered radicals that initiate lipid peroxidation, yielding breakdown 
products that activate the uncoupling proteins (176). Because MitoQ reacts mainly with lipid 
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peroxidation products (M. Murphy, unpublished observations) the present findings may 
suggest that rotenone acts through these products to increase mitochondrial outgrowth. 
However, further research is required to define the exact site of action of MitoQ. The present 
findings support recent insights that intracellular oxidants may act as specific signaling 
molecules under both physiological and pathological conditions (75). 
The present study shows that 100 nM rotenone causes a 2-fold increase in the rate of 
mitochondrial superoxide production in intact human skin fibroblasts. In agreement with this 
finding, NADH-stimulated mitochondrial superoxide formation was found to be increased in 
mitochondrial membranes isolated from complex I deficient human skin fibroblasts 
(204,214). These findings support the existence of a site of electron leakage upstream of the 
rotenone binding site (84). A considerably higher concentration of 10 µM rotenone was used 
to evoke a significant increase in NADH-stimulated mitochondrial superoxide formation in 
mitochondrial membranes isolated from control human skin fibroblasts (204). Therefore, the 
present method of determining the accumulation of Et in intact cells incubated for a short 
period of time in the presence of HEt is highly sensitive and most suitable for quantification 
of the rate of mitochondrial superoxide production in patient fibroblasts.  
 
In conclusion, the data presented are compatible with the existence of a superoxide-induced 
mechanism of mitochondrial outgrowth that is activated at subapoptotic levels of complex I 
inhibition and leads to a possibly adaptive increase in complexity of the mitochondrial 
reticulum. Importantly, we show that this mechanism is activated at pathological levels of 
complex I inhibition. Detailed analysis of mitochondrial morphology in patient fibroblasts will 
reveal whether this mechanism is activated or whether activation of this mechanism is 
impaired in human complex I deficiency.  
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Chapter VIII 
Currently, our understanding of the consequences of mitochondrial complex I (CI) deficiency 
at the cellular level is still limited, thereby severely hampering the development and testing of 
possible therapeutics. One of the possible pathological consequences of inherited CI 
deficiency is enhanced ROS formation by a malfunctioning CI (208). Increased cellular ROS 
levels could induce a vicious cycle of oxidative injury (2,47,141) or activate redox sensitive 
signaling pathways in an attempt to counterbalance these detrimental effects (14,80,153). 
The aim of the research described in this thesis was to gain quantitative insight into the 
interrelationship between the degree of CI deficiency, CI expression, cellular ROS handling 
and redox homeostasis in human CI deficiency.  
 
Inherited CI deficiency: a catalytic defect or an expression problem? 
To aid clinical diagnosis, CI activity is routinely measured as rotenone-sensitive NADH 
consumption in crude homogenates of muscle tissue and mitochondria-enriched fractions of 
cultured skin fibroblasts (119,245). In fibroblasts, CI activity values are routinely normalized 
to the activity of CIV and subsequently expressed as percentage of lowest control ratio. 
Although these measurements clearly demonstrate a reduction in CI activity, they are not 
informative about the mechanism which is causing this decrease. For research purposes, 
activity of CI can also be determined in an alternative assay by separation of CI protein from 
other OXPHOS complexes by Blue native electrophoresis (BNP) followed by measurement 
of its in-gel activity (IGA) (132,182,300). A major advantage of BNP is that it also allows 
visualization of the amount of fully assembled CI protein (~1 MDa) by Western blot analysis. 
Quantitative BNP/IGA and subsequent Western Blot analysis revealed a variable reduction 
in steady-state CI protein and activity (chapter 3) and allowed us to estimate the ‘intrinsic CI 
activity’ (IGA/BNP) in patient fibroblasts (chapter 3).  
In addition to the amount of CI protein, it was found that also the intrinsic activity of CI was 
decreased in patient cells. This finding was further substantiated using the antioxidant Trolox. 
Trolox-treatment revealed that both CI activity (IGA) and protein content (BNP) increased in 
control and patient cells. However, calculation of the ratio between the increases in these 
two parameters (∆IGA/∆BNP) revealed that newly formed CI was fully active in control cells 
(i.e. ∆IGA/∆BNP=1) whereas ∆IGA < ∆BNP in patient cells, indicating that newly formed CI 
was functionally impaired (chapter 3). These findings demonstrate that mutations in nuclear-
encoded subunits of CI lead to a decreased amount of intrinsically less active CI protein. 
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Inherited CI deficiency: do mutations in the NDUFS4 subunit prevent CI 
assembly? 
In addition to the quantitative determination of CI protein content, BNP and subsequent 
Western Blot analysis is also very informative about the assembly status of CI, regarding the 
mutated subunit causing disease (chapter 3,4). Mutations in the NDUFA1, NDUFS2, 
NDUFS7, NDUFS8 and the B17.2L protein are all associated with a decline in the steady 
state amounts of the fully assembled (~1 MDa) CI protein complex (chapter 3; 74,185,271). 
BNP analysis of patient fibroblasts harboring NDUFS4 mutations revealed that they only 
contain an inactive CI subcomplex of ~830 kDa and no fully assembled CI (chapter 4; 
223,271). In these patient cells no NDUFS4 protein was detectable by whole cell Western 
blot analysis (223). Moreover it has been demonstrated that the CI subcomplex does not 
contain the NADH-binding subunit NDUFV1 (47,185), thereby explaining the lack of IGA. A 
similar inactive ~830 kDa subcomplex is observed in patients harboring mutations in 
NDUFV1, NDUFS1 (chapter 3; 116,185) and NDUFS6 (130) in addition to a fully assembled 
CI. It’s therefore suggestive that these subunits are also missing from the ~830 kDa 
subcomplex.  
Surprisingly, a significant rotenone-sensitive NADH consumption (e.g. CI activity) was 
detected in mitochondria-enriched fractions isolated from NDUFS4 patient fibroblasts (40) 
when a biochemical assay was used. Using the same cells we here demonstrate the 
presence of rotenone-sensitive NADH consumption using single life cell microscopy 
(chapter 4). These findings indicate that a functional NADH consuming, rotenone-sensitive 
CI is expressed in NDUFS4 deficient cells in sharp contrast to the inactive CI subassembly 
found using BNP/IGA analysis.  
This conclusion is somewhat controversial and strongly contrasts with previous studies 
claiming that no functional CI can be assembled in the absence of the NDUFS4 protein 
(116,199,223). The latter hypothesis is largely based on results obtained in serum starved 
cells, in which cAMP phosphorylates the NDUFS4 protein and thereby stimulates CI activity. 
However, serum starvation leads in principle to a decrease in CI activity (202) and specific 
NDUFS4 phosphorylation is highly debated (48).  
Taken together, our findings suggest that fully assembled CI is less stable in patient 
fibroblasts harboring a mutation in the NDUFS4 protein. As a consequence the CI complex 
disintegrates during the BNP isolation procedure leaving only an inactive CI subcomplex. 
This implies a role for NDUFS4 in CI stabilization.  
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Superoxide levels are specifically increased in fibroblasts of patients with CI 
deficiency 
To investigate if the decline in CI activity and protein content was related to altered ROS 
production in CI deficient fibroblasts, we first developed two fluorescent reporter assays 
allowing the selective quantification of the primary source of cellular ROS, superoxide (O2-; 
chapter 2,3,5,7) and its downstream products including H2O2 (chapter 4-7) in a non-invasive 
way. To obtain a quantitative understanding of its relationship with human CI deficiency we 
measured O2--levels, CI protein content and activity in two model systems for human CI 
deficiency. To this extent rotenone-treated control cells and skin fibroblasts derived from a 
cohort of 21 CI deficient patients were used and the obtained results were compared with 
healthy controls (chapter 3). Superoxide levels were elevated in 19 out of 21 CI deficient cell 
lines and inversely related to CI activity in both rotenone-treated controls and the cohort of 
patient cell lines. In the cohort of CI deficient cell lines, the decrease in CI activity was 
paralleled by a decline in CI protein content, whereas protein content increased in the 
rotenone-treated controls. In the latter case, however, the amount of CI increased rather 
than decreased, indicating that superoxide production can increase in the absence of 
mutations in CI subunits. Based on the latter finding we conclude that in isolated human CI 
deficiency increased cellular superoxide production is primarily a consequence of decreased 
cellular CI activity and not of further electron leakage due to the presence of a mutated 
subunit. Superoxide levels were not related to the residual CIII and CIV activities of these CI 
deficient cell lines (table 1, R=0.03, p=0.91 for CIII; R=0.26, p=0.28 for CIV). Importantly, 
patient-derived cell lines with other single-enzyme OXPHOS deficiencies did not show a 
detectable increase in O2- (table 2), suggesting that increased cellular O2--levels are a 
specific consequence of the reduction in CI activity.  
 
As shown in chapter 3, 5, 6 and table 1 we observed increased free radical levels in all 
patients with an identified disease-causing mutation with the exception of patient 2. This 
patient is one of the two brothers (P1 and P2) with exactly the same mutation in the 
NDUFV1 subunit of CI (234). Both fibroblast cell lines show a similar decrease CI activity 
and fully assembled CI (chapter 3). Nevertheless, superoxide and cytosolic oxidant levels 
were only elevated in P1 illustrating that additional factors, such as ROS scavenging activity, 
play a role in determining cellular ROS production in inherited CI deficiency as found by 
others (116,204).  
 130
 
 
Chapter VIII 
The striking difference in ROS levels between these two particular NDUFV1 deficient cell 
lines might be explained by a difference in the expression of metallothionein (MT). These 
small (6-7 kDa) metal binding proteins with high cysteine content can scavenge ROS in a 
similar way to glutathione. Induction of MT-expression occurs after CI inhibition by rotenone 
treatment (100 nM, 24h) in Hela cells (211) and in CI deficient fibroblasts with a nuclear-
inherited mutation during transition from glucose to galactose as carbon source (275). In the 
latter study, induction of MT-transcripts was similar to controls for P2 (~2-fold) whereas this 
was 5-fold for P1 and up to 14-fold in other CI deficient cell lines. The lack of MT-induction 
observed in P2, could mean that the transcripts (and amount of protein) are already elevated 
in P2, leading to normalization of cellular ROS levels in this particular patient.  
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Table 1. OXPHOS activities of the complex I deficient fibroblast cell lines used in this thesis  
CELL LINE$ AFFECTED SUBUNIT 
AND MUTATION₤
CLINICAL 
PHENOTYPE
%
CI   
ACTIVITY# 
COX
CIII 
ACTIVITY# 
COX
CIV 
ACTIVITY#
CS
SUPEROXIDE 
LEVELS& ROS LEVELS& NAD(P)H 
LEVELS&
Control range n.a. n.a. 100 – 236% 100 – 206% 100 – 175% 91 – 112% 100-125% 88-108% 
         
P1   (#5171) NDUFV1-R59X/T423M MLM/LL 73 126    159 186±6 (84) 242±19 (78) 137±8 (40) 
P2   (#5866) NDUFV1-R59X/T423M MLM/LL 64 148 147 110±3 (61) 135±12 (49) 144±4 (112) 
P3   (#6173) NDUFS1-D618N/R577X L/LD 31 120   126 176±4 (83) 171±13 (87) 138±5 (77) 
P4   (#5170) NDUFS2-R228Q HCEM 39 141    171 205±8 (66) 169±7 (124) 147±6 (82) 
P5   (#5067) NDUFS2-P229Q HCEM 36 111   88 264±9 (100) 351±41 (28) 184±6 (119) 
P6   (#4605) NDUFS2-S413P HCEM 40 239    322 301±21 (40) n.d. n.d.
P7   (#5077) NDUFS4-W97X L/LL 59 114    173 170±4 (100) n.d. n.d.
P8   (#5260) NDUFS4-R106X L/LL 36 80   132 174±8 (64) 187±12 (160) 128±3 (132) 
P9   (#4827) NDUFS4-R106X L/LL 58 n.d.    n.d. 238±8 (93) n.d. n.d.
P10 (#5737) NDUFS4-VPEEHI67/VEKSIstop L/LL 53 127   114 131±4 (92) 202±12 (98) 128±5 (93) 
P11 (#4608) NDUFS4-K158fs L/LL 75 97    162 195±6 (106) 289±46 (29) 136±4 (84) 
P12 (#5175) NDUFS7-V122M L/LL 68 n.d.   141 151±5 (94) 212±15 (76) 115±5 (57) 
P13 (#6603) NDUFS8-R94C L/LL 18 88    229 222±7 (147) 275±20 (117) 178±6 (87) 
P14 (#4611) Unknown      L/LL 36 107 140 395±27 (36) n.d. n.d.
P15 (#5409) Unknown      FILA 45 165 141 265±11 (104) n.d. n.d.
P16 (#4591) Unknown      UEM 39 144 112 189±5 (79) n.d. n.d.
P17 (#4554) Unknown      L/LL 42 163 135 175±6 (60) n.d. n.d.
P18 (#4590) Unknown      FILA 60 160 102 217±7 (70) n.d. n.d.
P19 (#4606) Unknown      FILA 63 201 118 197±9 (42) n.d. n.d.
P20 (#4617) Unknown        L/LL 85 n.d. n.d. 127±5 (56) n.d. n.d.
P21 (#5671) Unknown      L/LL 27 115 133 331±18 (38) n.d. n.d.
 
$Numbers indicate the designation of the cell lines within the Nijmegen Centre for Mitochondrial Disorders (NCMD). P indicate patient cell lines, respectively. 
     ₤Human subunit designation corresponds to the following nomenclature in Bos taurus: NDUFV1 (51-kDa), NDUFS1 (75-kDa), NDUFS2 (49-kDa),  
       NDUFS4 (18-kDa), NDUFS7 (PSST), NDUFS8 (TYKY). Mutations are given at the protein level.  
     %FILA: Fatal infantile lactic acidosis, HCEM: Hypertrophic cardiomyopathy and encephalomyopathy, L/LD: Leigh syndrome and leukodystrophy, L/LL: Leigh  
      syndrome and Leigh-like syndrome, MLM: Macrocephaly, leukodystrophy and myoclonic epilepsy, UEM: Unspecified encephalomyopathy.  
    #Enzymatic activities were measured in mitochondria-enriched fractions and expressed as % of the lowest control value (18.9 mU/mg protein; 100 
    mU/U CS and 110 mU/U COX for CI activity and 1270 mU/U COX and 680 mU/CS for CIII and CIV activity respectively).  
&Cellular superoxide, ROS and NAD(P)H levels were expressed as percentage of CT-1 = 100% and tested for significance against the highest  
    control value in the assay. Values in bold are significantly different (p < 0.05) from the lowest control (CI activity) or highest control value    
    (superoxide, ROS and NAD(P)H. Abbreviations: n.a., not appropriate, n.d., not determined. 
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Table 2. Cellular superoxide levels in OXPHOS deficient fibroblasts and controls 
OXPHOS DEFICIENCY $ RESIDUAL ACTIVITY% CELLULAR SUPEROXIDE LEVEL&
  Untreated Rotenone* 
    
Controls (106 ± 2) 145 ± 24 98  ± 1 171 ± 4 
    
CI 50 ± 4 188 ± 10 249 ± 12 
CII 31 ± 6 105 ± 7 166 ± 14 
CIII 65 ± 6 113 ± 11 197 ± 14 
CIV 20 ± 2 60 ± 9 108 ± 15 
 
 $CI-CIV represent the enzyme complex  deficient in the OXPHOS system. #Enzymatic activities were measured 
in mitochondria-enriched fractions and expressed as % of the lowest control value (110 mU/U COX for CI; 536 
mU/U COX for CII; 1270 mU/U COX for CIII and 680 mU/CS for CIV activity, respectively).
&Cellular superoxide levels were expressed as % of CT1 (277). Values are the mean + SEM of 7 control cell  
lines; 21 CI; 6 CII; 3 CIII; 4 CIV cell lines for vehicle-treated cells and 5 control cell lines; 21 CI; 6 CII; 2 CIII and 4 
CIV cell lines treated with rotenone. Statistics: Values in bold are below the lowest control value (OXPHOS 
activity) or significantly different (p<0.05) from CT1 (superoxide level) *Rotenone treatment (10 min, 100 nM, 
resulted in a significant increase in superoxide levels in all single enzyme deficiencies analyzed.  
 
Strikingly, patient-derived fibroblasts with an isolated CIV deficiency caused by mutations in 
CIV assembly factor SURF-1 displayed lower superoxide levels than controls. Decreased 
cellular superoxide levels could mean that superoxide dismutase (SOD) activity is 
upregulated in these cells. However, decreased superoxide was paralleled by a decline in 
cytosolic ROS levels in two of the abovementioned patients (data not shown) and SOD 
activity was unchanged in another study using a similar cell line (85). This suggests a 
decrease in cellular free radical production rather than enhanced scavenging in CIV 
deficiency. 
 
Increased superoxide levels are not a consequence of reverse electron-flow  
Regarding CI, the use of mitochondrial preparations and purified CI protein have 
demonstrated that single electron reduction of oxygen can occur at the Q-binding site, the 
iron-sulfur clusters, or the FMN binding site. (47,84,143,144,154,186). In addition to 
electrons derived from NADH oxidation, CI can accept electrons from CII via reverse 
electron flow, resulting superoxide formation (144,154). The latter process can be effectively 
blocked by CI inhibitors like rotenone (154). To investigate if the observed increase in 
superoxide in CI deficiency was due to reverse electron flow, cells were acutely treated with 
rotenone. Rotenone administration elevated cellular O2--levels in the whole cohort of CI 
deficient cell lines (chapter 3) and fibroblasts with other single-enzyme deficiencies (table 2). 
These results indicate that reverse electron flow does not underlie the increased O2--levels 
observed in the patient cells. Moreover, we can conclude that CI functions in its forward 
mode (i.e. is oxidizing NADH) in the latter cells.   
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Increased O2--levels are paralleled by elevated cytosolic oxidant and NADH 
levels  
As depicted in table I, increased O2- levels were paralleled by proportional increases in the 
levels of O2--derived cytosolic oxidant levels (as reported by CM-DCF formation; chapter 2-4, 
6) in nine out of ten CI deficient patients. However, rotenone-induced O2- formation was not 
associated with increased cytosolic oxidant levels in control cells. As reverse electron flow is 
not involved in cellular superoxide production, our data suggest that electrons derived from 
NADH are the most important source of superoxide. Using isolated mitochondrial 
preparations and purified CI, it has been shown that mitochondrial free radical production is 
intimately associated with NADH levels as high NADH levels resulted in elevated H2O2 
(94,141,142,252) and O2- formation (143). Life cell analysis of NAD(P)H autofluorescence 
(table 1) revealed that NAD(P)H levels were elevated in all but one patient. Although NADH 
can also stimulate superoxide production from other cellular sources (2), regression analysis 
revealed that superoxide and NAD(P)H levels and residual CI activity were linearly 
correlated (Figure 1a and b). These results implicate CI activity as an important determinant 
for cellular superoxide and mitochondrial NAD(P)H levels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1. Relationship between cellular NAD(P)H levels and superoxide levels and CI activity - (A) Linear 
correlation between cellular NAD(P)H and superoxide levels in CI deficient fibroblasts (R=0.85, p=0.0002)  B) 
Inverse relationship between CI activity and cellular NAD(P)H levels (R=-0.80, p=0.001). CI activity was 
determined in a fibroblast-derived mitochondrial enriched fraction and normalized to CIV activity. Next CI/CV 
activity ratios were expressed as % of lowest control ratio (110mU/U COX). Values for P (patient cell lines) and 
CT (control cell lines) are depicted in table 1. 
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Increased O2- and cytosolic oxidant levels do not detectably alter cellular redox 
status or degree of lipid peroxidation in fibroblasts of patients with CI 
deficiency  
Increased ROS production from a malfunctioning CI could lead to oxidative stress and 
changes in redox environment resulting in cellular damage (117,209). In cells, the 
GSSG/2GSH redox couple is believed to be the major determinant of cellular redox 
homeostasis and antioxidant capacity (111,226,297). Despite the increased ROS levels in CI 
deficient patients, no differences were detected in cellular GSH content (total, oxidized and 
reduced) between a cohort of ten patient cell lines and ten controls. Furthermore, 
mitochondrial and cytosolic thiol redox state, determined in living cells with redox sensitive 
green fluorescent proteins (roGFP1) (64,95), was similar between the cohort of control and 
patient cell lines (chapter 6). In agreement with an unchanged redox environment, cellular 
damage in the form of lipid peroxidation was not observed.  
 
In contrast to inherited CI deficiency, rotenone treatment caused a small but significant 
increase in the degree of roGFP1 oxidation (chapter 6) and induced a two-fold increase in 
lipid peroxidation (chapter 7). In further contrast with the data obtained in CI deficient patient 
fibroblasts, rotenone-induced superoxide levels (chapter 5) did not result in elevated 
cytosolic oxidant levels (chapter 6). The reason for these discrepancies can be due to the 
biogenesis of the mitochondrial network (136) as this adaptation has been suggested to lead 
to increased sharing of mitochondrial oxidants, possibly resulting in normalization of 
cytosolic oxidant levels (181,277). 
 
Possible ROS- or redox-sensitive factors in human CI deficiency  
The abovementioned results suggest that the cohort of CI deficient patient cell lines 
somehow adapted to the elevated free radical levels possibly via ROS and/or redox-
sensitive signaling pathways. Although these pathways remain elusive, they could possibly 
involve the mitochondrial Fe-S protein glutaredoxin 2 (Grx2) (106) and the hypoxia inducible 
factor 1a (HIF-1a) (123), a transcription factor which is normally stabilized and activated 
under hypoxic conditions (238). HIF-1a can be of particular interest in human CI deficiency 
as it can also be activated under normoxic conditions as a consequence of elevated levels of 
ROS (243), intermediates of the Krebs cycle (36,114,236) and pyruvate (159), conditions 
which are also found in CI deficient patients (71) and derived cell lines (this thesis). 
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Mechanistic aspects of inherited CI deficiency: evidence that the cell’s 
oxidative balance controls CI protein expression 
Our results obtained in CI deficient patient fibroblasts demonstrate a link between CI activity, 
CI protein content, NAD(P)H metabolism and cellular ROS levels. We propose a mechanism 
(Fig. 2) in which nDNA-encoded mutations in CI subunits lower the expression of the fully 
assembled complex and thereby decrease overall CI activity. As a result, cellular NAD(P)H 
and free radical levels are increased depending on the severity of the deficiency. If (local) 
ROS levels are sufficiently high, they can change cellular redox state and might cause 
additional damage to CI or other cellular constituents (48). However, elevated ROS levels 
will also induce a signalling cascade counterbalancing increased ROS production by 
inducing the expression of endogenous antioxidants (204,211,296) or mitochondrial 
biogenesis (171,183,201,256).  
 
 
Fig 2. Proposed model for cell biological consequences in human CI deficiency 
 
A similar situation can be envisioned for NADH as physiological concentrations are 
associated with transcriptional regulation (76,303) whereas excessive cellular [NADH] 
disturbs the NADH:NAD+ ratio, leading to altered lactate:pyruvate ratio’s and build up of 
lactic acid (215). Using the antioxidant Trolox we show that the cell’s oxidative balance is 
important for the expression of CI as scavenging of ROS using this compound results in 
reduced ROS levels and a variable increase in CI protein expression and activity in all CI 
deficient patients investigated. In addition a functional relation between ROS production and 
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mitochondrial morphology is proposed. Excessive ROS leads to fragmented mitochondria 
and is proposed to lead to further functional impairment (46). In contrast mildly elevated 
ROS levels promote mitochondrial biogenesis (136,147,171) leading to a filamentous 
mitochondrial structure. It is hypothesized that the latter morphology is directly beneficial for 
mitochondrial function (203) in that it facilitates the sharing of intramitochondrial antioxidants 
and ROS-damaged mitochondrial constituents thereby reducing the detrimental effects of 
ROS (181). This relation is supported by recent findings in Chang cells (an immortalized 
normal hepatocyte cell line) where chronic (12 h) application of a high concentration of 
hydrogen peroxide (1 mM) induced mitochondrial fragmentation, whereas lower doses (100 - 
200 µM) induced the formation of elongated ‘giant’ mitochondria (299).  
 
Possible therapeutics and future perspectives 
Although there is currently no cure available for inherited CI deficiency, mitigating therapy 
might be provided using different approaches (61). Most promising are symptomatic therapy 
in the form of exercise training (260,261) and administration of nutritional cofactors 
(42,163,220). The assays for quantitative profiling of cellular ROS production and 
mitochondrial shape and function described in this thesis provide a novel approach for the 
screening of novel compounds that restore mitochondrial function and/or promote 
mitochondrial health. The most important conclusion of our integrated quantitative approach 
is that it provides an experimental basis for antioxidant treatment of inherited human CI 
deficiency.  
As Trolox administration is associated with normalized ROS levels and improved CI protein 
content and activity, our results suggest that CI expression is under control of the cells 
oxidative balance. However, similar to vitamin E (232,259,270), Trolox could have other non-
ROS related effects on cellular function possibly leading to the observed improvement in CI 
deficiency. To investigate if Trolox really exerts its beneficial effect on mitochondrial protein 
expression by scavenging of mitochondria-derived ROS, mitochondrial targeted antioxidants 
like MitoQ (117,177,241) can be used. Of these compounds, MitoVit E, a mitochondrially 
targeted Trolox variant, (250) is very promising as it resembles Trolox, can also be delivered 
to mitochondria in vivo (249), and has already proven to have beneficial effects in a cellular 
model of Friedreich’s ataxia (121). 
Testing of potential therapeutics requires a platform which allows rapid identification of the 
effective concentration and incubation time of the compound of interest. As this is rather 
time-consuming and therefore not feasible using manual single cell imaging, the developed 
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protocols described in this thesis might be adapted to high-throughput fluorescence 
microscopy (73,100,145,198). Using the existing array of protocols, a cell biological 
fingerprint of a particular patient cell line can then be developed and refined using novel 
sensors to detect mitochondrial superoxide (217), cellular H2O2 (19) NO (15) and oxygen 
consumption (170,191).  
 
Conclusions 
The data included in this thesis demonstrate that human isolated CI deficiency caused by 
mutations in nuclear-encoded CI subunits leads to a reduction in the amount and intrinsic 
activity of CI protein. The decrease in CI activity increases cellular ROS and NAD(P)H levels 
but does not induce alterations in cellular thiol redox status or lipid peroxidation. Treatment 
of these cells with the antioxidant Trolox alleviates cytosolic ROS production and increases 
CI protein content and activity to a variable extent, stressing the importance of an oxidative 
component in the pathology of human CI deficiency.  
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ABBREVIATIONS 
 
∆Ψ   mitochondrial membrane potential     
Ø  diameter        
AR aspect ratio 
ADP adenosine diphosphate       
ATP   adenosine triphosphate       
BNP   blue native polyacrylamide gel electrophoresis    
BSO   D,L-butathione-(S,R)-sulphoximine     
CI   complex I or NADH:ubiquinone oxidoreductase    
CII   complex II or succinate dehydrogenase:ubiquinone oxidoreductase  
CIII   complex III or ubiquinol:cytochrome c oxidoreductase   
CIV   complex IV or cytochrome c oxidase     
CV   complex V or F0/F1-ATP-synthase     
C11-BODIPY581/591 4,4-difluoro-5-(4-phenyl-1,3-butadienyl)-4-bora-3a,4a-diaza-s-
indacene-3-undecanoic acid       
Ca2+   calcium         
cDNA   copy DNA        
CM-H2DCFDA  5-(and-6)-chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate  
CM-H2DCF  dichlorodihydrofluorescein      
CM-DCF  dichlorofluorescein       
CoQ   ubiquinone (Coenzyme Q) 
CoQH2   ubiquinol 
COX   cytochrome c oxidase   
CO2   carbon dioxide       
CS   citrate synthase        
CT   control cell line        
CuZnSOD  copper-zinc superoxide dismutase      
Cyt c   Cytochrome c        
DMSO   dimethyl sulfoxide       
DNA   deoxyribonucleic acid       
DTT   dithiothreitol        
Et   ethidium        
ETC   electron transport chain       
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F   formfactor (perimeter2/4π.area)      
FCCP   p-trifluoromethoxy carbonyl cyanide phenyl hydrazone   
F/Nc   mitochondrial network complexity     
FADH2   flavin adenine dinucleotide (reduced form) 
Fe2+   ferrous iron        
FILA   fatal infantile lactic acidosis      
FMN   flavin mononucleotide       
FP   flavoprotein        
GSH   glutathione (reduced form)      
GSSG   glutathione disulfide (oxidized form)     
H+   proton         
HCEM   hypertrophic cardiomyopathy and encephalomyopathy   
H2O2   hydrogen peroxide       
HO2.   hydroperoxyl radical       
HE(t)   hydroethidine        
HP   hydrophobic protein       
HPLC   High-performance liquid chromatography    
IGA   in-gel activity        
IP   iron-sulfur protein       
IMS   inner membrane space 
IMM   inner mitochondrial membrane      
LD   Leigh disease        
L/LD   Leigh syndrome and leukodystrophy     
L/LL   Leigh syndrome and Leigh-like syndrome    
MDa   megadalton         
MG   Mitotracker Green FM       
Mfn2   Mitofusin-2        
MILS   Maternally inherited Leigh syndrome     
MitoQ   Mitoquinone       
MLM   macrocephaly, leukodystrophy and myoclonic epilepsy   
MnSOD  manganese superoxide dismutase     
MR   Mitotracker Red CMXRos      
MT   metallothionein  
mtDNA  mitochondrial DNA       
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NAD+   nicotinamide adenine dinucleotide (oxidized form)  
NADH   nicotinamide adenine dinucleotide (reduced form)   
NADPH  nicotinamide adenine dinucleotide phosphate (reduced form)  
NARP   Neuropathy, Ataxia and Retinitis Pigmentosa    
Nc   number of mitochondria per cell      
nDNA   nuclear DNA        
NDUF   NADH dehydrogenase ubiquinone flavoprotein subunit   
ND   NADH dehydrogenase subunit     
NBT   nitro blue tetrazolium        
NO   nitric oxide        
1O2   singlet oxygen 
O2-   superoxide        
OH.   hydroxyl radical        
OMIM   online Mendelian inheritance in man     
OMM   outer mitochondrial membrane      
ONOO-  peroxynitrite       
OXPHOS  oxidative phosphorylation   
P   patient cell line  
Pi   inorganic phosphate      
PBS   phosphate buffered saline      
PUFAOO.  polyunsaturated fatty acid peroxyl radicals 
roGFP1  reduction-oxidation sensitive green fluorescent protein 1 
R123   rhodamine 123    
ROI   region of interest       
ROS   reactive oxygen species       
RNS   reactive nitrogen species        
SE(M)   standard error of the mean      
SOD   superoxide dismutase 
TIM   translocator of the inner mitochondrial membrane   
TOM   translocator of the outer mitochondrial membrane   
Trolox   6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid  
UEM   Unspecificied encephalomyopathy     
VCM-DCF   rate of CM-DCF fluorescence increase 
WB   Western Blot      
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SUMMARY 
 
Mitochondria fulfill a central role in cellular physiology. They are composed of a double 
membrane encompassing two aqueous compartments (the mitochondrial matrix and 
intermembrane space, IMS) and posses their own genetic material (mtDNA). Virtually all 
mitochondrial functions require the presence of a negative potential (∆Ψ) across the inner 
mitochondrial membrane (IMM). The generation of ∆Ψ is coupled to the production of cellular 
energy (adenosine triphosphate or ATP) by the oxidative phosphorylation (OXPHOS) system. 
The OXPHOS system consists of five multi-protein assemblies (complex I-V, CI-CV) and is 
embedded in the IMM. The first four complexes comprise the electron transport chain, which 
oxidizes NADH at CI and succinate at CII to release electrons. These are transported to CIV 
via two mobile electron carriers (ubiquinone and cytochrome c) and CIII, ultimately resulting 
in oxygen consumption and water formation. Energy released during electron transport is 
used by CI, CIII and CIV to transfer protons (H+) from the mitochondrial matrix into the IMS 
resulting in the electrochemical proton gradient ∆Ψ that powers the fifth complex (CV) to 
produce ATP. With the exception of CII, which is entirely nuclear-encoded, all OXPHOS 
complexes are under dual genetic control of both the mtDNA and nuclear DNA (nDNA).  
One in approximately 5000 children is born with a severe deficiency in the ATP generating 
system due to a genetic alteration affecting one or more of the OXPHOS complexes. 
OXPHOS deficiency mainly affects tissues with a high energy demand including brain, heart, 
and skeletal muscle. Frequently, the disease course is progressive, leading to multi-system 
deterioration and early death. In most cases, defective OXPHOS function is associated with 
a deficiency of NADH:ubiquinone oxidoreductase (complex I, CI), the first and largest 
complex of the OXPHOS system.  
Complex I forms a ~1 MDa, L-shaped structure and is composed of 45 different proteins. 
Seven of these subunits are encoded by the mtDNA whereas genetic information for the 
remainder is on the nDNA. Mutations in nuclear-inherited CI genes are the most frequent 
cause of human CI deficiency. At present, our understanding of the molecular and cellular 
consequences of these mutations is still limited, which severely hampers the rational design 
and testing of effective therapeutics. 
Although CI deficiency is generally associated with a decreased capacity to produce cellular 
energy, this may not be the only cause of disease. For example, abnormalities in cellular 
calcium homeostasis and mitochondrial morphology have been demonstrated in patient-
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derived cell lines. In addition, CI deficiency is associated with alterations in reduction-
oxidation (redox) homeostasis, which is of critical importance to a wide variety of cellular 
processes. A disturbed redox homeostasis can lead to oxidative stress and is associated 
with elevated levels of reactive oxygen species (ROS). Under physiological conditions, ROS 
are formed as ‘by products’ of oxidative phosphorylation. They comprise a group of 
chemically diverse molecules (e.g. superoxide (O2-), hydrogen peroxide (H2O2) and hydroxyl 
radical (OH.)) and differ in their mechanism of production, diffusion range, biological targets 
and detoxification pathways. Although excessive formation of these molecules is hazardous 
to a cell, inflicting damage to all cellular constituents, low level ROS production is implicated 
to play a role in diverse cellular signaling pathways.  
The aim of the research described in this thesis was to gain more insight into the cell 
biological consequences of human CI deficiency in relation to ROS (patho)physiology. For 
this purpose we used control fibroblasts treated with rotenone (a CI inhibitor) and patient-
derived skin fibroblast cell lines harboring a mutation in a nuclear-encoded structural CI 
subunit. With the aid of fluorescent reporters and life-cell imaging combined with biochemical, 
immunohistochemical and enzymatic techniques, we investigated the effect of these 
mutations on CI activity and expression, cellular ROS levels and redox homeostasis. 
In chapter 1 a detailed introduction is given about the concept of OXPHOS and CI 
deficiency in relation to ROS production and cellular redox state and describes the 
objectives of this thesis. Chapter 2 describes and validates a novel method for simultaneous 
quantification of oxidative stress. Chapter 3 describes the use of the antioxidant Trolox to 
study the effect of cellular ROS levels on CI expression and activity in cultured fibroblasts of 
six children with inherited CI deficiency. It was demonstrated that CI deficient cell lines 
displayed increased cellular ROS levels which could be alleviated by Trolox-treatment. In 
addition to ROS scavenging, Trolox-treatment also increased CI protein content and activity 
in all patient cell lines studied and in controls. The use of this antioxidant revealed a variable 
intrinsic catalytic problem in most CI deficient patient cell lines as Trolox increased CI protein 
content to a larger extent than it’s activity. In controls both CI activity and CI protein content 
increased proportionally after Trolox-treatment. Chapter 4 deals with the use of Trolox as a 
tool to investigate the pathological mechanism of CI deficiency in a subset of patient-derived 
cell lines harboring a mutation in the NDUFS4 subunit of CI. Although NDUFS4 deficient cell 
lines display an inactive CI subassembly in a gel-based assay, our results indicate that they 
retain functionally active CI protein in living cells albeit in lower amount as controls. In 
chapter 5, a cohort of 21 CI deficient cell lines was studied to investigate a possible 
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relationship between superoxide levels, CI activity and CI protein content. Our results 
demonstrate that inherited CI deficiency results in reduced CI activity and CI protein content, 
the extent of which is inversely related to elevated superoxide levels. In chapter 6 we 
investigated whether the observed decrease in CI protein and elevation in cellular ROS 
levels in human deficiency were associated with an altered cellular redox state and caused 
cellular damage. However, no differences in cellular thiol redox status were observed 
between control and patient cell lines in living cells using the redox-sensitive green 
fluorescent protein 1 or after biochemical determination of cellular glutathione content 
(oxidized and reduced). Similarly, lipid peroxidation was not different from controls. Chapter 
7 reports on a cellular model for CI deficiency using healthy human skin fibroblasts, treated 
with the classic inhibitor of CI activity, rotenone. It is demonstrated that chronic (72h) 
rotenone treatment leads to increased levels of superoxide and lipid damage, and induces 
changes in mitochondrial morphology. Treatment of these CI inhibited cells with the 
antioxidant Mitoquinone (MitoQ) normalized cellular lipid damage and mitochondrial 
morphology but had no effect on superoxide levels or the abovementioned parameters in 
healthy cells. Therefore it is suggested that CI deficiency results in altered mitochondrial 
morphology through superoxide formation and lipid damage. In chapter 8, the result 
described in this thesis are discussed 
 
In summary, we have demonstrated that CI deficiency caused by mutations in nuclear-
inherited structural CI subunits results in a decline in the amount of active CI protein which is 
associated with elevated superoxide, NAD(P)H levels and cytosolic ROS  levels. Although 
free radical production is increased in these CI deficient cell lines, no changes are observed 
in cellular thiol redox status. Finally, treatment of these cells with the antioxidant Trolox 
alleviates cytosolic ROS production and increases CI protein content and activity to a 
variable extent, stressing the importance of an oxidative component in the pathology of 
human CI deficiency in a cellular model. So far no treatment strategy is available for human 
CI deficiency. Hopefully, these cell biological findings might aid in the development of future 
therapeutics to slow down the disease progress and improve the quality of life of these 
patients. 
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SAMENVATTING 
   
Mitochondriën zijn essentiële subcellulaire structuren die een centrale rol vervullen binnen 
de cel. Ze bestaan uit twee membranen die een barrière vormen voor twee waterig milieus 
(de mitochondriële tussenmembraan ruimte en de matrix). Ook bezitten deze organellen hun 
eigen genetisch materiaal, het mitochondriële DNA (mtDNA). Vrijwel alle mitochondriële 
functies zijn afhankelijk van de mitochondriële membraanpotentiaal (∆Ψ). Dit is een negative 
lading over de mitochondriële binnenmembraan. De generatie van ∆Ψ is gekoppeld aan de 
productie van adenosine trifosfaat (ATP), de universele brandstof van de cel. Dit wordt 
bewerkstelligd door het oxidatieve fosforylerings (OXPHOS) systeem.  
Het OXPHOS systeem bestaat uit vijf multi-eiwit complexen (complex I-V of CI-CV) die zijn 
gelegen in de mitochondriële binnenmembraan. De eerste vier complexen vormen samen 
met de electronen dragers coenzym Q (CoQ) en cytochroom c (Cyt c) de electronen 
transportketen. Oxidatie van energie dragende substraten door CI en CII maakt electronen 
vrij. Deze worden vervolgens via CoQ, CIII en Cyt c naar CIV geleid, wat uiteindelijk 
resulteerd in zuurstof consumptie en de vorming van water. Tijdens dit transport komt 
energie vrij, die door CI, CIII en CIV wordt gebruikt om protonen (H+) vanuit de 
mitochondriële matrix naar de tussenmembraanruimte te transporteren. Dit resulteert in de 
electrochemische gradient ∆Ψ, die gebruikt wordt door CV om ATP te produceren. Het 
merendeel van de OXPHOS complexen is opgebouwd uit eiwitten van nucleaire en 
mitochondriële origine. De uitzondering hierop is CII, waarvan alle bouwstenen door het kern 
DNA (nucleair DNA/nDNA) worden gecodeerd.  
Eén op de 5000 kinderen wordt geboren met een ernstige functionele tekortkoming 
(deficiëntie) van het OXPHOS systeem. Deze wordt veroorzaakt door een mutatie in het 
mtDNA of nDNA en zorgt ervoor dat één of meerdere OXPHOS complexen minder goed 
werken. OXPHOS deficiëntie resulteert in een verlaagde capaciteit om energie (ATP) te 
produceren en manifesteert zichzelf vooral in weefsels met een hoge energievraag zoals 
hart- en skeletspier en de hersenen. Het verloop van de ziekte is progressief en resulteert 
meestal in vroegtijdig overlijden. In de meeste gevallen wordt OXPHOS deficiëntie 
veroorzaakt door een slecht functionerend NADH:ubiquinone oxidoreductase (complex I of 
CI). Complex I heeft een molaire massa van ~1 MegaDalton, heeft een L-vormige structuur 
en bestaat uit 45 verschillende subunits. Zeven eiwitten worden door het mtDNA gecodeerd 
terwijl de genen voor de overige subunits op het nDNA gelegen zijn. De meeste gevallen 
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van CI deficiëntie worden veroorzaakt door mutaties in kern-gecodeerde subunits van CI. 
Tot op heden is er weinig inzicht in de consequenties van deze mutaties op moleculair en 
cellulair niveau. Dit vormt een duidelijke belemmering in de ontwikkeling en het testen van 
therapeutica. 
Hoewel CI deficiëntie in het algemeen geassocieerd wordt met een verlaagde energie 
productie, is dit waarschijnlijk niet de enige oorzaak die leidt tot ziekte. Cellijnen van CI 
deficiënte patiënten, vertonen een veranderde cellulaire calcium huishouding en 
veranderingen in de uiterlijke kenmerken van de mitochondriën, de mitochondriële 
morfologie. Tevens leidt CI deficiëntie tot veranderingen in cellulaire reductie-oxidatie (redox) 
status. Een gezonde redox status is zeer belangrijk voor een grote verscheidenheid aan 
cellulaire processen. Pathologische condities zoals CI deficiëntie kunnen leiden tot een 
veranderde redox status en resulteren in oxidatieve stress. Dit gaat gepaard met verhoogde 
niveaus van reactieve zuurstof radicalen, of ‘reactive oxygen species’ (ROS). Normaliter 
worden ROS gevormd als bijproducten van oxidatieve fosforylering. ROS bestaan uit een 
groep chemisch diverse moleculen, zoals superoxide (O2-), waterstof peroxide (H2O2) en het 
hydroxyl radicaal (OH.). Ze verschillen in hun productie mechanisme, diffusie mogelijkheden, 
biologische targets en afbraak routes. Hoewel ROS alle primaire cellulaire bouwstenen 
(eiwitten, suikers, vetten en DNA) kunnen beschadigen en dus een potentieel gevaar 
vormen voor cellulaire functie, vervullen deze moleculen ook een belangrijke positieve rol in 
tal van cellulaire signaaltransductie routes. 
Het doel van het in dit proefschrift beschreven onderzoek was het verkrijgen van meer 
inzicht in de celbiologische consequenties van humane CI deficiëntie in relatie tot ROS 
biologie. Hierbij is gebruik gemaakt van gezonde huid fibroblasten, wel of niet behandeld 
met de CI remmer rotenone en patiënten cellijnen met een geїdentificeerde mutatie in één 
van de kern-gecodeerde eiwitten van CI. Met behulp van fluorescente reporter moleculen en 
kwantitatieve video-microscopie in combinatie met biochemische, immunochemische en 
enzymatische technieken is het effect van CI deficiëntie op CI activiteit, expressie, ROS 
niveaus en redox status op cellulair niveau onderzocht.  
Hoofdstuk 1 geeft een introductie over het OXPHOS systeem en CI deficiëntie in relatie tot 
ROS productie en cellulaire redox status en beschrijft de doelstellingen van het onderzoek 
beschreven in dit proefschrift. Hoofdstuk 2 beschrijft de validatie van een nieuwe methode 
waarmee gelijktijdig cellulaire oxidanten en spreiding van cellen gemeten kan worden. In 
experimenten beschreven in hoofdstuk 3 en 4 is het antioxidant Trolox gebruikt. 
Antioxidanten zijn stoffen die ROS of oxidanten kunnen wegvangen. In hoofdstuk 3 is 
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Trolox gebruikt om het effect van cellulaire ROS op de expressie en activiteit van CI te 
onderzoeken in fibroblasten van zes kinderen met een geїsoleerde CI deficiëntie. Deze 
cellijnen vertoonden verhoogde ROS niveaus die normaliseerden na Trolox-behandeling. De 
verlaging in ROS was geassocieerd met een verhoging van de hoeveelheid CI eiwit en 
activiteit in alle patiënten cellijnen en in controle cellen. Door het gebruik van dit antioxidant 
werd een intrinsiek catalytisch probleem in CI binnen dit patiëntencohort blootgelegd. In 
deze cellijnen was de Trolox geїnduceerde toename in de hoeveelheid CI eiwit namelijk 
altijd groter dan de toename in CI activiteit terwijl in Trolox behandelde controle cellen CI 
activiteit en eiwit proportioneel toenamen. In hoofdstuk 4 is met behulp van Trolox het 
pathogene mechanisme van CI deficiëntie onderzocht dat veroorzaakt wordt door mutaties 
in de NDUFS4 subunit van CI. Mitochondriële fracties van NDUFS4 deficiënte cellijnen 
vertonen een CI eiwit complex dat niet volledig geassembleerd is en ook geen activiteit 
vertoont in een in-gel CI activiteitsassay. Deze resultaten suggereren dat onvolledige CI 
assemblage de oorzaak van ziekte is in patiënten met een mutatie in NDUFS4. In 
tegenstelling tot de resultaten in mitochondriële fracties, tonen onze bevindingen in levende 
cellen aan dat NDUFS4 deficiënte cellen wel degelijk een functioneel CI kunnen maken. 
Behandeling met Trolox zorgde verder voor een afname in de hoeveelheid ROS en een 
verhoging van de hoeveelheid CI eiwit en activiteit. In hoofdstuk 5 is materiaal van 21 CI 
deficiënte patiëntencellijnen gebruikt om een mogelijke relatie tussen superoxide niveaus, de 
hoeveelheid CI eiwit en CI activiteit te onderzoeken. Hieruit is naar voren gekomen dat 
humane CI deficiëntie veroorzaakt wordt door een verminderde hoeveelheid actief CI eiwit 
en geassocieerd is met verhoogde superoxide niveaus. In hoofdstuk 6 is onderzocht of de 
verlaging in actief CI eiwit en de verhoging in cellulaire ROS in CI deficiënte cellen 
resulteerde in een veranderde cellulaire redox status en celschade. Hiervoor is gebruik 
gemaakt van de redox gevoelige probe ‘redox-sensitive green fluorescent protein 1’ en zijn 
de cellulaire concentraties glutathione en glutathione disulfide (geoxideerd glutathione) 
gemeten. Ondanks verhoogde ROS productie zijn er geen verschillen gevonden in cellulaire 
thiol redox status tussen patiënten en controle cellen. Ook lipide schade was niet veranderd 
tussen controle en CI deficiënte patiënten cellijnen. Hoofdstuk 7 beschrijft de bevindingen 
met een cellulair model voor CI deficiëntie, gebruikmakend van gezonde huid fibroblasten 
die behandeld zijn met een klassieke remmer van CI activiteit, rotenone. Chronische 
remming van CI (72 uur) leidt tot verhoogde superoxide niveaus, schade aan vetzuren en 
veroorzaakt een verandering in de mitochondriële morfologie. Behandeling van deze CI 
geremde cellen met het mitochondriële antioxidant Mitoquinone (MitoQ) leidde tot een 
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normalisatie van vetzuur schade en mitochondriële morfologie maar had geen effect op 
superoxide productie. Deze resultaten suggereren dat CI deficiëntie gepaard gaat met een 
veranderde mitochondriële morfologie via verhoogde superoxide productie en lipide schade. 
In hoofdstuk 8 worden de bevindingen beschreven in dit proefschrift bediscussieerd. 
 
Samenvattend is er aangetoond dat humane CI deficiëntie veroorzaakt door mutaties in 
kern-gecodeerde structure CI eiwitten resulteert in een verlaagde hoeveelheid actief CI eiwit. 
De verlaagde CI activiteit is geassocieerd met verhoogde superoxide, NAD(P)H en 
cytosolische ROS niveaus. Hoewel de cellulaire vrije radicaal niveaus verhoogd zijn, zijn er 
geen veranderingen gemeten in cellulaire thiol redox status. Behandeling van deze cellen 
met het antioxidant Trolox leidt tot een verlaging in ROS niveaus en een verhoging in de 
hoeveelheid CI eiwit en activiteit. Dit illustreert het belang van een oxidative component in de 
pathologie van humane CI deficiëntie in een celmodel. Tot op heden is er geen effectieve 
behandeling aanwezig voor patiënten met een geїsoleerde CI deficiëntie. Hopelijk dragen 
deze celbiologische bevindingen bij aan de ontwikkeling van therapeutica om de progressie 
in het ziekteproces te verminderen en de kwaliteit van het leven voor deze patiënten te 
verbeteren. 
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Je laat je niet gek maken en ondanks alles blijf je met beide benen op de grond en sterk in je 
schoenen staan. Ontzettend bedankt voor jouw bijdrage aan dit proefschrift en ik hoop dat je 
het leuk vindt één van mijn paranimfen te zijn. 
 
Tijdens mijn onderzoek heb ik ook een aantal studenten mogen begeleiden. Bij deze wil ik 
Maarten, Eva en Julia dan ook hartelijk bedanken voor hun medewerking aan de diverse 
hoofdstukken van dit proefschrift. Miss Julia Cheek, I had the pleasure of working with you 
for almost a year in which you struck me as a motivated, punctual and well-ordered student 
with excellent pipetting skills. I wish you all the best and hopefully we will meet again in the 
future.  
 
Omdat ik graag business with pleasure afwissel in de vorm van koffiepauzes ging ik ook veel 
om met de afdeling Farmacologie/Toxicologie. Met name wil ik noemen Juffrouw Janny, 
Jeroen, Joke, Miriam en Suzanne. Het drinken van koffie/thee werd al snel uitgebreid met 
diners en barbecues en werkbezoeken in Leuven en Tessin. Dit heeft geleid tot een hechte 
vriendschap die we hopelijk nog lang in stand kunnen houden. Hartelijk bedankt voor de 
luisterende oren en al jullie steun.  
 
Hetzelfde geldt voor mijn tweede paranifm Martijn. Celkweken in Nijmegen en bierdrinken in 
Aarhus gaat je goed af (en mij ook). Ook jij bent het promotietraject ingegaan. Bij deze wil ik 
je bedanken voor je steun de afgelopen jaren en succes wensen met jouw promotie. 
  
Tot slot wil ik mijn ouders, Joost (voor de laatste loodjes) vrienden en familie bedanken voor 
hun onvoorwaardelijke steun als ik het even niet zag zitten.  
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En last but not least: Viv. Jij hebt de minst leuke kanten van mijn promotie van dichtbij 
meegemaakt maar hebt me altijd gesteund en opgebeurt. Samen hebben we er ons 
doorheen geslagen. We zijn de trotse ouders geworden van onze zoon Bram waaraan we 
heel veel plezier beleven.  
 
Dit is afgerond, op naar een nieuwe uitdaging. 
 
Sjoerd 
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diploma heeft behaald aan het Eckart College in Eindhoven begint hij in 1995 met de 
opleiding tot HLO-analist in Etten-Leur. Na een praktische stage aan de Erasmus 
Universiteit Rotterdam (afdeling Hematologie onder leiding van Dr. E. Wiemer) wordt deze 
opleiding in 1999 afgerond met biotechnologie als specialisatie. Vervolgens gaat hij verder 
studeren aan de Radboud Universiteit Nijmegen, opleiding Medische Biologie. Deze 
opleiding wordt na een wetenschappelijk stage aan dezelfde universiteit (afdeling 
Autoimuunbiochemie onder leiding van Dr. M. Fouraux en Dr. G. Pruijn) begin 2002 
afgerond. In juni 2002 start hij verbonden aan de afdelingen Kindergeneeskunde en 
Neurologie en Membraanbiochemie zijn promotieonderzoek aan de Radboud Universiteit 
Nijmegen onder leiding van Prof. Dr. J. Smeitink en Dr. P. Willems. Vanaf februari 2007 is hij 
werkzaam als postdoc op de afdeling Celfysiologie aan de Radboud Universiteit Nijmegen 
onder leiding van Dr. J. Hoenderop en Prof. Dr. R. Bindels. 
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